<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Chem Biomed Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Chem Biomed Imaging</journal-id><journal-id journal-id-type="publisher-id">im</journal-id><journal-id journal-id-type="coden">cbihbp</journal-id><journal-title-group><journal-title>Chemical &#x00026; Biomedical Imaging</journal-title></journal-title-group><issn pub-type="epub">2832-3637</issn><publisher><publisher-name>Nanjing University and American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863161</article-id><article-id pub-id-type="doi">10.1021/cbmi.4c00064</article-id><article-categories><subj-group><subject>Review</subject></subj-group></article-categories><title-group><article-title>Application of Nanomaterials
in Early Imaging and
Advanced Treatment of Atherosclerosis</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Zhou</surname><given-names>Qianru</given-names></name><xref rid="notes2" ref-type="notes">#</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Wang</surname><given-names>Yujie</given-names></name><xref rid="notes2" ref-type="notes">#</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Si</surname><given-names>Guangxiang</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Chen</surname><given-names>Xingbiao</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath5"><name><surname>Mu</surname><given-names>Dan</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath6"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4860-2620</contrib-id><name><surname>Zhang</surname><given-names>Bing</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department
of Radiology, Nanjing Drum Tower Hospital Clinical College of Traditional
Chinese and Western Medicine, <institution>Nanjing University
of Chinese Medicine</institution>, Nanjing 210008, <country>China</country></aff><aff id="aff2"><label>&#x02021;</label>Department
of Radiology, <institution>Nanjing Drum Tower Hospital
Clinical College of Jiangsu University</institution>, Nanjing 210008, <country>China</country></aff><aff id="aff3"><label>&#x000a7;</label>Jiangsu
Key Laboratory for Biomaterials and Devices, School of Biological
Science and Medical Engineering, <institution>Southeast
University</institution>, Nanjing 210000, <country>China</country></aff><aff id="aff4"><label>&#x02225;</label>Clinical
Science, <institution>Philips Healthcare</institution>, Shanghai 200233, <country>China</country></aff><aff id="aff5"><label>&#x022a5;</label>Department
of Radiology, Nanjing Drum Tower Hospital, Affiliated Hospital of
Medical School, <institution>Nanjing University</institution>, No. 321 Zhongshan Road, Nanjing 210008, <country>China</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>E-mail: <email>mudan118@126.com</email>.</corresp><corresp id="cor2"><label>*</label>E-mail: <email>zhangbing_nanjing@nju.edu.cn</email>.</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>01</month><year>2025</year></pub-date><pub-date pub-type="collection"><day>24</day><month>02</month><year>2025</year></pub-date><volume>3</volume><issue>2</issue><fpage>51</fpage><lpage>76</lpage><history><date date-type="received"><day>28</day><month>08</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>26</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors. Co-published by Nanjing University and American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0014" id="ab-tgr1"/></p><p>Atherosclerosis
(AS) is a serious disease that poses
a significant
threat to the global population. In this review, we analyze the development
of AS from multiple perspectives, aiming to elucidate its molecular
mechanisms. We also focus on imaging techniques and therapeutic approaches,
highlighting the crucial role of nanomaterials in both imaging and
therapy for AS. By leveraging their compatibility and targeting capabilities,
nanomaterials can be integrated with traditional medical imaging and
therapeutic agents to achieve targeted drug delivery, controlled release,
and precise localization and imaging of atherosclerotic plaques.</p></abstract><kwd-group><kwd>atherosclerosis</kwd><kwd>molecular mechanism</kwd><kwd>imaging</kwd><kwd>treatment</kwd><kwd>nanomaterials</kwd><kwd>plaque</kwd><kwd>cardiovascular disease</kwd><kwd>molecular</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>Jiangsu Commission of Health</institution><institution-id institution-id-type="doi">10.13039/100017962</institution-id></institution-wrap></funding-source><award-id>M2022066</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Nanjing Medical Science and Technique Development Foundation</institution><institution-id institution-id-type="doi">10.13039/501100019349</institution-id></institution-wrap></funding-source><award-id>ZKX23019</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Nanjing Drum Tower Hospital</institution><institution-id institution-id-type="doi">10.13039/501100019155</institution-id></institution-wrap></funding-source><award-id>XJSFZLX202114</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Nanjing Drum Tower Hospital</institution><institution-id institution-id-type="doi">10.13039/501100019155</institution-id></institution-wrap></funding-source><award-id>XJSFZJJ202026</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>China Postdoctoral Science Foundation</institution><institution-id institution-id-type="doi">10.13039/501100002858</institution-id></institution-wrap></funding-source><award-id>2022T150317</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>82272065</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>im4c00064</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>im4c00064</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>Cardiovascular disease
(CVD) is a major global health issue and
the leading cause of death among Chinese residents. In 2019, over
17 million deaths were attributed to CVD.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> The
2022 China Cardiovascular Health and Disease Report indicated that
the prevalence of unhealthy lifestyles and the accelerating population
aging have led to a significant population in China with CVD risk
factors, with incidence and mortality rates continuing to rise. Projections
suggest that the number of CVD patients in China may reach 330 million,
exacerbating the burden of CVD. Coronary atherosclerotic heart disease
(CHD) is a primary contributing factor, with atherosclerosis (AS)
being the main cause of CHD.<sup><xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref4">4</xref></sup> Annually, AS accounts
for half of global mortality. Consequently, global medical organizations
persist in researching the pathogenesis and treatment of AS, aiming
to enhance prevention and treatment strategies and reduce morbidity
and mortality rates worldwide.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup></p><p>The
symptoms of AS primarily depend on vascular lesions and the
degree of ischemia in the affected organs. Coronary atherosclerosis
can lead to angina pectoris, myocardial infarction, arrhythmia, or
even sudden death if the diameter of the coronary artery is narrowed
by more than 75%.</p><p>In response to this serious situation, doctors
often use drugs
to control the treatment, for very serious blood vessel blockage need
to take surgical means of treatment, these conventional treatments
are mainly to alleviate the symptoms of atherosclerosis, slow down
the development of the rate, so as to prolong the patient&#x02019;s
survival time. However, these methods have some drawbacks, such as
drug resistance, side effects, or the risk of trauma and complications.</p><p>In recent years, the development of nanomaterials has accelerated
as researchers have recognized their significant potential in enhancing
disease diagnosis and imaging. This review explores novel diagnostic
and therapeutic approaches to effectively treat diseases using nanomaterials
by various research teams in recent years, with a focus on atherosclerosis.
It not only presents traditional imaging and therapeutic techniques
for atherosclerosis but also highlights the critical roles of various
nanomaterials in treating the condition. This review examines these
nanomaterials from the perspectives of disease pathogenesis and molecular
mechanisms of action and discusses their future potential in plaque
imaging and therapy, aiming to improve the effectiveness of disease
treatment.</p></sec><sec id="sec2"><label>2</label><title>The Molecular Mechanism and Pathogenesis of
Atherosclerosis</title><p>Atherosclerosis is the formation of atheromatous
lipid-containing
necrotic lesions and hardening of the vessel wall in the intima of
the arteries due to the deposition of lipids and other blood constituents,
proliferation of smooth muscle cells, and increase in collagen fibers
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). If left
unchecked, secondary lesions such as calcification, atheromatous ulcer
formation, thrombosis and intraplaque hemorrhage can occur as the
lesions continue to worsen. From the perspective of disease development,
Multiple factors contribute to the development of atherosclerosis
(AS).</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Endothelial Dysfunction in Atherosclerosis. The cross-sectional
and longitudinal views of the vessel demonstrate that as plaque forms
and expands, the lumen narrows, reducing the space available for blood
flow.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0001" id="gr1" position="float"/></fig><p>Lipid infiltration leading to
the development of
AS is one of the
hypotheses for the pathogenesis of AS. Other hypotheses include thrombosis
and platelet aggregation, injury response, and monoclonalism. These
different factors influence the formation and development of AS in
different ways. In the lipid infiltration theory, lipids enter the
vessel wall through various pathways and are deposited beneath the
endothelial cells of the vessels, and the deposited lipids gradually
increase to form lipid spots, which then develop into lipid streaks.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> As lipid deposition intensifies, smooth muscle
cells and macrophages, etc. within the vessel wall begin to proliferate
and secrete large amounts of collagen fibers and other matrix components,
forming fibrous tissue proliferation, with the fibrous tissue wrapping
around the lipids to form the underlying structure of the plaque.<sup><xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref8">8</xref></sup> At the same time, calcium salts and other substances are gradually
deposited within the plaque and on the vessel wall. Calcium deposition
further exacerbates the hardening of the vessel wall and the narrowing
of the lumen, and the extent and location of calcium deposition has
an important impact on the stability of the plaque and the risk of
rupture. As lipid deposition, fibrous tissue proliferation, and calcium
deposition continue to progress, the structure of the vessel wall
changes. The gradual calcification of the arterial intima-media causes
the vessel wall to lose its original elasticity and toughness, leading
not only to thickening and hardening of the vessel wall, but also
to narrowing or even blocking of the lumen, which affects the normal
flow of blood. Due to the combined effects of lipid deposition, fibrous
tissue proliferation, calcium deposition and structural changes in
the vessel wall, the lumen of the arteries becomes narrowed or even
occluded, which may lead to insufficient blood supply to vital organs
such as the heart and the brain, and lead to angina pectoris, myocardial
infarction, cerebral infarction and other serious complications. In
summary, atherosclerosis begins with the excessive accumulation of
lipids in the endothelium, which leads to plaque formation, blockage
and narrowing of blood vessels, thus causing malignant cardiovascular
events.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup></p><p>Atherosclerotic plaques
are formed by deposits of cholesterol (Ch),
lipoproteins, and other cells and molecules. Over time, the plaque
grows in size, leading to narrowing and blockage of the arterial lumen.
This interferes with the normal delivery of blood and nutrients, leading
to a variety of symptoms and diseases associated with cardiovascular
disease (CVD). The lipid testing can effectively monitor the concentration
of triglycerides(TG), Ch, low density lipoprotein cholesterol (LDL-C),
and high-density lipoprotein cholesterol (HDL-C) in the blood. Early
symptoms of A are difficult to detect, and LDL is an important factor
in promoting the formation of AS. High levels of lipids such as LDL
promote the development of AS. Also, LDL shows high levels after plaque
formation. Therefore, regardless of whether plaque is already present
or not, control of the lipid profile is an important means of preventing
serious cardiovascular events.</p><p>The molecular mechanism of disease
occurrence is briefly described
as follows.</p><sec id="sec2.1"><label>2.1</label><title>Vascular Endothelial Cell Dysfunction</title><p>Atherosclerosis can be triggered by factors such as hypertension,
hyperlipidemia, diabetes, tobacco smoke exposure, or other poor lifestyle
habits.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> Hypertension causes damage to
the endothelial cells of the arteries by enhancing the impact of blood
on the arterial walls, and the damaged endothelium triggers an inflammatory
response that further aggravates vascular damage. Hyperlipidemia patients
have a slower blood circulation due to elevated concentrations of
fat and cholesterol, resulting in a decrease in the oxygen-carrying
capacity of the blood and accelerated damage to the mucous membranes
lining the walls of the blood vessels. The immune system of diabetics
is in a state of hyperactivity and is prone to inflammatory reactions.
The inflammatory response promotes vascular endothelial cell damage.
Harmful substances such as nicotine and CO<sub>2</sub> produced during
smoking can damage the endothelial cells of blood vessels, causing
the integrity of the blood vessel wall to be undermined. These factors
damage or even rupture the endothelial cells, increasing the permeability
of the vascular endothelium to blood lipids, particularly LDL, which
accumulates more readily under these conditions.</p><p>Protein kinase
C (PKC) expression levels are upregulated in conditions such as inflammation
and hypertension. It usually leads to the activation of RhoA/Rho kinase-dependent
signaling and the phosphorylation of occluding, which weakens the
endothelial barrier.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> In response to PKC
stimulation, the protein phosphatase 1 regulatory subunit 14A (PPP1R14A),
an inhibitor of smooth muscle actin phosphatase, is activated. This
activation results in cytoskeletal rearrangement, disruption of cell&#x02013;cell
contacts, and increased permeability.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Consequently, lipid molecules can more easily enter the subendothelial
space.</p></sec><sec id="sec2.2"><label>2.2</label><title>Lipid Oxidation and Accumulation</title><p>Cholesterol is often present in the blood as lipoproteins, and plasma
LDL is the main carrier of endogenous cholesterol transport, which
is degraded and transformed by binding to the low-density lipoprotein
receptor (LDL-R) on its cell membrane.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Cardiovascular risk factors lead to enhanced production of ROS generated
by NADPH oxidase, xanthine oxidase, mitochondrial electron transport
chain (ETC) and dysfunctional endothelial nitric oxide synthase (eNOS).
Oxidative stress occurs when there is an imbalance between oxidative
and antioxidant effects in the body, favoring oxidation.<sup><xref ref-type="bibr" rid="ref14">14</xref>&#x02212;<xref ref-type="bibr" rid="ref16">16</xref></sup> In the presence of increased oxidative stress in the arterial endothelium,
LDL and other substances are oxidized to oxidized low-density lipoprotein
(ox-LDL) by myeloperoxidase (MPO), hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), and other strong oxidative agents. Ox-LDL can activate
endothelial cells and trigger both inflammatory and immune responses,
promoting the development of atherosclerosis.</p></sec><sec id="sec2.3"><label>2.3</label><title>Environment
in Which Inflammation and Immune
Reactions Occur</title><p>Excessive accumulation of ox-LDL leads to
the activation of vascular endothelial cell adhesion molecules (VCAMs),<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> recruiting and aggregating inflammatory cells,
such as monocytes and T cells, at the lesion site. CD4+ T cells are
activated and differentiate into effector T cells, including helper
type 1 (Th1) cells, which produce interferon &#x003b3; (IFN-&#x003b3;)
and other inflammatory factors.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> Monocytes
in the vascular lumen adhere to the endothelium, penetrate through
endothelial gaps, and are activated into macrophages by ox-LDL and
other agonists, releasing additional inflammatory factors.</p></sec><sec id="sec2.4"><label>2.4</label><title>Formation of Foam Cells</title><p>Macrophages
ingest large amounts of ox-LDL and other liposomes in blood vessels,
transforming into foam cells (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). Foam cell formation is a key factor in the development
of atherosclerosis.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup></p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Atherosclerotic Plaque
Formation. Low-density lipoprotein (LDL)
enters the subendothelial space and is oxidized to oxidized LDL. The
accumulation of oxidized LDL stimulates endothelial cells to produce
inflammatory factors. Monocytes are recruited and accumulate in the
subendothelium, where they are activated by inflammatory cells to
become macrophages. These macrophages phagocytose surrounding lipid
molecules, transforming into foam cells. These foam cells accumulate
in the vascular wall to form fibrous plaques. Smooth muscle cells
then migrate to form a fibrous cap, enhancing the stability of the
plaque.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0002" id="gr2" position="float"/></fig><p>Studies have identified several
scavenger receptors
on the surface
of macrophages, such as SR-A1, CD36, and lectin-like oxidized low-density
lipoprotein receptor-1 (LOX-1), which are activated or upregulated
by various factors and exhibit strong affinity for ox-LDL. These receptors
facilitate the uptake of environmental ox-LDL into macrophages, leading
to its accumulation and the formation of foam cells. Pro-inflammatory
cytokines stimulate nuclear factor-&#x003ba;B (NF-&#x003ba;B),<sup><xref ref-type="bibr" rid="ref20">20</xref>,<xref ref-type="bibr" rid="ref21">21</xref></sup> which enhances the expression of SR-A1 and further mediates the
phagocytosis of ox-LDL by macrophages, exacerbating foam cell formation.</p><p>CD36, a B-type scavenger receptor, also has a strong affinity for
ox-LDL.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> The expression of CD36 in macrophages
is influenced by several factors.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> In
monocytes, chondroitin activates CD36 expression through the induction
of serine production.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> Higher levels of
CD36 bind ox-LDL more efficiently, promoting macrophage phagocytosis.</p><p>The level of LOX-1 is influenced by external factors, such as elevated
ox-LDL levels and pro-inflammatory factors, which stimulate LOX-1
expression. This further mediates macrophage uptake of lipids and
intensifies the process of foam cell formation.</p><p>Under normal
conditions, macrophages metabolize intracellular free
cholesterol through various transporter carriers, such as ATP-binding
cassette transporter A1 (ABCA1), ATP-binding cassette transporter
G1 (ABCG1), and scavenger receptor class B type I (SR-BI), or store
it in the cytoplasm as ester droplets. When excess lipids enter macrophages,
this balance between lipid uptake and clearance is disrupted. Scavenger
receptor expression significantly increases, while the expression
of transporter carriers is inhibited, blocking cholesterol efflux
and leading to increased intracellular deposition. Under abnormal
conditions, upregulation of ACAT1 and downregulation of neutral cholesteryl
ester hydrolase (NCEH) result in excessive cholesteryl ester deposition
in macrophages, further promoting foam cell formation (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Mechanisms of Lipid Handling
in Macrophages. When excess ox-LDL
damages the endothelium and enters the subendothelial space, it is
phagocytized by macrophages via receptors such as LOX-1, CD36, and
SR-A1, which are highly expressed on macrophages. In lysosomes, cholesteryl
esters in LDL are broken down into free cholesterol by lysosomal acid
lipase (LAL). At this point, cholesteryl ester accumulation predominates
due to high expression of acetyl coenzyme A acetyltransferase 1 (ACAT1)
and low levels of NCEH. Increased scavenger receptor expression leads
to enhanced ox-LDL uptake by macrophages, while the expression of
cholesterol transporters such as ABCA1, ABCG1, and SR-BI is relatively
low. This imbalance results in the accumulation of cholesteryl esters
in macrophages, further promoting their transformation into foam cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0003" id="gr3" position="float"/></fig><p>Overall, intravascular ox-LDL has a strong affinity
for scavenger
receptors on the surface of macrophages, thus promoting phagocytosis
of ox-LDL by macrophages. Meanwhile, when excess lipid enters macrophages,
the expression level of scavenger receptor increases, ACAT1 is upregulated,
and NCEH decreases, whereas the expression of transporter carriers
is inhibited, and cholesterol efflux is impeded, leading to an increase
in intracellular cholesterol deposition, which collectively promotes
the formation of foam cells.</p></sec><sec id="sec2.5"><label>2.5</label><title>Formation of Fibrous Plaques</title><p>Over
time, foam cells, cell debris, extracellular matrix components, and
smooth muscle cells (SMCs) accumulate in the vascular wall, forming
fibrous plaques. The migration and proliferation of SMCs, along with
the accumulation of collagen and other matrix proteins, contribute
to increased plaque stability.</p></sec><sec id="sec2.6"><label>2.6</label><title>Plaque
Stability and Complications</title><p>Plaque stability determines the
risk of complications. Plaques can
be divided into stable and unstable plaques. Stable plaques have thick
fiber caps and small lipid cores and do not rupture easily. Stable
plaques, on the other hand, can cause gradual narrowing of blood vessels,
restricting blood flow and potentially leading to tissue ischemia.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Unstable plaques have histological features
such as more macrophages and foam cells, larger necrotic centers,
thinner fibrous caps and plaque erosion and calcified nodules.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Unstable plaques may rupture, leading to thrombosis
and potentially causing myocardial infarction or stroke. The thin
fibrous cap of vulnerable plaques is highly susceptible to rupture
under dynamic changes in blood flow or blood pressure, leading to
thrombosis.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> Therefore, identifying and
treating vulnerable plaques is essential to prevent major cardiovascular
events.<sup><xref ref-type="bibr" rid="ref28">28</xref>&#x02212;<xref ref-type="bibr" rid="ref30">30</xref></sup></p></sec></sec><sec id="sec3"><label>3</label><title>Nanomaterials for Atherosclerosis
Imaging and
Treatment</title><p>Nanomaterials are materials that have certain nanoscale
characteristics
at least on a one-dimensional scale. Depending on their morphology
and structure, nanomaterials can be classified into many different
types, such as nanoparticles, nanowires and nanotubes, nanofilms,
nanoporous materials, and nanocomposites. For the specific classification
of nanomaterials see <xref rid="sec3.1.2" ref-type="other">3.1.2</xref><xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> for details. Nanomaterials
generally range in size from 1 to 100 nm, and semiconductor nanoparticles
smaller than 10 nm are also known as quantum dots due to the quantization
of electron energy levels.<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> Nanomaterials are capable
of penetrating membrane cells and traveling along nerve cell synapses,
blood vessels and lymphatic vessels. At the same time, some nanomaterials
can selectively accumulate in different cells and certain cellular
structures. It is these properties that allow nanomaterials to be
used for research applications in the medical field.</p><p>Nanomaterials
enter cells in two main ways, phagocytosis and cytophagy.
Phagocytosis refers to the uptake of conditioned particulate matter
and solutes by cells through vesicles that are micrometer in size.
Cytophagy refers to the uptake of fluid containing solutes and particles
by vesicles, but the size of vesicles in cytophagy is smaller than
those produced during phagocytosis. This mechanism of endocytosis
can be categorized into macropinocytosis and receptor-mediated endocytosis
(RME).<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> Macropinocytosis permits the uptake
of raw materials through large vesicles, varying in size, called macropinosome.
Upon internalization of macropinosomes, the pH gradually decreases
and endosomal markers begin to appear. Subsequently, acidified macropinosomes
can either fuse with late endosomes, bind to lysosomes or recycle
the material they transport to the cell membrane. Receptor-mediated
endocytosis is one of the most common routes by which nanoparticles
enter the cell interior. Receptor-mediated endocytosis begins when
a ligand attached to a nanoparticle binds to a specific receptor on
the cell membrane, and the binding triggers a conformational change
leading to plasma membrane invagination and the generation of early
endosomes. There are different types of RME, one being clathrin-mediated
endocytosis (CME), and the other being caveolin-mediated Endocytosis
(CVME). There are also pathways that do not require either of these
two protein-mediated pathways, but these pathways have less impact
on nanoparticle uptake.</p><p>Nanomaterials applied to AS generally
need to have good biocompatibility
and targeting properties, and the surface of nanomaterials can be
biologically or physically or chemically modified to improve the targeting
ability, which is expected to be utilized for precise targeted imaging
and treatment of AS lesion sites.<sup><xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup> For example,
in order to improve the targeting ability of nanomaterials for lesion
sites, ligands with strong affinity for the lesion area can be modified
on the surface of nanomaterials. Since AS lesion sites have a stronger
inflammatory response, increased ROS production, and decreased pH,
pH and ROS responsive nanomaterials can also be designed to enhance
the targeting effect.</p><p>In addition, modification of biomimetic
cell membranes on the surface
of nanomaterials can significantly enhance their biocompatibility,
such as nanoparticles with surface-encapsulated platelet membranes.
Since the endothelial cells on the vulnerable surface are activated
and damaged, collagen is exposed, and macrophages inside the plaque
are overaggregated and easily adhere to platelet membrane proteins,
nanoparticles wrapped around platelet membranes can be rapidly targeted
and aggregated in the lesion area. As a result, such nanoparticles
exert a targeting effect while maintaining excellent biocompatibility
and safety.</p><p>Liposomes (LNPs) are formed from phospholipids to
form closed vesicles
with a bilayer structure, which can efficiently load the drug and
protect it from metabolic processes. After targeted modification,
liposomes can be highly enriched at the site of the lesion and, due
to their slow-release characteristics, can improve retention while
reducing cellular toxicity and improving safety.<sup><xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup> Studies on LNPs in cardiovascular diseases have shown that they
possess good biocompatibility and biodegradability,<sup><xref ref-type="bibr" rid="ref38">38</xref>,<xref ref-type="bibr" rid="ref39">39</xref></sup> and LNPs stabilize compounds for therapeutic use and overcome barriers
to cell and tissue uptake.<sup><xref ref-type="bibr" rid="ref40">40</xref>&#x02212;<xref ref-type="bibr" rid="ref42">42</xref></sup></p><p>Studies have shown that
LNPs can interact with apolipoprotein E
(ApoE) APOE and HDL proteins in vivo with strong hepatic targeting.
It can reach hepatocytes by passive adsorption of ApoE, leading to
LDL-R mediated endocytosis.<sup><xref ref-type="bibr" rid="ref43">43</xref>&#x02212;<xref ref-type="bibr" rid="ref46">46</xref></sup> Therefore, they are often used in liver disease treatment
and vaccines. Therefore, the targeting of extrahepatic organs and
tissues is of particular importance. Surface modification of liposomes
can enhance the targeting of loaded drugs.</p><p>HDL consists of apolipoproteins,
phospholipids, cholesterol and
a small number of fatty acids. HDL particles are small and can move
freely in and out of the arterial wall, and can ingest harmful substances
such as LDL, cholesterol, and triglycerides that are immersed in the
bottom layer of the intima of the vessel wall, and transport them
to the liver for catabolism and excretion. Previous studies have demonstrated
that HDL can be actively transported into lymphatic vessels via SR-BI
expressed on lymphatic endothelial cells.<sup><xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref48">48</xref></sup> Researchers therefore developed a cancer nanovaccine based on HDL-mimicking
LNP, R837/LNP-M-L, capable of efficiently targeting the lymphatic,
which packages tumor-specific membrane antigens and encapsulates them
with the hydrophobic immunoadjuvant imiquimod (R837) adjuvant for
personalized cancer immunotherapy. The optimized nanovaccine promotes
codelivery of antigen and adjuvant to lymph nodes and maintains antigen
presentation to dendritic cells, resulting in long-term immune surveillance
as cytotoxic T-lymphocyte (CTL) frequency rises in lymphoid organs
and tumor tissues, which inhibits tumor formation and growth and enhances
therapeutic efficacy of checkpoint inhibitors.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup></p><p>By the same token then, it is also possible to design
nanomaterials
for atherosclerotic diseases based on HDL targets expressed on the
surface of macrophages. For example, Diditchenko et al. successfully
prepared a novel recombinant high-density lipoprotein (rHDL), CSL112,
using phosphatidylcholine (PC) reconstituted apolipoprotein (Apo A-I),
and demonstrated that it effectively promotes cholesterol efflux and
ameliorates atherosclerotic conditions.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> A team of researchers used two components, a single peptide and
saturated dimyristoylphosphatidylcholine (DMPC), to construct a peptide-based
recombinant high-density lipoprotein (pHDL) by microfluidic means,
a nanocarrier with atherosclerosis-targeting properties.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> pHDL not only has its own therapeutic effect
on atherosclerosis, but also has a unique hydrophilic&#x02013;hydrophobic
structure and a large lipid core, which can be used as a carrier to
provide storage space for lipid-soluble drugs, with highly efficient
drug delivery. pHDL also has the advantages of small particle size,
nonimmunogenic, completely degraded in vivo, and is not recognized
by the reticuloendothelial system and is not rapidly cleared, which
makes pHDL as a drug carriers show unique advantages in improving
plaque-targeted distribution of drugs.</p><p>Nandwana et al. successfully
mimicked high-density lipoprotein-like
magnetic nanostructures (HDL-MNS) resembling natural HDL particles
by modifying phospholipids to the surface of the magnetic nanostructures
and incorporating apolipoprotein A1 (Apo A1), which can carry HDL.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> In contrast to the T2MRI contrast agent Ferumoxytol,
HDL-MNS provides 5 times the contrast in 7T MRI. In addition, HDL-MNS
functioned in the same way as natural HDL, promoting cholesterol efflux
and achieving the efficiency of natural HDL excretion.</p><p>LDL nanoparticles
are similar to HDL nanoparticles and are highly
biocompatible. Similarly, LDL recognizes and binds to LDLR.<sup><xref ref-type="bibr" rid="ref53">53</xref>,<xref ref-type="bibr" rid="ref54">54</xref></sup> on the surface of macrophages, which gives LDL nanoparticles natural
plaque targeting properties. HDL and LDL nanoparticles are uniquely
suited to target plaques, mainly due to the affinity between the relevant
gene molecules.</p><p>From these, it can be seen that, When combined
with gene therapy,
nanomaterials can effectively target specific biomolecules in AS plaques,
thereby achieving therapeutic effects.</p><sec id="sec3.1"><label>3.1</label><title>Application
of Nanomaterials in the Imaging
of Atherosclerosis</title><sec id="sec3.1.1"><label>3.1.1</label><title>Traditional Imaging Methods</title><p>AS
often presents with rapid onset and subtle early clinical symptoms,
making medical imaging essential for diagnosis and treatment. With
advancements in science and technology, imaging methods have continuously
improved, resulting in enhanced image resolution and greater diagnostic
accuracy for AS. These developments have significantly improved diagnostic
efficiency.</p><p>As shown in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>, contemporary imaging techniques have higher imaging
resolution and faster imaging speeds, and digital subtraction angiography
(DSA) has always been the gold standard for diagnosis in atherosclerotic
disease. At the same time, however, traditional imaging techniques
have some exposure of patients to radiation and may not be as effective
in imaging small vessels.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Advantages and Disadvantages
of Traditional
Imaging Methods</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">Imaging Methods</th><th style="border:none;" align="center">Advantages</th><th style="border:none;" align="center">Disadvantages</th><th style="border:none;" align="center">ref</th></tr></thead><tbody><tr><td rowspan="5" style="border:none;" align="left">Ultrasound</td><td style="border:none;" align="left">1. No radiation exposure</td><td style="border:none;" align="left">1.
Limited for bones and air-filled structures</td><td rowspan="5" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref55">55</xref>)</td></tr><tr><td style="border:none;" align="left">2. Real-time imaging</td><td style="border:none;" align="left">2. Sensitivity to gas and
bone</td></tr><tr><td style="border:none;" align="left">3. High safety</td><td style="border:none;" align="left">3. Difficulty
in imaging deep structures</td></tr><tr><td style="border:none;" align="left">4. Ease of use
and cost-effectiveness</td><td style="border:none;" align="left">4. Potential for artifacts</td></tr><tr><td style="border:none;" align="left">5. Versatility</td><td style="border:none;" align="left">5. Operator dependence</td></tr><tr><td rowspan="7" style="border:none;" align="left">MRI</td><td style="border:none;" align="left">1. No radiation exposure</td><td style="border:none;" align="left">1. Long scan time</td><td rowspan="7" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref56">56</xref>, <xref ref-type="bibr" rid="ref57">57</xref>)</td></tr><tr><td style="border:none;" align="left">2. High resolution</td><td style="border:none;" align="left">2. Sensitive to patient movement</td></tr><tr><td style="border:none;" align="left">3.
Multiparametric imaging</td><td style="border:none;" align="left">3. Loud noise</td></tr><tr><td style="border:none;" align="left">4. Multiplanar imaging</td><td style="border:none;" align="left">4. Insensitive to calcification</td></tr><tr><td style="border:none;" align="left">5. Excellent soft tissue contrast</td><td rowspan="3" style="border:none;" align="left">5. Inferior imaging of lung lesions</td></tr><tr><td style="border:none;" align="left">6. No bone artifact</td></tr><tr><td style="border:none;" align="left">7. Versatile for
whole-body imaging</td></tr><tr><td rowspan="4" style="border:none;" align="left">CT</td><td style="border:none;" align="left">1. High density resolution</td><td style="border:none;" align="left">1. Ionizing radiation</td><td rowspan="4" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref58">58</xref>)</td></tr><tr><td style="border:none;" align="left">2. Cross-sectional imaging</td><td style="border:none;" align="left">2. Limited soft tissue contrast</td></tr><tr><td style="border:none;" align="left">3. Reconstructable
images</td><td style="border:none;" align="left">3. Motion artifacts</td></tr><tr><td style="border:none;" align="left">4. High spatial resolution</td><td style="border:none;" align="left">4. Metal artifacts</td></tr><tr><td rowspan="3" style="border:none;" align="left">PET-CT</td><td style="border:none;" align="left">1. Comprehensive
imaging</td><td style="border:none;" align="left">1. Radiation exposure</td><td rowspan="3" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref59">59</xref>, <xref ref-type="bibr" rid="ref60">60</xref>)</td></tr><tr><td style="border:none;" align="left">2. High sensitivity and specificity</td><td style="border:none;" align="left">2. Radiation
exposure</td></tr><tr><td style="border:none;" align="left">3. Staging and treatment planning</td><td style="border:none;" align="left">3. Special considerations</td></tr></tbody></table></table-wrap><p>The limited spatial resolution of ultrasound testing
may not allow
for detailed visualization of the internal structure of the atherosclerotic
plaque. For example, it may be difficult to accurately detect calcification
foci smaller than 0.2 mm within the plaque. In addition, ultrasonography
has difficulty in showing the spatial status of the plaque vessels
and may not be able to reflect the overall condition of the plaque
in a comprehensive and accurate manner. Although three-dimensional
ultrasound as well as ultrasonography can overcome the deficiencies
of two-dimensional ultrasound to a certain extent, there are still
some problems. For example, three-dimensional ultrasonography is easily
affected by the examiner&#x02019;s operating experience and variations
in the cut surface; ultrasonography lacks a standard evaluation method
for analyzing plaque neovascularization, and existing analysis methods
suffer from operator variation and poor reproducibility.</p><p>In
contrast, other imaging techniques such as MRI may have superior
performance in some aspects.<sup><xref ref-type="bibr" rid="ref61">61</xref></sup></p><p>For
example, MRI is able to sensitively and effectively detect
plaques of different natures, visualize vessel walls and perivascular
tissues, and is a safe and noninvasive examination. MRI has the highest
soft-tissue contrast resolution of all medical imaging tools, and
is able to clearly display soft-tissue structures such as muscle,
tendon, fascia, and fat. In atherosclerosis imaging, MRI can accurately
show structural changes in the vessel wall and its surrounding tissues,
which can help to identify pathological changes such as thickening
of the vessel wall and plaque formation.<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> MRI can also differentiate between structures such as plaques and
the surrounding vessel wall, and can even show the fibrous cap and
lipid core to assess plaque vulnerability. Through the use of specific
contrast agents, MRI can also identify the different components of
a plaque, thus assessing the stability of the plaque. However, MRI
takes longer and is not suitable for patients with pacemakers or metallic
implants, and is prone to artifacts.</p><p>CT is the opposite of MRI,
with CT imaging being short and efficient.<sup><xref ref-type="bibr" rid="ref63">63</xref></sup> However, CT examination has a certain degree
of radiation, although the radiation dose of modern CT equipment has
been greatly reduced, but long-term or frequent acceptance of CT examination
may still cause potential radiation damage to patients.</p><p>In addition,
some of the contrast agents used in the imaging process
may pose safety risks to the patient.</p><p>In general, traditional
imaging methods can achieve good results
with the assistance of contrast agents. Common contrast agents include
I, Gd, and BaSO<sub>4</sub>, each exhibiting distinct adverse reactions
over prolonged use.</p><p>For example, iodine provides significant
advantages in clear visualization
of lesions and enhanced CT imaging. However, some patients have allergic
reactions to iodine contrast agents, and in mild cases, symptoms such
as skin rash and itching may occur, while in severe cases, severe
reactions such as anaphylaxis may occur. Traditional small molecule
iodine contrast agents, such as iohexol and iopanoic acid, have small
molecular weights and are easily and rapidly excreted from the body
via the kidneys after injection, so they may cause some damage to
the kidneys, especially for patients with renal insufficiency, the
risk is greater.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> Gadolinium contrast
agents have a certain degree of nephrotoxicity, especially linear
gadolinium contrast agents, which may lead to serious kidney diseases,<sup><xref ref-type="bibr" rid="ref65">65</xref></sup> such as nephrogenic systemic fibrosis. Despite
the low incidence of allergic reactions to gadolinium contrast agents,
there is a risk of anaphylactoid reactions. Barium sulfate, which
is widely used for gastrointestinal tract imaging, has a relatively
high safety profile but still suffers from poor biocompatibility and
is not suitable for specific populations.<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> Consequently, clinicians must decide on the use of these agents
based on the patient&#x02019;s specific circumstances. Additionally,
these contrast agents typically lack targeting functions.</p></sec><sec id="sec3.1.2"><label>3.1.2</label><title>The Application of Nanomaterials in Imaging</title><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Summary Table of Nanomaterials</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">Common Nanomaterials</th><th style="border:none;" align="center">Advantages</th><th style="border:none;" align="center">Disadvantages</th><th style="border:none;" align="center">ref</th></tr></thead><tbody><tr><td rowspan="3" style="border:none;" align="left">SPIONs</td><td style="border:none;" align="left">1. Superparamagnetic</td><td style="border:none;" align="left">1. T2 negative
contrast agent</td><td rowspan="3" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref69">69</xref>&#x02212;<xref ref-type="bibr" rid="ref72">72</xref>)</td></tr><tr><td style="border:none;" align="left">2. Excellent biocompatibility</td><td rowspan="2" style="border:none;" align="left">2. Limited resolution</td></tr><tr><td style="border:none;" align="left">3. Multimodal
imaging</td></tr><tr><td rowspan="3" style="border:none;" align="left">Au NPs</td><td style="border:none;" align="left">1. High X-ray absorption properties</td><td rowspan="3" style="border:none;" align="left">1.
Poor stability in vivo</td><td rowspan="3" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref73">73</xref>, <xref ref-type="bibr" rid="ref74">74</xref>)</td></tr><tr><td style="border:none;" align="left">2. Easy surface
modification</td></tr><tr><td style="border:none;" align="left">3. Excellent biocompatibility
and low toxicity</td></tr><tr><td rowspan="2" style="border:none;" align="left">Bi<sub>2</sub>S<sub>3</sub> based nanomaterials</td><td style="border:none;" align="left">1. Strong near-infrared
absorption and high efficiency of photothermal
conversion, can be used for photothermal therapy</td><td rowspan="2" style="border:none;" align="left">1. Potential security risks</td><td rowspan="2" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref75">75</xref>, <xref ref-type="bibr" rid="ref76">76</xref>)</td></tr><tr><td style="border:none;" align="left">2. Excellent CT imaging</td></tr><tr><td rowspan="2" style="border:none;" align="left">WO3</td><td style="border:none;" align="left">1. Excellent CT imaging</td><td rowspan="2" style="border:none;" align="left">1. Poor biocompatibility</td><td rowspan="2" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref77">77</xref>)</td></tr><tr><td style="border:none;" align="left">2. Excellent photothermal performance</td></tr><tr><td rowspan="3" style="border:none;" align="left">LNPs</td><td style="border:none;" align="left">1. Excellent biocompatibility and
degradability</td><td rowspan="3" style="border:none;" align="left">1. Possible decrease in environmental
stability
in the body</td><td rowspan="3" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref78">78</xref>&#x02212;<xref ref-type="bibr" rid="ref82">82</xref>)</td></tr><tr><td style="border:none;" align="left">2. High drug loading capacity</td></tr><tr><td style="border:none;" align="left">3. Easily targeted modifications</td></tr><tr><td rowspan="3" style="border:none;" align="left">Dendritic macromolecules</td><td style="border:none;" align="left">1. High drug loading
capacity</td><td rowspan="3" style="border:none;" align="left">1. Complex metabolism in the body</td><td rowspan="3" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref83">83</xref>)</td></tr><tr><td style="border:none;" align="left">2. Excellent biocompatibility and water
solubility</td></tr><tr><td style="border:none;" align="left">3. Easily targeted modifications</td></tr><tr><td rowspan="3" style="border:none;" align="left">Polymer micelles</td><td style="border:none;" align="left">1. Can
integrate multiple imaging agents to achieve multimodality
imaging and improve diagnostic accuracy</td><td rowspan="3" style="border:none;" align="left">1. Vulnerability to in vivo distribution</td><td rowspan="3" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref84">84</xref>)</td></tr><tr><td style="border:none;" align="left">2. Excellent biocompatibility and stability</td></tr><tr><td style="border:none;" align="left">3. High drug loading capacity</td></tr><tr><td rowspan="4" style="border:none;" align="left">PBNPs</td><td style="border:none;" align="left">1. Multimodal imaging capability
with MRI and photoacoustic
imaging</td><td rowspan="4" style="border:none;" align="left">1. Lack of targeting of unmodified
nanoparticles</td><td rowspan="4" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref85">85</xref>)</td></tr><tr><td style="border:none;" align="left">2. Potential for photothermal
imaging</td></tr><tr><td style="border:none;" align="left">3. Excellent biocompatibility and
low toxicity</td></tr><tr><td style="border:none;" align="left">4. Easily surface modified and
functionalized</td></tr><tr><td rowspan="3" style="border:none;" align="left">Biomimetic membrane
nanoparticles</td><td style="border:none;" align="left">1. Excellent biocompatibility and stability</td><td rowspan="3" style="border:none;" align="left">1. Complicated preparation</td><td rowspan="3" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref86">86</xref>&#x02212;<xref ref-type="bibr" rid="ref92">92</xref>)</td></tr><tr><td style="border:none;" align="left">2. Strong targeting properties</td></tr><tr><td style="border:none;" align="left">3. High drug-carrying capacity</td></tr></tbody></table></table-wrap><p>While conventional organic contrast
agents may exhibit
varying
degrees of toxicity, some modified nanoparticles are often nontoxic,
and at the same time can be endowed with a number of desirable imaging
properties, making them ideal candidates for contrast agents.</p><p>Nanoparticles can be labeled with fluorescent dyes or radioactive
isotopes for use in imaging techniques such as CT, MRI, and PET.</p><p>A significant role of nanomaterials in imaging is their function
as probes for precise lesion area visualization. Targeted probes are
commonly employed for this purpose.<sup><xref ref-type="bibr" rid="ref67">67</xref></sup> These
probes typically consist of signal components and affinity components.
The signaling component, such as radioactive nuclides, fluorescein,
or paramagnetic atoms, generates imaging signals detectable by imaging
devices. The affinity components, also known as targeted molecules,
specifically bind to the target, such as antibodies or ligands.<sup><xref ref-type="bibr" rid="ref68">68</xref></sup></p><p>Nanomaterials widely used in AS can be
mainly classified into metallic
nanomaterials, organic nanomaterials and biological nanomaterials.
Common metallic nanomaterials include superparamagnetic iron oxide
nanoparticles (SPIONs), gold nanoparticles (Au NPs), cerium oxide
(CeO<sub>2</sub>) nanoparticles, bismuth sulfide (Bi<sub>2</sub>S<sub>3</sub>) based nanomaterials, nano tungsten oxide (WO3) and so on.
Organic nanomaterials include liposome nanoparticles (LNPs), dendritic
macromolecules, polymer micelles, Prussian blue nanoparticles (PBNPs),
etc. Biomimetic membrane nanoparticles are mainly some nanoparticles
modified in a way that mimics cell membranes.</p><p>While general
contrast agents can only monitor the overall morphology,
size and other characteristics of the plaque, nanomaterials can observe
the extent of the lesion at the molecular level. For example, surface-targeted
modification of magnetic iron oxide nanoparticles can obtain information
at the molecular level within the plaque, which is beneficial for
MRI detection of AS.<sup><xref ref-type="bibr" rid="ref93">93</xref>,<xref ref-type="bibr" rid="ref94">94</xref></sup> Dendrimers are a class of macromolecular
compounds with a regular structure and monodisperse nature, with a
typical symmetric core, inner shell and outer shell. The outer shell
has multiple terminal functional groups that provide a wide range
of space and binding sites for targeting molecules and therapeutic
agents.<sup><xref ref-type="bibr" rid="ref95">95</xref>,<xref ref-type="bibr" rid="ref96">96</xref></sup> More importantly, dendritic macromolecules
are able to overcome the short half-life, poor specificity and high
nephrotoxicity of traditional conventional imaging agents.<sup><xref ref-type="bibr" rid="ref97">97</xref>,<xref ref-type="bibr" rid="ref98">98</xref></sup> Thus, it can be used as an excellent carrier for molecular imaging
and contrast agents.</p><p>Nanomaterials such as these can be used
in disease imaging to more
accurately monitor disease states and can be effective in minimizing
many adverse effects.</p><sec id="sec3.1.2.1"><label>3.1.2.1</label><title>Ultrasound</title><p>Ultrasound is a technique
that uses high-frequency ultrasound waves to penetrate the human body
and visualize its internal structures,<sup><xref ref-type="bibr" rid="ref99">99</xref></sup> with the significant advantage of no damage from ionizing radiation,
and is therefore widely used in clinical practice as a low-cost, real-time,
noninvasive and safe imaging tool. Although ultrasound imaging can
reveal the basic morphological features of diseases, there are limitations
in its resolution, especially when displaying tiny lesions or fine
structures, which may be difficult to achieve the desired clarity.</p><p>To overcome this challenge, ultrasound molecular imaging has been
developed to improve the sensitivity and specificity of ultrasound
imaging. This technology greatly enhances the ultrasound signal in
the lesion area by introducing targeted contrast agents, providing
powerful support for early diagnosis of disease and real-time monitoring
of treatment efficacy. These ultrasound molecular contrast agents
typically consist of highly efficient carriers such as microbubbles
and nanoparticles, whose surfaces are carefully modified to carry
high-affinity molecules such as antibodies, peptides or small molecule
drugs, ensuring that they can precisely target-bind to pathologically
altered tissues or cells to provide accurate imaging of disease.</p><p>Triple-negative breast cancer (TNBC) is challenging to treat with
immunotherapy alone due to the tumor microenvironment. It has been
demonstrated that lactic acid produced by tumor cells affects tumor-associated
macrophages (TAMs), promoting the conversion from M1 to M2 macrophages.<sup><xref ref-type="bibr" rid="ref100">100</xref>&#x02212;<xref ref-type="bibr" rid="ref103">103</xref></sup> Additionally, the unfavorable tumor microenvironment can impair
the immune response, facilitating immune escape by tumor cells.<sup><xref ref-type="bibr" rid="ref104">104</xref></sup> Cisplatin can upregulate inflammation-related
genes and increase the proportion of dendritic or macrophage cells,
contributing to the formation of a more favorable microenvironment
for tumor therapy. However, cisplatin also upregulates certain autophagy
behaviors in tumor cells. Tumor autophagy is a key mediator of cytotoxic
T-lymphocyte immune escape and can inhibit the production of immune
cytokines. Therefore, inhibiting tumor cell autophagy may enhance
the efficacy of immunotherapy. Chloroquine (CQ), a drug that inhibits
autophagy by blocking the fusion of autophagosomes and lysosomes,
can be used in combination with cisplatin to attenuate the increase
in autophagy induced by cisplatin.</p><p>To enhance targeting and
reduce adverse reactions, researchers
utilized nanomaterials to load the drug and incorporated the imaging
agent perfluoroethane (PFH)<sup><xref ref-type="bibr" rid="ref105">105</xref></sup> to assist
with imaging. This approach facilitated phase change localization
and imaging through ultrasound treatment.<sup><xref ref-type="bibr" rid="ref106">106</xref></sup> The drug was released smoothly when the nanoparticles were exposed
to sonication and the hydrazone bonds were broken in the acidic environment.
The HPLC results indicated that the release rates of Pt and CQ from
the nanoparticles were significantly higher in the combination of
sonication than in the absence of sonication, and showed a significant
delayed release effect.</p><p>PFH undergoes a phase transition in
the presence of ultrasound,
resulting in enhanced ultrasound visualization of nanoparticles. In
the imaging effect evaluation experiment, the results indicated that
the negative control group produced almost no signal, whereas both
the experimental group and the positive control group exhibited strong
echogenic signals and clear ultrasound images. These findings demonstrated
that Pt(IV)/CQ/PFH NPs-DPPA-1 provides effective ultrasound imaging
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>).</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>(a) The mechanism
of Pt(IV)/CQ/PFH NPs-DPPA-1. (b) In vitro and
in vivo imaging maps, showing the negative control, positive control,
and experimental group from left to right. Reproduced with permission
from reference (<xref ref-type="bibr" rid="ref106">106</xref>). Copyright 2022 American Chemical Society.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0004" id="gr4" position="float"/></fig><p>As shown in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>b, the experimental group exhibited excellent imaging
results.</p><p>In addition to imaging with ultrasound alone, researchers
have
also tried to combine ultrasound with other imaging modalities. Based
on the potential of ultrasound as a source of energy to stimulate
molecules to emit light, combined with the principle of acoustic luminescence,
researchers have developed an innovative &#x02018;ultrasonic luminescence
imaging&#x02019; technology. The new imaging method uses ultrasound
to stimulate fluorescent molecules to generate luminescent signals
in vivo, enabling a new method of imaging with high-intensity optical
signal output.<sup><xref ref-type="bibr" rid="ref107">107</xref></sup> Compared to conventional
fluorescence imaging, this technique demonstrates multiple advantages
with lower background noise, higher signal-to-noise ratio, better
imaging sensitivity and deeper imaging depth. By implementing a two-step
internal energy conversion process, the research team successfully
screened trianthracene derivative-based nanoparticles (TD NPs), which
achieved significant enhancement in in vivo ultrasound-induced luminescence
imaging. The research data revealed that their ultrasound-induced
fluorescence intensity not only surpassed that of acoustic luminescence,
but also performed better in terms of signal-to-noise ratio, imaging
sensitivity and imaging depth. The ultrasound-excited luminescent
molecules developed in this study achieved a multifold enhancement
in luminescence intensity compared to conventional aqueous acoustic
luminescence signals. Compared to fluorescence imaging, the signal-to-noise
ratio of ultrasound-excited luminescence imaging is significantly
improved due to the absence of interference between the ultrasound
signal and the optical signal emission, while maintaining high resolution
and tissue penetration.</p></sec><sec id="sec3.1.2.2"><label>3.1.2.2</label><title>MR</title><p>MRI contrast
is usually generated
by inducing water proton relaxation, and Gd is an ideal candidate
for proton relaxation and therefore widely used in MRI.<sup><xref ref-type="bibr" rid="ref108">108</xref>,<xref ref-type="bibr" rid="ref109">109</xref></sup> However, free Gd<sup>3+</sup> is highly nephrotoxic and must be
administered in its stabilized form to prevent serious human toxicity.
Gd chelators can fulfill these conditions.<sup><xref ref-type="bibr" rid="ref110">110</xref></sup> The Gd chelator derivative Gd-DTPA can shorten the proton T1 relaxation
time and improve blood brightness, and thus is widely used in MR diagnosis
of vascular diseases.<sup><xref ref-type="bibr" rid="ref111">111</xref>,<xref ref-type="bibr" rid="ref112">112</xref></sup> Based on the great damage caused
by free Gd<sup>3+</sup> to the human body, stable chelating agents
can be chosen for the preparation of Gd contrast agents, which can
firmly encapsulate Gd<sup>3+</sup> and prevent it from freeing, thus
reducing the toxicity. Chelators with high thermodynamic and kinetic
stability can reduce the chance of Gd<sup>3+</sup> dissociation from
the chelator. In addition, the chelator structure can be optimized,
such as increasing the number of ligands or introducing more stable
ligands, thus improving the binding ability of the chelator to Gd<sup>3+</sup>. However, due to the small hydrodynamic size of small molecule
Gd chelates and the short blood circulation time, there are still
great challenges in high-resolution vascular imaging.<sup><xref ref-type="bibr" rid="ref113">113</xref></sup> Attachment of Gd chelates to the surface of
nanoparticles increases relativity, which may enhance MRI contrast.
Therefore, if gadolinium chelates are combined with functionalized
nanomaterials, the imaging benefits of gadolinium can be effectively
exploited and adverse effects can be reduced. For patients unable
to use Gd chelates, functionalized nanomaterials modifying Gd chelators
can present a safer alternative. Additionally, current research on
nanoparticles often integrates targeting, imaging, and drug delivery
functions, which are crucial for guiding clinical disease imaging
and treatment.</p><p>For example, the researchers coupled DTPA and
PAA to prepare a magnetic polymer carrier. Gd<sup>3+</sup> was then
cleaved with DTPA, resulting in a metal-chelating polymer called PAA-Gd.<sup><xref ref-type="bibr" rid="ref114">114</xref></sup> The ideal hydrodynamic size and structure gave
it an appropriate blood half-life and low immunogenicity. After a
series of experiments, it was determined that PAA-Gd exhibited a strong
safety profile. And in a disease model of atherosclerosis in mice,
the carotid artery, carotid vein, aortic arch and even vertebral artery
were clearly visualized after injection of PAA-Gd in the tail vein.
And fibrous stenosis could be seen in the middle of the common carotid
artery (yellow dashed part), which indicated that the 3D vascular
MRI contrast based on PAA-Gd could achieve precise targeting of the
thrombus portion (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>). To verify the MRI results, the experimenters performed
histological studies on mice. Endothelial damage and thrombosis of
aortic vessels could be detected by H&#x00026;E staining maps, which coincided
with the results of MRI, indicating that PAA-Gd can effectively improve
the imaging ability of MRI.</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>(a) Schematic drawing of the atherosclerosis
plaque model establishment.
(b) Representative PAA-Gd-enhanced 3D MR angiography at 5 min postcontrast,
for showing the vascular stenosis site (yellow dotted circle). (c)
Representative <italic>T</italic><sub>1</sub>-weighted images of plaque
section acquired pre- and at different time points postinjection of
PAA-Gd. Triplicates were performed independently with similar results.
(d) H&#x00026;E and &#x003b1;-SMA staining of tissue slices from external
carotid arteries. Triplicates were performed independently with similar
results. (e) Schematic drawing of the thrombosis and thrombolytic
therapy. (f) PAA-Gd-enhanced 3D angiography of mouse carotid thrombosis
pretreatment (obtained at 5 min after PAA-Gd injection), and the real-time
monitoring of thrombolytic therapy post-treatment of urokinase (uPA).
(The carotid thrombosis was identified by yellow dotted circle). (g)
Representative 2D time-of-flight (TOF) angiography of thrombus section
acquired pre- and 40 min post-treatment of uPA. Triplicates were performed
independently with similar results. (h) H&#x00026;E staining of bilateral
common carotid arteries. Triplicates were performed independently
with similar results. The embedded scale bar of frame (c), (c) inset,
(d), (g), and (h), corresponded to 2 mm, 0.5 mm, 50 &#x003bc;m, 2 mm,
and 100 &#x003bc;m. Reproduced with permission from reference (<xref ref-type="bibr" rid="ref114">114</xref>). Copyright 2023 PubMed
Central.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0005" id="gr5" position="float"/></fig><p>Phosphatidylinositol (PS) residues
externalized
in apoptotic cells
can trigger phagocytosis via the macrophage scavenger receptor pathway.
Imaging plaques with PS-containing liposomes to mimic apoptosis is
a promising approach. Researchers study PS-rich (Gd-PS) paramagnetic
liposomes in atherosclerotic plaques.<sup><xref ref-type="bibr" rid="ref115">115</xref></sup> Similarly, a research team prepared a Gd-containing liposome containing
CD36 ligand based on CD36 on the surface of macrophages, and showed
through experimental results that this functionalized liposome not
only highly accumulates in the area of plaque lesions, but also significantly
improves the imaging clarity.<sup><xref ref-type="bibr" rid="ref116">116</xref></sup></p><p>Ce is a key component of human glutathione peroxidase (GSH-PX)
and plays a critical role in antioxidant activity. Doping Gd into
CeO<sub>2</sub> nanoparticles effectively increases the surface ratio
of Ce<sup>3+</sup>, thereby simulating the activities of catalase
(CAT) and superoxide dismutase (SOD). This enhancement allows for
the effective clearance of reactive oxygen species (ROS),<sup><xref ref-type="bibr" rid="ref117">117</xref>&#x02212;<xref ref-type="bibr" rid="ref121">121</xref></sup> significantly alleviating vascular disease by reducing lipid accumulation
in macrophages and lowering inflammatory factors, which helps inhibit
the progression of atherosclerosis.<sup><xref ref-type="bibr" rid="ref122">122</xref></sup> Furthermore,
Gd/CeO<sub>2</sub> can act as a T1-weighted MRI contrast agent, providing
sufficient contrast to distinguish plaque locations during live imaging
(<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>). Due to
the damaged vascular endothelium in the plaque region, it may have
promoted a high degree of aggregation of nanoparticles in the plaque
region, further enhancing the imaging treatment effect.</p><fig id="fig6" position="float"><label>Figure 6</label><caption><p>Imaging effect
after Gd addition. (a) T1 images obtained after
coincubation of cells with the nanoparticle at different Gd concentrations.
(b) Linear plot of 1/T1 versus Gd concentration. (c) MR imaging of
the nanoparticles applied to C57 and ApoE<sup>&#x02013;/&#x02013;</sup> mice, respectively. Reproduced with permission from reference (<xref ref-type="bibr" rid="ref122">122</xref>). Copyright 2023 American
Chemical Society.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0006" id="gr6" position="float"/></fig><p>As shown in the figure,
T1 imaging efficiency for
this nanoparticle
is positively correlated with Gd concentration, enhancing MR imaging
effects in both in vitro and in vivo experiments.</p><p>Some nanomaterials
not only serve as carriers but also possess
physicochemical properties that aid in imaging or target specific
cells in the body. SPIONs exhibit magnetic targeting properties and
provide effective imaging in MRI. Liu Y synthesized a degradable amphiphilic
polymer, PIA-g-PEG-g-DDA, grafted with polyethylene glycol via free
radical polymerization. 5-Hydroxytryptamine (5-HT) was grafted onto
PIA-g-PEG-g-DDA through an esterification reaction to produce 5-HT-g-PIA-g-PEG-g-DDA.
This carrier specifically targets MPO within plaques.<sup><xref ref-type="bibr" rid="ref123">123</xref></sup> The carrier, coated on the surface of SPIONs,
facilitates precise imaging of the lesion area. Carbon fluorescence
quantum dots are adsorbed via electrostatic interactions to produce
dual-mode imaging nanoprobes with T2 imaging and optical imaging functions.
This nanocarrier not only offers precise targeted imaging but also
features low toxicity and easy degradation, making it advantageous
as both a contrast agent and a carrier.</p></sec><sec id="sec3.1.2.3"><label>3.1.2.3</label><title>CT</title><p>Bismuth-based nanomaterials
are highly sensitive to X-rays and hold significant potential for
CT imaging and other applications. Studies have shown that inorganic
bismuth-based materials, with their high atomic numbers and X-ray
attenuation coefficients, are ideal contrast agents for CT imaging.
Consequently, bismuth-based nanomaterials have promising prospects
in imaging and tumor treatment.</p><p>Initially, bismuth was investigated
as a protective agent to reduce radiation during CT examinations.
Subsequent studies found that bismuth agents could reduce radiation
in superficial areas without compromising image quality. Some bismuth-based
nanoparticles, due to their high X-ray absorption and extended in
vivo circulation time, can serve as alternatives to conventional iodine-based
CT contrast agents. Bi<sub>2</sub>S<sub>3</sub> nanoparticles prepared
by Rabin&#x02019;s team demonstrated minimal cytotoxicity compared
to the same dose of free Bi<sup>3+</sup>, thereby ensuring high-quality
CT imaging while reducing the risk of adverse effects associated with
conventional contrast agents.<sup><xref ref-type="bibr" rid="ref124">124</xref></sup></p><p>To significantly enhance the CT imaging effect of bismuth-based
nanomaterials,<sup><xref ref-type="bibr" rid="ref125">125</xref></sup> researchers prepared
ultrasmall (BiO)<sub>2</sub>CO<sub>3</sub> nanoclusters (BNCs) from
bismuth subcarbonate ((BiO)<sub>2</sub>CO<sub>3</sub>) nanotubes (BNTs)
(<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>). The preparation
considered two critical factors: X-ray attenuation and cyclic half-life.
Experimental results demonstrated that BNTs exhibited strong targeting
capability and an excellent plasma half-life.<sup><xref ref-type="bibr" rid="ref126">126</xref></sup> BNTs can be decomposed into BNCs in acidic environments,
thus providing powerful imaging capabilities.</p><fig id="fig7" position="float"><label>Figure 7</label><caption><p>Schematic diagram of
the synthesis and principle of action of BNTs.
(a) Schematic illustration of the formation of BNTs. (b) Schematic
illustration of tumor-homing of elongated BNTs, CT imaging-guided
radio-/chemotherapy mediated by the BNTs/drug, and subsequent BNTs
disassembly and renal clearance. Reproduced with permission from reference (<xref ref-type="bibr" rid="ref124">124</xref>). Copyright 2018 American
Chemical Society.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0007" id="gr7" position="float"/></fig><p>In vivo experiments showed
that BNCs had a short
plasma half-life
and were rapidly cleared from the body, whereas BNTs remained in the
target area for a longer duration and demonstrated superior imaging
effects. CT imaging confirmed that BNTs provided better imaging capabilities
compared to BNCs.</p></sec><sec id="sec3.1.2.4"><label>3.1.2.4</label><title>Multimodal Imaging</title><p>With the growing
recognition of the advantages of multimodal imaging, researchers have
been developing nanoparticles that integrate multiple imaging modalities
to further enhance imaging effects for disease treatment.<sup><xref ref-type="bibr" rid="ref127">127</xref>,<xref ref-type="bibr" rid="ref128">128</xref></sup></p><p>Tu&#x02019;s team developed a contrast agent capable of cleaving
nanoparticles with multifunctional imaging effects based on matrix
metalloproteinases in macrophages (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref>a). The researchers derivatized iron oxide
nanoparticles with 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA),
labeled them with <sup>64</sup>Cu as a nuclear tracer, and modified
the MMP-2 cleavage peptide with PEG2000.<sup><xref ref-type="bibr" rid="ref129">129</xref></sup> This led to the creation of a multimodal imaging nanoparticle named <sup>64</sup>Cu-NOTA-IONP@MMP2cPEG2K (MMP2cNPs).<sup><xref ref-type="bibr" rid="ref130">130</xref></sup> These nanoparticles demonstrated multimodal precision imaging capabilities,
as confirmed by combined experimental results.</p><fig id="fig8" position="float"><label>Figure 8</label><caption><p>(a) The mechanism of
MMP2cNPs. (b) The representative in vivo PET,
CT, and PET/CT images of mice models with carotid atherosclerotic
plaques at 4 h after injection of MMP2cNPs. (c) Coronal PET images
of mice models with carotid atherosclerotic plaques at 1 h, 2 h, 4
h, 12 and 24 h after injection of MMP2cNPs or MMP2ncNPs. (d) In vivo
CL57/BL6 mice with carotid atherosclerotic plaque MRIs obtained before
and 24 h after administration of MMP2cNPs or MMP2ncNPs at a dose of
10 mg iron/kg (red arrow, cross section of the carotid artery). <italic>International Journal of Nanomedicine</italic><bold>2022</bold>, <italic>17</italic>, 6773&#x02013;6789. Originally published by and used with
permission from Dove Medical Press Ltd. Reproduced with permission
from reference (<xref ref-type="bibr" rid="ref130">130</xref>). Copyright 2022 PubMed Central.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0008" id="gr8" position="float"/></fig><p>Atherosclerotic lesions in the left carotid artery
were clearly
visible 4 h after injection of MMP2cNPs, showing high contrast with
the low background in the contralateral artery (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref>b). In contrast, no PET signal was detected
in the carotid plaques of mice injected with MMP2ncNPs, indicating
that cleavable nanoparticles offer significant in vivo imaging capabilities
and prolonged action.</p><p>Imaging was clearer following the injection
of MMP2cNPs. MMP2cNPs,
being less water-soluble than MMP2ncNPs, exhibited slower diffusion
in the plaques, resulting in extended in vivo retention and enhanced
imaging selectivity and sensitivity (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref>c, <xref rid="fig8" ref-type="fig">8</xref>d).</p><p>Additionally,
researchers can optimize the lifespan, tissue distribution,
biocompatibility, and targeting of nanoparticles by modifying their
surface chemistry, size, and shape, thereby improving their utilization.<sup><xref ref-type="bibr" rid="ref131">131</xref>,<xref ref-type="bibr" rid="ref132">132</xref></sup></p><p>For instance, researchers evaluated lipid, macrophage, and
cholesterol
crystal properties in atherosclerosis-prone plaques using media depolarization
index based on catheter-based polarized bright&#x02013;dark optical
coherence tomography (PS-OCT).<sup><xref ref-type="bibr" rid="ref133">133</xref></sup> This
study demonstrated that EMDI has a high plaque recognition rate and
that PS-OCT provides excellent imaging results.</p></sec></sec></sec><sec id="sec3.2"><label>3.2</label><title>Application of Nanomaterials in the Treatment
of Atherosclerosis</title><sec id="sec3.2.1"><label>3.2.1</label><title>Traditional Treatment
Methods</title><p>The
treatment of AS can generally be categorized into medications and
other therapeutic approaches (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>).</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Advantages and Disadvantages of Traditional
Treatment Methods</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">Treatment methods</th><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">Advantages</th><th style="border:none;" align="center">Disadvantages</th><th style="border:none;" align="center">ref</th></tr></thead><tbody><tr><td rowspan="9" style="border:none;" align="left">Drugs</td><td rowspan="2" style="border:none;" align="left">Lipid-Lowering Drugs</td><td style="border:none;" align="left">1. Therapeutic effectiveness</td><td style="border:none;" align="left">1. Side effects</td><td rowspan="9" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref134">134</xref>)</td></tr><tr><td style="border:none;" align="left">2. Multiple targets</td><td style="border:none;" align="left">2. Drug
interactions</td></tr><tr><td rowspan="4" style="border:none;" align="left">Anti-Inflammatory
Drugs</td><td style="border:none;" align="left">1. Significant anti-inflammatory effect</td><td style="border:none;" align="left">1. Liver function impairment</td></tr><tr><td style="border:none;" align="left">2. Improvement
of endothelial function</td><td style="border:none;" align="left">2. Renal injury</td></tr><tr><td style="border:none;" align="left">3. Antithrombotic and antioxidant effects</td><td rowspan="2" style="border:none;" align="left">3. Rhabdomyolysis</td></tr><tr><td style="border:none;" align="left">4. Enhanced
therapeutic effect</td></tr><tr><td rowspan="3" style="border:none;" align="left">Vasodilators</td><td style="border:none;" align="left">1. Improvement of blood flow</td><td style="border:none;" align="left">1. Potential for
tolerance</td></tr><tr><td style="border:none;" align="left">2. Relief of symptoms</td><td style="border:none;" align="left">2. Drug interactions</td></tr><tr><td style="border:none;" align="left">3. Prevention of complications</td><td style="border:none;" align="left">3. Side effects</td></tr><tr><td rowspan="11" style="border:none;" align="left">Others</td><td rowspan="4" style="border:none;" align="left">CABG surgery</td><td style="border:none;" align="left">1. Improved blood supply</td><td style="border:none;" align="left">1. Invasive procedure</td><td rowspan="11" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref135">135</xref>, <xref ref-type="bibr" rid="ref136">136</xref>)</td></tr><tr><td style="border:none;" align="left">2.
Long-term survival</td><td style="border:none;" align="left">2. Potential complications</td></tr><tr><td rowspan="2" style="border:none;" align="left">3. Wider applicability</td><td style="border:none;" align="left">3. Limited graft availability</td></tr><tr><td style="border:none;" align="left">4. Reoperation
risk</td></tr><tr><td rowspan="3" style="border:none;" align="left">PCI</td><td style="border:none;" align="left">1. minimally
invasive</td><td style="border:none;" align="left">1. Restenosis</td></tr><tr><td style="border:none;" align="left">2. Effective
treatment</td><td style="border:none;" align="left">2. Need for long-term medication</td></tr><tr><td style="border:none;" align="left">3. Wide applicability</td><td style="border:none;" align="left">3. Limited durability</td></tr><tr><td rowspan="4" style="border:none;" align="left">RA</td><td style="border:none;" align="left">1. Effective removal
of calcified plaque</td><td style="border:none;" align="left">1. Potential complications</td></tr><tr><td style="border:none;" align="left">2. Treatment of complex lesions</td><td style="border:none;" align="left">2.
Restenosis</td></tr><tr><td style="border:none;" align="left">3. Distinction between plaque
and healthy tissue</td><td rowspan="2" style="border:none;" align="left">3. Need for adjunctive
therapies</td></tr><tr><td style="border:none;" align="left">4. Advanced technology</td></tr></tbody></table></table-wrap><p>Additionally, methods such
as coronary radiation therapy
are also
available. The choice of specific treatment should be tailored to
the patient&#x02019;s individual condition to achieve the best therapeutic
outcomes.</p></sec><sec id="sec3.2.2"><label>3.2.2</label><title>Application of Nanomaterials
in Treatment</title><p>Nanomaterials are incorporated into nanomedicines
using nanotechnology,
entering the body through various forms of nano dispersion systems
to exert their therapeutic effects (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>). With advancements in nanotechnology, nanoparticles,
nanoliposomes, solid lipid nanoparticles (SLNs), nanospheres, nanocapsules,
nanoemulsions, and polymer micelles are among the popular nanomaterials.<sup><xref ref-type="bibr" rid="ref137">137</xref></sup></p><fig id="fig9" position="float"><label>Figure 9</label><caption><p>Mechanisms of nanomaterials. Common and desirable nanomaterials
generally function as carriers while also providing targeting and
imaging capabilities for precision therapy. Besides drug delivery,
nanoparticles often encapsulate fluorescent or contrast agents. To
avoid phagocytosis and prolong their half-life, nanoparticles may
incorporate components with high biocompatibility, such as macrophage
membranes. Additionally, bioactive substances on the surface of nanoparticles
can enhance precision therapy through high affinity to the target.
In animal experiments, nanoparticles reach the plaque site following
tail vein injection and release various components that influence
inflammatory factors in the plaque environment. Some nanoparticles
can even promote macrophage polarization to the M2 phenotype, contributing
to disease treatment. For imaging, the inclusion of contrast agents
enhances MRI efficiency, while fluorescent agents significantly improve
fluorescence imaging, resulting in clearer visualization of diseases.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0009" id="gr9" position="float"/></fig><p>Nanomaterials as drug carriers can enhance the
absorption of poorly
soluble oral drugs, deliver drugs with poor bioavailability or efficacy
via conventional routes more accurately to the target, and reduce
waste and adverse reactions. Additionally, nanomaterials can serve
as contrast agents to target lesion locations, thereby facilitating
clinical treatment.<sup><xref ref-type="bibr" rid="ref138">138</xref></sup> Key characteristics
of nanocarriers generally include: Affinity: This includes the affinity
between the nanocarrier and the loaded drug, as well as the affinity
with the in vivo target. Stability: This refers to the binding stability
of drugs and targets, as well as the stability of the internal environment.
Effective nanocarriers maintain stable efficacy over time, exhibit
slow metabolism and easy excretion, and do not cause biological accumulation.</p><p>Nanomaterials not only function as probes for targeted imaging
but also integrate imaging, drug delivery, and targeted localization.
They exhibit varying effects at different stages and reactions in
the treatment of AS.</p><sec id="sec3.2.2.1"><label>3.2.2.1</label><title>Inhibiting Inflammatory
Response</title><p>During the development of AS, the release of inflammatory
factors
promotes the transformation of monocytes into macrophages, which then
become foam cells.<sup><xref ref-type="bibr" rid="ref139">139</xref></sup> This inflammatory
reaction contributes to vascular endothelial damage, lipid metabolism
disorders, and plaque expansion in AS. Given the numerous inflammatory
targets, inhibiting inflammation is a critical aspect of AS treatment.</p><p>In AS plaques, CD4+ helper T (Th) cells are the primary adaptive
effector cells, responding to presented apolipoproteins. Th1 cells
secrete factors that stimulate macrophage transformation and AS formation,
while Th2 cells promote the production of IL-4, IL-5, IL-13, and IL-33.
IL-4 promotes AS, whereas IL-5, IL-13, and IL-33 have anti-inflammatory
effects and inhibit AS formation. Macrophages activated by different
stimuli primarily differentiate into M1 and M2 phenotypes. M1 macrophages,
driven by Th1 responses, produce inflammatory factors, while M2 macrophages,
influenced by Th2 responses, exhibit anti-inflammatory effects. Therefore,
polarizing M1 macrophages to M2 macrophages can effectively counteract
inflammation and support AS development.</p><p>The sulfonylurea derivative
glyburide, a medication for type 2
diabetes, exhibits anti-inflammatory properties. It can polarize proinflammatory
M1 macrophages into M2 macrophages and inhibit T cell immune responses.
However, glyburide&#x02019;s hydrophobic nature and instability in
the circulatory system pose challenges. To address this, a research
team developed PLGA nanoparticles loaded with anti-inflammatory liposomes
and coated with red blood cell membranes.<sup><xref ref-type="bibr" rid="ref140">140</xref></sup> These nanoparticles were characterized both physically and chemically,
and their drug release profiles were studied after confirming biocompatibility.
RT-PCR results demonstrated a reduction in inflammatory gene expression,
including NLRP3, IL-1&#x003b2;, IL-18, caspase-1, caspase-8, and caspase-9,
indicating potential for cellular uptake, inhibition of inflammatory
genes, and prevention of plaque formation in rabbit AS models.</p><p>During AS onset, a significant number of inflammatory cells are
recruited near white blood cells (WBCs). To exploit this, white blood
cell membranes were used to encapsulate magnetic nanoclusters (MNCs)
with excellent superparamagnetism. These MNCs were embedded with the
anti-inflammatory drug simvastatin and modified with the targeted
apolipoprotein A-I mimetic peptide L-4F (AP) to produce MNC@M-ST/AP.
This nanoparticle targets early AS lesions, achieves precise drug
release, blocks further inflammatory responses, and delays or prevents
plaque formation and diffusion.<sup><xref ref-type="bibr" rid="ref141">141</xref></sup> Additionally,
the membrane shell allows for the loading of hydrophobic drugs, addressing
issues of poor water solubility. The embedded AP inhibits the assimilation
of ox-LDL, facilitates TC outflow, and demonstrates excellent safety
in pathological and clinical biochemical analyses.</p><p>Due to its
excellent targeting and immune escape capabilities,
the macrophage membrane has recently emerged as a crucial biological
membrane material for nanoparticles. Studies have demonstrated that
macrophage membranes contain CD47 protein and integrin &#x003b1;4/&#x003b2;1
receptors. The CD47 protein effectively prevents cells from being
engulfed, while integrin &#x003b1;4/&#x003b2;1 binds to macrophages via
endothelial adhesion factors on vascular endothelial cells, thereby
facilitating plaque targeting. Building on this concept, our team
designed and prepared macrophage membrane-coated colchicine nanoparticles,
modified with CD47 and integrin, named MMM/COL NPs.<sup><xref ref-type="bibr" rid="ref142">142</xref></sup> The CD47 protein protects the nanoparticles from being
engulfed, while integrin guides them to precisely target macrophages
infiltrating plaques. Colchicine is then released to exert its anti-inflammatory
therapeutic effects. In vitro and in vivo experimental results demonstrate
that these nanoparticles effectively reduce foam cell formation, downregulate
pro-inflammatory factor expression, exhibit excellent plaque targeting,
stabilize plaques, and show good safety for major organs.</p></sec><sec id="sec3.2.2.2"><label>3.2.2.2</label><title>Inhibiting Oxidative Stress</title><p>Oxidative
Stress (OS) is a state in which there is an imbalance between oxidative
and antioxidant effects in the body, tending to oxidize, resulting
in an inflammatory infiltration of neutrophils, an increase in the
secretion of proteolytic enzymes, and the production of large amounts
of oxidative intermediates. Oxidative stress is a negative effect
produced in the body by free radicals and has been implicated as an
important factor in the exacerbation of AS.</p><p>ROS are byproducts
of oxidative metabolism in the body with strong oxidizing properties.
ROS can oxidize LDL to form ox-LDL, which damages endothelial cells,
induces monocyte adhesion and chemotaxis to the endothelium, and promotes
macrophage foam cell formation, thereby contributing to plaque development.
Consequently, utilizing nanotechnology to efficiently eliminate free
radicals is a major therapeutic approach for AS.</p><p>In recent years,
iron oxide-cerium oxide core&#x02013;shell nanoparticles
have emerged as promising materials for addressing ROS-related inflammatory
diseases such as AS.<sup><xref ref-type="bibr" rid="ref143">143</xref></sup> Research indicates
that these nanoparticles can effectively clear ROS and provide excellent
MRI performance in vitro.</p><p>To counteract ROS effects, Liu R developed
ROS-responsive and scavenging
material TPCD, which was loaded with the anti-inflammatory drug Darapladib
that selectively inhibits lipoprotein-associated phospholipase A2
(LP-PLA2), creating TPCD-DA NP through nanotechnology.<sup><xref ref-type="bibr" rid="ref144">144</xref></sup> In vitro cell experiments revealed that the
nanoparticles effectively reduce intracellular ROS levels and oxidative
stress-induced cellular aging. In vivo studies demonstrated that TPCD-DA
NP significantly reduced the area of aortic plaques and effectively
modulated atherosclerosis development. Additionally, the nanoparticles
improved the reduction in gut microbiota abundance caused by a high-fat
diet, thus reducing aortic plaque area.</p><p>Based on the mechanism
by which epigallocatechin gallate (EGCG)
blocks fatty acid-induced expression of caveolin-1 and cyclooxygenase-2
(COX-2), EGCG can act as an antioxidant, while Distearoylphosphatidylcholine
(DSPC) serves as the main carrier to load Simvastatin (SIM), forming
liposome nanoparticles (SE LNPs).<sup><xref ref-type="bibr" rid="ref145">145</xref></sup></p><p>Experimental results have demonstrated that these nanoparticles
exhibit ROS responsiveness, antioxidant properties, antiapoptotic
effects, and promote M2 macrophage polarization.<sup><xref ref-type="bibr" rid="ref146">146</xref></sup> Additionally, the liposomal formulation provides sustained
drug release, thereby prolonging the drug&#x02019;s in vivo retention
time and enhancing its therapeutic efficacy.</p><p>NF-E2 related factor
2 (Nrf2) is a transcription factor activated
by high levels of ROS, which regulates downstream target genes encoding
detoxification factors, antiapoptotic proteins, antioxidant enzymes,
and drug efflux transporters. Activation of Nrf2 leads to the reduction
of oxidative damage and repair of damaged proteins.<sup><xref ref-type="bibr" rid="ref147">147</xref></sup> To selectively deliver Nrf2 activators, CDDO-Me (a potent
Nrf2 activator) is encapsulated into nanoparticles to produce antioxidant-activated
nanoparticles (ARAPas).<sup><xref ref-type="bibr" rid="ref148">148</xref></sup> In vitro experiments
have shown that ARAPas significantly induce the activation of the
antioxidant enzyme HO-1 in macrophages. This effectively provides
anti-inflammatory effects, inhibits disease progression due to inflammation,
and plays a crucial role in managing atherosclerosis.</p><p>Based
on the inflammatory mechanism of AS pathology, Liu Shun designed
a multifunctional drug delivery system targeting macrophages, with
sensitivity to pH and ROS. One component is a nano micelle targeting
macrophages with ROS sensitivity (HASC@Cur).<sup><xref ref-type="bibr" rid="ref149">149</xref></sup> Another component is a multifunctional nanocarrier responsive to
hyaluronic acid and pH, designed for chemical and photothermal synergistic
therapy for AS (Cus@DMSN-N = C-HA). This system has successfully achieved
precise drug delivery and controlled release, as well as synergistic
chemical and photothermal therapy. Compared to single-targeted treatment
methods, this multifunctional drug delivery system has demonstrated
significant advancements in both innovation and therapeutic efficacy.</p><p>Our team synthesized a nanoparticle combining targeted delivery
and ROS responsiveness. This nanoparticle uses a biodegradable polymer
micelle composed of polyethylene glycol-poly(tyrosine-ethyl oxaloacetate)
(PEG-Pyr-EO) encapsulated in hyaluronic acid (HA), carrying Simvastatin
(SIM). This formulation aims to inhibit macrophages and reduce ROS
levels to treat atherosclerosis.</p><p>HA targets inflammatory macrophages
due to CD44, a specific marker
that is highly expressed in inflammatory regions. As a result, HA
enhances targeting to inflammatory sites in plaques. PEG-Pyr-EO reacts
with H<sub>2</sub>O<sub>2</sub>, consuming it in a concentration-dependent
manner, which means that the drug delivery rate increases with higher
concentrations of H<sub>2</sub>O<sub>2</sub>. This specificity minimizes
the impact on normal tissues, thereby improving safety (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>).</p><fig id="fig10" position="float"><label>Figure 10</label><caption><p>Preparation route and
targeted delivery process of SIM from SHPEMs.
SIM: simvastatin; HA: hyaluronic acid; SHPEMs: SIM-loaded amino-PEG-Ptyr-EO
micelles; SHPEMs: SIM-loaded HA-coated amino-PEG-Ptyr-EO micelles.
Reproduced with permission from ref (<xref ref-type="bibr" rid="ref150">150</xref>). Copyright 2020 PubMed Central.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0010" id="gr10" position="float"/></fig><p>Simultaneously, the SIM released at the lesion
site can maximize
antioxidant effects, enhance synergistic treatment, and improve efficacy.
Our results show that the nanoparticles effectively reduced cholesterol
content in atherosclerotic mice and produced significant therapeutic
effects without causing adverse reactions (<xref rid="fig11" ref-type="fig">Figure <xref rid="fig11" ref-type="fig">11</xref></xref>).<sup><xref ref-type="bibr" rid="ref150">150</xref></sup></p><fig id="fig11" position="float"><label>Figure 11</label><caption><p>Results of
pathological experiments in mice. (a) Ratio of plaque
area to total area. (b) H&#x00026;E staining of the heart, liver, spleen,
lung, and kidney from mice in each group. (c) SIM: simvastatin; SPEMs:
SIM-loaded amino-PEG-Ptyr-EO micelles; SHPEMs: SIM-loaded HA-coated
amino-PEG-Ptyr-EO micelles. Reproduced with permission from ref (<xref ref-type="bibr" rid="ref150">150</xref>). Copyright 2020 PubMed
Central.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0011" id="gr11" position="float"/></fig><p>In the ApoE<sup>&#x02013;/&#x02013;</sup> AS mouse
model, dandelion
polysaccharides were administered as treatment. After treatment, levels
of HDL-C, SOD, and GSH-PX in the serum increased, while LDL-C, malondialdehyde
(MDA) were significantly reduced.<sup><xref ref-type="bibr" rid="ref151">151</xref></sup> This
indicates that dandelion polysaccharides have antioxidant effects
in AS and hold potential as an important drug for its treatment. This
advancement could significantly enhance the field of antioxidant drugs,
potentially elevating AS treatment methods to a higher level.</p><p>Wei Tao&#x02019;s team synthesized BPNSs-PEG-S2P/R based on black
phosphorus nanosheets (BPNSs) as the main body, modified S2P peptide,
and loaded with Resolvin D1 (RvD1), which promotes the process of
cytosolic burial.<sup><xref ref-type="bibr" rid="ref152">152</xref></sup> The study demonstrated
that the BPNSs possessed an excellent ROS scavenging effect,<sup><xref ref-type="bibr" rid="ref153">153</xref>,<xref ref-type="bibr" rid="ref154">154</xref></sup> and the S2P had a high affinity with stablin-2 expressed on the
macrophages&#x02019; surface in the plaques.<sup><xref ref-type="bibr" rid="ref155">155</xref></sup> The experimental results showed that BPNSs-PEG-S2P/R significantly
reduced ROS levels and elevated the expression levels of antioxidant
factors such as glutathione (GSH) and SOD. It also facilitated oxidative
phosphorylation and fatty acid oxidation at the plaques, thus promoting
cytosolic burial, reducing necrotic cores, and stabilizing plaques.</p></sec><sec id="sec3.2.2.3"><label>3.2.2.3</label><title>Adjusting Ferroptosis</title><p>Ferroptosis,
an iron-dependent form of nonapoptotic cell death, has an important
role in the development of cardiovascular disease.<sup><xref ref-type="bibr" rid="ref156">156</xref>,<xref ref-type="bibr" rid="ref157">157</xref></sup> The key to ferroptosis is the iron-catalyzed peroxidation of phospholipids
(PLs) containing polyunsaturated fatty acids (PUFA&#x02013;PLs), leading
to the lethal accumulation of lipid peroxides in the cell membrane
and cell membrane rupture, which ultimately leads to cell death.<sup><xref ref-type="bibr" rid="ref158">158</xref>&#x02212;<xref ref-type="bibr" rid="ref160">160</xref></sup> Ferroptosis plays a significant role in exacerbating AS. Therefore,
exploring the mechanism of ferroptosis is a crucial step in treating
AS.</p><p>The mechanisms of ferroptosis can be categorized into two
main processes: the Fenton reaction induced by free iron and the lipid
peroxidation process catalyzed by fatty acid enzymes.<sup><xref ref-type="bibr" rid="ref161">161</xref></sup> During transport, Fe<sup>3+</sup> in the body
is reduced to Fe<sup>2+</sup> by the STEAP3 protein. Fe<sup>2+</sup> then reacts with peroxides to form peroxide bonds, which oxidize
lipids, ultimately leading to plaque formation.</p><p>The clearance
of intracellular peroxides primarily depends on the
action of glutathione peroxidase 4 (GPX4).<sup><xref ref-type="bibr" rid="ref162">162</xref></sup> GPX4 uses GSH as a substrate to reduce lipid peroxides to normal
phospholipid molecules. Consequently, GPX4 is a key target for many
therapeutic agents aimed at inhibiting ferroptosis.</p><p>Ferroptosis
is closely related to lysosomal function: activating
iron autophagy, such as molecular chaperone-mediated autophagy, promotes
the degradation of GPX4, leading to increased lipid peroxidation and
ferroptosis.<sup><xref ref-type="bibr" rid="ref163">163</xref></sup> Additionally, the release
of lysosomal cathepsin (CTSB) can also trigger ferroptosis.<sup><xref ref-type="bibr" rid="ref164">164</xref></sup> Furthermore, the accumulation of lysosomal
iron or nitric oxide strongly promotes ferroptosis.<sup><xref ref-type="bibr" rid="ref165">165</xref></sup></p><p>During oxidative phosphorylation, increased ROS in
mitochondria
further contributes to ferroptosis, which can be inhibited by mitochondria-targeted
antioxidants or enzymes.<sup><xref ref-type="bibr" rid="ref166">166</xref></sup> Thus, iron
death inhibitors can be categorized into those targeting iron ions,
ROS, lysyl oxidase (LOX), etc.<sup><xref ref-type="bibr" rid="ref167">167</xref></sup></p><p>Regulating ferroptosis is crucial in treating AS. Researchers have
employed nanomaterials to study ferroptosis in vivo, aiming to control
the pathological progression of AS. Nanoparticles such as MoS2 can
cause lysosomal dysfunction, leading to Fe<sup>2+</sup> release, lipid
peroxidation through the Fenton reaction, and subsequent ferroptosis.
Zero-valent iron (ZVI) induces the oxidation of ZVI to Fe<sup>2+</sup>, assisting in oxidative reactions, promoting mitochondrial lipid
peroxidation, and regulating ferroptosis. Iron-based nanoparticles
(FeNPs) can release Fe<sup>2+</sup> or Fe<sup>3+</sup> in acidic lysosomes,
inducing cellular ferroptosis.<sup><xref ref-type="bibr" rid="ref168">168</xref></sup> Nanoparticles
similar to Au increase the expression of the intercellular adhesion
protein E-cadherin, thereby inhibiting ferroptosis.<sup><xref ref-type="bibr" rid="ref169">169</xref></sup></p><p>Based on the principle of the Fenton reaction, we
prepared nanoparticles
called HFTNPs through chemical treatment. HFTNPs is mainly composed
of three parts: dopamine-modified hyaluronic acid(HD), ferricion,
Tannic acid (TA). As mentioned, HA has a high affinity for CD44 on
macrophage membranes, making it a targeted approach.<sup><xref ref-type="bibr" rid="ref170">170</xref>,<xref ref-type="bibr" rid="ref171">171</xref></sup> TA serves both as an iron carrier and a reductant of iron ions.
Ferricion is a key component in the Fenton reaction and also functions
as an important contrast agent for MRI.<sup><xref ref-type="bibr" rid="ref172">172</xref></sup></p><p>Our results indicate that the nanoparticles are highly concentrated
in inflammatory macrophages, enhancing ROS production and promoting
the apoptosis of inflammatory macrophages without impairing normal
cell activity.</p><p>ROS levels increased after LPS treatment, while
ROS production
decreased in the presence of TA (<xref rid="fig12" ref-type="fig">Figure <xref rid="fig12" ref-type="fig">12</xref></xref>). However, with HFTNPs, ROS levels increased,
inducing inflammatory macrophage death via the Fe response and exerting
an antiatherosclerotic effect. The regulation of the ferroptosis process
and related cellular molecules can also serve as a novel approach
for treating AS.</p><fig id="fig12" position="float"><label>Figure 12</label><caption><p>Rate of intracellular ROS production with different treatments
over time. (a) Representative fluorescent images of LPS-activated
Raw264.7 macrophages incubated with TA, HD-Fe<sup>3+</sup>, and HFTNPs
for 15, 30, and 60 min, respectively. Raw264.7 macrophages were treated
with PBS as control. TA: 29.4 &#x003bc;M, iron: 117.6 &#x003bc;M. Scale
bars: 100 nm. (b) Quantitative analysis of LPS-activated Raw264.7
cells incubated with PBS, TA, HD-Fe<sup>3+</sup>, and HFTNPs for 15,
30, and 60 min by flow cytometry. LPS + HFTNPs vs LPS: **<italic>p</italic> &#x0003c; 0.01; LPS + TA vs LPS: <sup><italic>#</italic></sup><italic>p &#x0003c;</italic>0.05 and <sup>##</sup><italic>p</italic> &#x0003c; 0.01.
Reproduced with permission from ref (<xref ref-type="bibr" rid="ref172">172</xref>). Copyright 2021 American Chemical Society.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0012" id="gr12" position="float"/></fig></sec><sec id="sec3.2.2.4"><label>3.2.2.4</label><title>Endothelial Protection</title><p>It is
well-known that the initiation of atherosclerosis, as well as the
key pathophysiological process of vascular restenosis after interventional
procedures, involves damage to the vascular endothelium. Therefore,
accelerating the process of reendothelialization of damaged vessels
and restoring the normal function of endothelial cells are essential
to promote positive regression of such diseases. Endothelial progenitor
cells (EPCs), derived from hematopoietic stem cells, combine the antigenic
characteristics of both stem cells and endothelial cells, and as the
precursor of endothelial cells, they play multiple roles. EPCs not
only stimulate endothelial cell proliferation and differentiation
through the release of cytokines, and at the same time inhibit the
proliferation of smooth muscle cells, thus regulating the process
of reconstruction of the vascular network; they are also able to differentiate
into mature endothelial cells, which participate directly in the construction
of vascular network. EPCs play a crucial role in maintaining endothelial
integrity and repairing damaged vessels.<sup><xref ref-type="bibr" rid="ref173">173</xref>,<xref ref-type="bibr" rid="ref174">174</xref></sup> When exposed to cardiovascular disease risk factors, EPCs biological
function declines, with a subsequent decrease in the ability to repair
vascular damage.<sup><xref ref-type="bibr" rid="ref175">175</xref></sup> Therefore, self-optimized
EPCs or transplantation of functionally improved EPCs may be able
to make up for this deficiency. Meanwhile, studies have shown that
statin lipid-lowering drugs can improve the functions of EPCs differentiation,
proliferation, adhesion and migration, and inhibit its apoptosis,
thus repairing the damaged endothelium and improving the vascular
endothelial function.<sup><xref ref-type="bibr" rid="ref176">176</xref></sup></p><p>Based on
this concept, Liu proposed to transplant EPCs endocytosed with pitavastatin
nanoparticles into rats with carotid endothelial injury to repair
the injured blood vessels.<sup><xref ref-type="bibr" rid="ref177">177</xref></sup> Experimenters
isolated spleen-derived EPCs from rats and treated them with pitavastatin
nanoparticles and injected them into carotid artery-injured rats.
Eventually, it was found that inhibition of pitavastatin nanoparticle-treated
EPCs could promote reendothelialization of injured blood vessels and
significantly inhibit intimal hyperplasia of injured blood vessels.
These results suggest that this endothelial repair-based therapy is
promising for the treatment of atherosclerosis or restenosis after
PCI.</p><p>The integrated stress response (ISR) of endothelial cells,
triggered
by a complex stress environment in the cardiovascular system and inflammatory
reactions, contributes to atherosclerosis. ROS produced by endothelial
cells activate proinflammatory factors,<sup><xref ref-type="bibr" rid="ref178">178</xref></sup> stimulate monocytes to differentiate into macrophages, and lead
to foam cell formation through lipid phagocytosis, thus inducing plaque
formation. Changes in endothelial permeability and increased Ca<sup>2+</sup> release result in the calcification of vascular smooth muscle
cells (VSMCs), accelerating atherosclerosis progression. Endothelial
damage can also cause rupture of the AS plaque, promoting thrombus
formation. SOD, CAT, and GPX effectively clear ROS, alleviating or
preventing ROS-induced peroxidation reactions and hindering the development
of AS.</p><p>When endothelial cells are subjected to stress, there
is often
an increase in HSP expression. Research indicates that HSP27, through
its interaction with the NF-&#x003ba;B pathway, can stabilize plaques
and reduce inflammation levels. HSP70 is hypothesized to protect against
the toxic effects of modified LDL particles on cells, making it a
potential target for reducing oxidative stress. The presence of HSP60
antibodies in AS patients may exacerbate endothelial damage and inflammatory
reactions in vascular walls, further advancing AS. Thus, HSP60 is
a critical focus for anti-AS strategies and may serve as a basis for
developing anti-AS vaccines. Evidence suggests that HSP60/HSP65 has
the potential to prevent or at least reduce the severity of atherosclerosis.<sup><xref ref-type="bibr" rid="ref179">179</xref></sup></p><p>In LDL receptor knockout (LDLR<sup>&#x02013;/&#x02013;</sup>) mice,
HSP65 tolerance induced by Mycobacterium significantly reduced lesions,
particularly in lymphocytes with reduced responsiveness to HSP60 and
increased IL-4 production. This suggests that IL-4 may play a protective
role in atherosclerosis development. In mice nasally administered
HSP65, there was a decrease in macrophage positivity in the aortic
arch, an increase in IL-10 production, a reduction in CD4+ T cell
count, and a decrease in IFN-&#x003b3; production, alongside an increase
in transforming growth factor-&#x003b2; (TGF-&#x003b2;) generation. Different
HSP subtypes play a crucial role in the treatment of AS.<sup><xref ref-type="bibr" rid="ref180">180</xref></sup></p><p>In the early stages of AS, inflammatory
reactions damage the endothelial
cells of blood vessels, leading to increased expression of adhesion
molecules such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular
adhesion molecule-1 (ICAM-1). These adhesion molecules facilitate
the extravasation of lymphocytes and monocytes from the bloodstream
to the subendothelial layer. However, studies have shown that brown
adipose tissue (BAT)-derived neuregulin 4 (Nrg4) inhibits endothelial
inflammation through the ErbB4-Akt-NF-&#x003ba;B pathway. Nrg4 reduces
leukocyte homing and macrophage aggregation in plaques, attenuates
adhesion reactions, and improves plaque stability, thereby effectively
protecting the endothelium.<sup><xref ref-type="bibr" rid="ref181">181</xref></sup></p><p>Studies
have also shown that Nrg4 reduces the number of macrophages
and improves inflammation in Crohn&#x02019;s disease, indicating its
anti-inflammatory effects.<sup><xref ref-type="bibr" rid="ref182">182</xref></sup> This finding
introduces new targets and treatment methods for anti-AS, expands
the approaches and research perspectives in AS treatment, and encourages
researchers to explore previously uncovered areas (<xref rid="fig13" ref-type="fig">Figure <xref rid="fig13" ref-type="fig">13</xref></xref>).</p><fig id="fig13" position="float"><label>Figure 13</label><caption><p>Schematic representation
of Nrg4&#x02019;s protective role in atherosclerosis
via the ErbB4-Akt-NF-&#x003ba;B signaling pathway. Reproduced with permission
from ref (<xref ref-type="bibr" rid="ref181">181</xref>). Copyright
2022 PubMed Central.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="im4c00064_0013" id="gr13" position="float"/></fig></sec><sec id="sec3.2.2.5"><label>3.2.2.5</label><title>Stem
Cell Utilization</title><p>In addition
to conventional cellular molecules, many researchers have attempted
to apply nanoparticles in stem cell therapy.</p><p>One of the main
problems with cardiac regeneration after myocardial infarction is
myocardial cell death, which is replaced by noncontractile fibrous
scar tissue instead of newly formed myocardial cells; Weakening the
ability of organs to contract normally increases the risk of further
heart attacks. Researchers have been trying to use regenerative medicine
technology to grow new muscles in damaged hearts using pluripotent
stem cells (PSCs). Currently, it is believed that human pluripotent
stem cells (hPSCs) can serve as a possible pathway for regenerative
medicine to treat AS. Due to the fact that these cells can now be
stimulated to differentiate into various types of cells, it is believed
that they can be directly injected into the site of injury, stimulating
the reconstruction of damaged blood vessels. Research has found that
stem cell transplantation improves the vascular function of recipient
animals by stimulating the formation of neointimal SMCs. Therefore,
this treatment method is expected to generate new myocardial cells.<sup><xref ref-type="bibr" rid="ref183">183</xref></sup> Recent research has mainly focused on effectively
targeting specific sites of stem cells, one of which is to use echogenic
liposome as stem cell carriers.<sup><xref ref-type="bibr" rid="ref184">184</xref></sup> In addition,
it was found that procoagulant liposomes can prevent the pathogenesis
of atherosclerosis.</p><p>The use of nanomaterials not only improves
the retention and proliferation
of implanted stem cells, but also enables imaging and tracking of
stem cells in vivo, accelerating the discovery of the driving mechanisms
of stem cells and their applications in medicine. For example, magnetic
nanoparticles (MNPs) have been successfully used to separate and sort
stem cells from various types of cell mixtures, with time-saving and
economical characteristics; Quantum dots have been used for molecular
imaging and tracking of stem cells. Carbon nanotubes (CNTs) and fluorescent
carbon nanotubes have also been proven effective.</p><p>However, tracking
stem cells in the body remains a major obstacle.
Therefore, introducing ultra bright contrast agents is an optimization
method.</p><p>Mesenchymal stem cells (MSCs) can differentiate into
various cell
types, including muscle, blood, blood vessels, fat, and bone cells.
We have developed a plasma active nanoplatform for tracking MSCs after
renal transplantation in mice.<sup><xref ref-type="bibr" rid="ref185">185</xref>,<xref ref-type="bibr" rid="ref186">186</xref></sup> This platform relies
on photoluminescence in principle and is composed of peptide functionalized
gold nanoparticles (TAT-GNS). Through experiments, it has been found
that the nanoplatform has better intracellular stability and sensitivity
in vitro, and can cross the vascular barrier in vivo, with transferability.
This platform can provide better tracking tools for stem cell therapy
research and promote the development of diagnostic and therapeutic
methods for cardiovascular diseases.</p></sec><sec id="sec3.2.2.6"><label>3.2.2.6</label><title>Others</title><p>In the routine treatment
of AS, the low effective utilization rate of drugs remains a pressing
issue. Some drugs suffer from low permeability and absorption in the
small intestine or are digested by enzymes in the internal environment,
making it difficult for them to penetrate the biofilm and gastrointestinal
mucus layer. Consequently, the bioavailability (F) of some oral drugs
is very low, ranging from 0.1% to 14%, as seen with amikacin, gentamicin,
neomycin, and carbendazim.</p><p>In the treatment of AS, taking the
antiplatelet drug aspirin as an example, its oral bioavailability
is about 40% &#x02212;50%, which is much higher than the above drugs.
However, after passing through the gastrointestinal first pass effect,
the effective dosage of aspirin that truly acts in the body is greatly
reduced, and the rate of action is slower. As a nonselective cyclooxygenase
(COX) inhibitor, aspirin has no significant inhibitory effect on both
COX-1 and COX-2, So it is inevitable to have an impact on the gastrointestinal
tract, kidneys and other parts, inducing adverse reactions such as
abdominal pain and gastrointestinal bleeding.<sup><xref ref-type="bibr" rid="ref187">187</xref></sup> Moderate aspirin can inhibit the synthesis of arachidonic
acid (AA), the synthesis of thromboxane A2 (TXA<sub>2</sub>), and
platelet activation by inhibiting COX-2. However, excessive intake
of aspirin can lead to a decrease in prostaglandin (PGI<sub>2</sub>) production due to its stronger COX inhibitory effect on the vascular
wall compared to platelet inhibition, PGI<sub>2</sub> and TXA<sub>2</sub> have physiological antagonism, which can lead to thrombosis.
For AS patients, it can worsen vascular embolism and even cause myocardial
infarction. Therefore, in such situations, the application of nanomaterials
greatly reduces the occurrence of such adverse reactions.<sup><xref ref-type="bibr" rid="ref188">188</xref></sup></p><p>Nawzat reviewed the literature on the
impact of Saudi Arabian nanocarriers
on the oral bioavailability of drugs. In the study, Group A received
drugs modified with various nanocarriers, including SLNs, polymer-based
nanoparticles (such as polymer nanoparticles and polymer micelles/dendritic
macromolecules), SNEEDS/nanoemulsion, liposomes/precursor liposomes,
and nanostructured lipid carriers (NLCs). The bioavailability was
represented by the area under the curve (AUC).<sup><xref ref-type="bibr" rid="ref189">189</xref></sup> The data showed that nanomodification of drugs and their
loading into nanocarriers significantly improved oral bioavailability
compared to unmodified drugs. This suggests that nanomaterials can
enhance drug bioavailability through various nanoformulations. Due
to their excellent biocompatibility, ability to carry both lipophilic
and hydrophilic drugs, and targeted drug release capabilities, SLNs
are among the most widely used nanocarriers.</p><p>Additionally, the
application of nanomaterials to macromolecular
drugs has recently become a research hotspot.</p><p>The Nano Drug
Delivery System (NDDS) for proteins and peptides
represents a significant advancement in the pharmaceutical field.<sup><xref ref-type="bibr" rid="ref190">190</xref></sup> By integrating molecular imaging with nanomaterials,
this system offers vast development potential, particularly for delivering
drugs through mucosal systems and utilizing antigen delivery methods
as a novel vaccination strategy.</p><p>Macromolecular drugs are often
prone to degradation in biological
environments due to their complex structures, and their ability to
cross biological barriers is limited.<sup><xref ref-type="bibr" rid="ref191">191</xref></sup> Research has demonstrated that nanomaterials can enhance the targeted
delivery of oral macromolecular drugs using various nanocarriers,
such as chitosan-encapsulated nano systems,<sup><xref ref-type="bibr" rid="ref192">192</xref></sup> liposomes,<sup><xref ref-type="bibr" rid="ref193">193</xref>,<xref ref-type="bibr" rid="ref194">194</xref></sup> lipid nanocarriers primarily
in the form of SLNs,<sup><xref ref-type="bibr" rid="ref195">195</xref>&#x02212;<xref ref-type="bibr" rid="ref197">197</xref></sup> biomimetic nano systems,<sup><xref ref-type="bibr" rid="ref198">198</xref></sup> and self-dispersed ionic liquid-based nanostructures,<sup><xref ref-type="bibr" rid="ref199">199</xref></sup> all of which show promising bioavailability.
Additionally, chitosan nanoparticles can be administered nasally to
achieve therapeutic effects.<sup><xref ref-type="bibr" rid="ref200">200</xref></sup></p><p>Conventional
noninjection routes often face challenges in reaching
target organs due to gastrointestinal mucosa, resulting in low drug
bioavailability and adverse reactions. To address this, researchers
have developed molecularly modified nanocarriers. These modified nanocarriers
exhibit enhanced surface properties, such as targeting, gating, and
pH sensitivity. They can specifically recognize receptors, increase
retention time in the mucus layer or penetrate it rapidly, and open
tight junctions in the gastrointestinal epithelial cell layer. This
enables the precise and efficient delivery of drugs to target sites,
significantly reducing drug loss.<sup><xref ref-type="bibr" rid="ref201">201</xref></sup> Moreover,
some modified nanoparticles can enhance the permeability of gastrointestinal
epithelial cells to carriers, thereby improving drug absorption in
the small intestine and increasing oral bioavailability.</p><p>Compared
to traditional synthetic drug treatments, natural drugs
or nutritional supplements generally have fewer toxic side effects.
Therefore, alternative artificial drugs can be explored as supplementary
treatments to reduce adverse reactions and prolong patient survival.<sup><xref ref-type="bibr" rid="ref202">202</xref></sup></p><p>Research has shown that commonly used
nanoparticles for AS imaging
and treatment, including SPIONs, Au NPs, polymer nanoparticles, and
LNPs, can effectively serve as carriers for nutrient delivery.<sup><xref ref-type="bibr" rid="ref203">203</xref></sup></p></sec></sec></sec></sec><sec id="sec4"><label>4</label><title>Conclusions</title><p>By combining molecular
imaging with nanomaterials, sensitive and
targeted nanoprobes can be developed. Imaging technology can effectively
detect the progression of AS before the onset of the disease, allowing
for early intervention. During AS progression, nanomedicines loaded
onto nanocarriers can target the lesion site, releasing drug particles
at the specific location to achieve optimal efficacy, which has significant
implications for clinical AS treatment.</p><p>Molecular imaging involves
using imaging techniques to visualize
specific molecules at the tissue, cellular, and subcellular levels,
reflecting molecular-level changes in living conditions to qualitatively
and quantitatively analyze their biological behavior.<sup><xref ref-type="bibr" rid="ref204">204</xref></sup> In essence, molecular imaging is a research
discipline that applies molecular biology to traditional medical imaging
techniques for tracking and treating living cells within organisms.</p><p>The integration of nanomaterials with modern molecular imaging
technology has made a significant impact on disease imaging and treatment.
Additionally, the use of nanomaterials in drug delivery has markedly
improved the bioavailability of poorly water-soluble and orally ineffective
drugs. Targeted administration with nanomaterials has also reduced
adverse drug reactions and improved safety while maintaining effectiveness.
Although substantial research exists on nanomaterials in the context
of tumors both domestically and internationally, exploration in cardiovascular
diseases remains underdeveloped. Therefore, this review aims to summarize
the current research on the application of nanomaterials in imaging
and treating AS plaques, both domestically and internationally, to
advance the application and development of nanomaterials in the cardiovascular
field. Although research on nanomaterials in cardiovascular diseases
is growing, most techniques remain focused on preclinical studies,
and several issues persist. For example, some nanocarriers may be
recognized and cleared by the immune system,<sup><xref ref-type="bibr" rid="ref205">205</xref></sup> metabolic mechanisms may not be fully understood,<sup><xref ref-type="bibr" rid="ref206">206</xref></sup> and intravascular biomimetic robots can be affected by
hemodynamics, complicating timely targeting. Consequently, research
on nanomaterials for AS still faces significant challenges. The development
of more convenient, efficient, and safe nanomaterial-based imaging
and treatment technologies, and the effective translation of basic
research into clinical practice, remains crucial.</p></sec></body><back><notes notes-type="" id="notes2"><title>Author Contributions</title><p><sup>#</sup> Q.Z. and Y.W.
equally contributed to this work.</p></notes><notes notes-type="COI-statement" id="notes3"><p>The authors
declare no competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>This work was supported by the National Natural
Science Foundation of China (82272065); Medical Research Project of
Jiangsu Health Commission in 2022 (M2022066); The Nanjing Medical
Science and technique Development Foundation (ZKX23019); The 15th
special supported project of China Postdoctoral Science Foundation
(2022T150317); Nanjing Gulou Hospital New Technology Development Fund
(XJSFZJJ202026, XJSFZLX202114).</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Min</surname><given-names>W.</given-names></name>; <name><surname>Qi</surname><given-names>L.</given-names></name>; <name><surname>Yang</surname><given-names>P.</given-names></name>
<article-title>Advances in studies on novel hypolipidemic drugs</article-title>. <source>Chin. J. New Drug.</source>
<year>2019</year>, <volume>28</volume> (<issue>19</issue>), <fpage>2367</fpage>&#x02013;<lpage>2374</lpage>.</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Du</surname><given-names>H.</given-names></name>; <name><surname>Li</surname><given-names>L.</given-names></name>; <name><surname>Bennett</surname><given-names>D.</given-names></name>; <name><surname>Guo</surname><given-names>Y.</given-names></name>; <name><surname>Key</surname><given-names>T. J.</given-names></name>; <name><surname>Bian</surname><given-names>Z.</given-names></name>; <name><surname>Sherliker</surname><given-names>P.</given-names></name>; <name><surname>Gao</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Yang</surname><given-names>L.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Du</surname><given-names>R.</given-names></name>; <name><surname>Su</surname><given-names>H.</given-names></name>; <name><surname>Collins</surname><given-names>R.</given-names></name>; <name><surname>Peto</surname><given-names>R.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>
<article-title>China Kadoorie Biobank
Study. Fresh fruit consumption and major cardiovascular disease in
China</article-title>. <source>New.Engl.J.Med.</source>
<year>2016</year>, <volume>374</volume> (<issue>14</issue>), <fpage>1332</fpage>&#x02013;<lpage>1343</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1501451</pub-id>.<pub-id pub-id-type="pmid">27050205</pub-id>
</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Roth</surname><given-names>G. A.</given-names></name>; <name><surname>Forouzanfar</surname><given-names>M. H.</given-names></name>; <name><surname>Moran</surname><given-names>A. E.</given-names></name>; <name><surname>Barber</surname><given-names>R.</given-names></name>; <name><surname>Nguyen</surname><given-names>G.</given-names></name>; <name><surname>Feigin</surname><given-names>V. L.</given-names></name>; <name><surname>Naghavi</surname><given-names>M.</given-names></name>; <name><surname>Mensah</surname><given-names>G. A.</given-names></name>; <name><surname>Murray</surname><given-names>C. J.</given-names></name>
<article-title>Demographic
and epidemiologic drivers of global cardiovascular mortality</article-title>. <source>New.Engl.J.Med.</source>
<year>2015</year>, <volume>372</volume> (<issue>14</issue>), <fpage>1333</fpage>&#x02013;<lpage>1341</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1406656</pub-id>.<pub-id pub-id-type="pmid">25830423</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Tao</surname><given-names>W.</given-names></name>; <name><surname>Yurdagul</surname><given-names>A.</given-names></name>; <name><surname>Kong</surname><given-names>Na.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>
<article-title>siRNA nanoparticles
targeting CaMKII&#x003b3; in lesional macrophages improve atherosclerotic
plaque stability in mice</article-title>. <source>Sci. Transl. Med.</source>
<year>2020</year>, <pub-id pub-id-type="doi">10.1126/scitranslmed.aay1063</pub-id>.</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Libby</surname><given-names>P.</given-names></name>; <name><surname>Buring</surname><given-names>J. E.</given-names></name>; <name><surname>Badimon</surname><given-names>L.</given-names></name>; <name><surname>Hansson</surname><given-names>G. K.</given-names></name>; <name><surname>Deanfield</surname><given-names>J.</given-names></name>; <name><surname>Bittencourt</surname><given-names>M. S.</given-names></name>; <name><surname>Tokgozoglu</surname><given-names>L.</given-names></name>; <name><surname>Lewis</surname><given-names>E. F.</given-names></name>
<article-title>Atherosclerosis</article-title>. <source>Nat. Rev. Dis. Primers</source>
<year>2019</year>, <volume>5</volume> (<issue>1</issue>), <fpage>56</fpage><pub-id pub-id-type="doi">10.1038/s41572-019-0106-z</pub-id>.<pub-id pub-id-type="pmid">31420554</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Llorente-Cortes</surname><given-names>V.</given-names></name>; <name><surname>Martinez-Gonzalez</surname><given-names>J.</given-names></name>; <name><surname>Badimon</surname><given-names>L.</given-names></name>
<article-title>LDL receptor-related
protein mediates
uptake of aggregated LDL in human vascular smooth muscle cells</article-title>. <source>Arterioscler.Thromb.Vasc.Biol.</source>
<year>2000</year>, <volume>20</volume>, <fpage>1572</fpage>&#x02013;<lpage>1579</lpage>. <pub-id pub-id-type="doi">10.1161/01.ATV.20.6.1572</pub-id>.<pub-id pub-id-type="pmid">10845874</pub-id>
</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Bennett</surname><given-names>M. R.</given-names></name>; <name><surname>Sinha</surname><given-names>S.</given-names></name>; <name><surname>Owens</surname><given-names>G. K.</given-names></name>
<article-title>Vascular
smooth muscle cells in atherosclerosis</article-title>. <source>Circ.
Res.</source>
<year>2016</year>, <volume>118</volume>, <fpage>692</fpage>&#x02013;<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.306361</pub-id>.<pub-id pub-id-type="pmid">26892967</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Boren</surname><given-names>J.</given-names></name>; <name><surname>Williams</surname><given-names>K. J.</given-names></name>
<article-title>The central role of arterial retention of cholesterol-rich
apolipoprotein B-containing lipoproteins in the pathogenesis of atherosclerosis:
a triumph of simplicity</article-title>. <source>Curr.Opin.Lipidol.</source>
<year>2016</year>, <volume>27</volume>, <fpage>473</fpage>&#x02013;<lpage>483</lpage>. <pub-id pub-id-type="doi">10.1097/MOL.0000000000000330</pub-id>.<pub-id pub-id-type="pmid">27472409</pub-id>
</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Ference</surname><given-names>B. A.</given-names></name>; <name><surname>Graham</surname><given-names>I.</given-names></name>; <name><surname>Tokgozoglu</surname><given-names>L.</given-names></name>; <name><surname>Catapano</surname><given-names>A. L.</given-names></name>
<article-title>Impact of Lipids
on Cardiovascular Health: JACC Health Promotion Series</article-title>. <source>J.Am.Coll.Cardiol.</source>
<year>2018</year>, <volume>72</volume> (<issue>10</issue>), <fpage>1141</fpage>&#x02013;<lpage>1156</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2018.06.046</pub-id>.<pub-id pub-id-type="pmid">30165986</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Vlachogiannis</surname><given-names>N. I.</given-names></name>; <name><surname>Legaki</surname><given-names>A.-I.</given-names></name>; <name><surname>Kassi</surname><given-names>E.</given-names></name>; <name><surname>Mikelis</surname><given-names>C. M.</given-names></name>; <name><surname>Tentolouris</surname><given-names>N.</given-names></name>; <name><surname>Sfikakis</surname><given-names>P. P.</given-names></name>; <name><surname>Protogerou</surname><given-names>A. D.</given-names></name>; <name><surname>Chatzigeorgiou</surname><given-names>A.</given-names></name>
<article-title>Association
of circulating Robo4 with obesity, hypertension and atherosclerotic
plaque burden</article-title>. <source>Thromb. Haemostasis</source>
<year>2024</year>, <pub-id pub-id-type="doi">10.1055/a-2437-6308</pub-id>.</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Jebari-Benslaiman</surname><given-names>S.</given-names></name>; <name><surname>Galicia-Garcia</surname><given-names>U.</given-names></name>; <name><surname>Larrea-Sebal</surname><given-names>A.</given-names></name>; <name><surname>Olaetxea</surname><given-names>J. R.</given-names></name>; <name><surname>Alloza</surname><given-names>I.</given-names></name>; <name><surname>Vandenbroeck</surname><given-names>K.</given-names></name>; <name><surname>Benito-Vicente</surname><given-names>A.</given-names></name>; <name><surname>Martin</surname><given-names>C.</given-names></name>
<article-title>Pathophysiology of
Atherosclerosis</article-title>. <source>Int. J. Mol. Sci.</source>
<year>2022</year>, <volume>23</volume> (<issue>6</issue>), <fpage>3346</fpage><pub-id pub-id-type="doi">10.3390/ijms23063346</pub-id>.<pub-id pub-id-type="pmid">35328769</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>van
Nieuw Amerongen</surname><given-names>G. P.</given-names></name>; <name><surname>Vermeer</surname><given-names>M. A.</given-names></name>; <name><surname>N&#x000e8;gre-Aminou</surname><given-names>P.</given-names></name>; <name><surname>Lankelma</surname><given-names>J.</given-names></name>; <name><surname>Emeis</surname><given-names>J. J.</given-names></name>; <name><surname>van Hinsbergh</surname><given-names>V. W.</given-names></name>
<article-title>Simvastatin
improves disturbed endothelial barrier function</article-title>. <source>Circulation</source>
<year>2000</year>, <volume>102</volume> (<issue>23</issue>), <fpage>2803</fpage>&#x02013;<lpage>2809</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.102.23.2803</pub-id>.<pub-id pub-id-type="pmid">11104736</pub-id>
</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Zu</surname><given-names>Y.</given-names></name>; <name><surname>Dhanasekara</surname><given-names>C. S.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Wu</surname><given-names>D.</given-names></name>
<article-title>Detection
and treatment of atherosclerosis using nanoparticles</article-title>. <source>Wires Nanomed. Nanobiol.</source>
<year>2016</year>, <pub-id pub-id-type="doi">10.1002/wnan.1412</pub-id>.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Ren</surname><given-names>W.</given-names></name>
<article-title>The Role of
NLRP3 and Oxidative Stress in Atherosclerosis</article-title>. <source>Adv. Clin. Exp. Med.</source>
<year>2023</year>, <volume>13</volume> (<issue>9</issue>), <fpage>14758</fpage>&#x02013;<lpage>14763</lpage>. <pub-id pub-id-type="doi">10.12677/ACM.2023.1392064</pub-id>.</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Horke</surname><given-names>S.</given-names></name>; <name><surname>F&#x000f6;rstermann</surname><given-names>U.</given-names></name>
<article-title>Oxidative
Stress in Vascular Disease
and Its Pharmacological Prevention</article-title>. <source>Trends.Pharmacol.Sci.</source>
<year>2013</year>, <volume>34</volume>, <fpage>313</fpage>&#x02013;<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2013.03.007</pub-id>.<pub-id pub-id-type="pmid">23608227</pub-id>
</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>F&#x000f6;rstermann</surname><given-names>U.</given-names></name>; <name><surname>Xia</surname><given-names>N.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>
<article-title>Roles of Vascular
Oxidative Stress and Nitric Oxide
in the Pathogenesis of Atherosclerosis</article-title>. <source>Circ.
Res.</source>
<year>2017</year>, <volume>120</volume> (<issue>4</issue>), <fpage>713</fpage>&#x02013;<lpage>735</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309326</pub-id>.<pub-id pub-id-type="pmid">28209797</pub-id>
</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>K&#x000e1;sa</surname><given-names>A.</given-names></name>; <name><surname>Csortos</surname><given-names>C.</given-names></name>; <name><surname>Verin</surname><given-names>A. D.</given-names></name>
<article-title>Cytoskeletal mechanisms
regulating
vascular endothelial barrier function in response to acute lung injury</article-title>. <source>Tissue Barriers.</source>
<year>2015</year>, <volume>3</volume> (<issue>1&#x02013;2</issue>), <elocation-id>e974448</elocation-id><pub-id pub-id-type="doi">10.4161/21688370.2014.974448</pub-id>.<pub-id pub-id-type="pmid">25838980</pub-id>
</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Hao</surname><given-names>Y.</given-names></name>; <name><surname>Zhu</surname><given-names>H.</given-names></name>
<article-title>The relationship between
regulatory immunological cells and atherosclerosis</article-title>. <source>Chin. J. Cardiovasc. Rev.</source>
<year>2023</year>, <volume>21</volume> (<issue>6</issue>), <fpage>499</fpage>&#x02013;<lpage>504</lpage>.</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>Q.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>
<article-title>Advances in
Research on the Role of Immune Cells in
the Process of Atherosclerosis</article-title>. <source>Prog. Pharm.
Sci.</source>
<year>2023</year>, <volume>47</volume> (<issue>7</issue>), <fpage>542</fpage>&#x02013;<lpage>550</lpage>. <pub-id pub-id-type="doi">10.20053/j.issn1001-5094.2023.07.009</pub-id>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Chistiakov</surname><given-names>D. A.</given-names></name>; <name><surname>Melnichenko</surname><given-names>A. A.</given-names></name>; <name><surname>Myasoedova</surname><given-names>V. A.</given-names></name>; <name><surname>Grechko</surname><given-names>A. V.</given-names></name>; <name><surname>Orekhov</surname><given-names>A. N.</given-names></name>
<article-title>Mechanisms
of foam cell formation in atherosclerosis</article-title>. <source>J.Mol.Med.</source>
<year>2017</year>, <volume>95</volume> (<issue>11</issue>), <fpage>1153</fpage>&#x02013;<lpage>1165</lpage>. <pub-id pub-id-type="doi">10.1007/s00109-017-1575-8</pub-id>.<pub-id pub-id-type="pmid">28785870</pub-id>
</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Karunakaran</surname><given-names>D.</given-names></name>; <name><surname>Nguyen</surname><given-names>M. A.</given-names></name>; <name><surname>Geoffrion</surname><given-names>M.</given-names></name>; <name><surname>Vreeken</surname><given-names>D.</given-names></name>; <name><surname>Lister</surname><given-names>Z.</given-names></name>; <name><surname>Cheng</surname><given-names>H. S.</given-names></name>; <name><surname>Otte</surname><given-names>N.</given-names></name>; <name><surname>Essebier</surname><given-names>P.</given-names></name>; <name><surname>Wyatt</surname><given-names>H.</given-names></name>; <name><surname>Kandiah</surname><given-names>J. W.</given-names></name>; <name><surname>Jung</surname><given-names>R.</given-names></name>; <name><surname>Alenghat</surname><given-names>F. J.</given-names></name>; <name><surname>Mompeon</surname><given-names>A.</given-names></name>; <name><surname>Lee</surname><given-names>R.</given-names></name>; <name><surname>Pan</surname><given-names>C.</given-names></name>; <name><surname>Gordon</surname><given-names>E.</given-names></name>; <name><surname>Rasheed</surname><given-names>A.</given-names></name>; <name><surname>Lusis</surname><given-names>A. J.</given-names></name>; <name><surname>Liu</surname><given-names>P.</given-names></name>; <name><surname>Matic</surname><given-names>L. P.</given-names></name>; <name><surname>Hedin</surname><given-names>U.</given-names></name>; <name><surname>Fish</surname><given-names>J. E.</given-names></name>; <name><surname>Guo</surname><given-names>L.</given-names></name>; <name><surname>Kolodgie</surname><given-names>F.</given-names></name>; <name><surname>Virmani</surname><given-names>R.</given-names></name>; <name><surname>van Gils</surname><given-names>J. M.</given-names></name>; <name><surname>Rayner</surname><given-names>K. J.</given-names></name>
<article-title>RIPK1 Expression
Associates With Inflammation in Early Atherosclerosis in Humans and
Can Be Therapeutically Silenced to Reduce NF-&#x003ba;B Activation and
Atherogenesis in Mice</article-title>. <source>Circulation.</source>
<year>2021</year>, <volume>143</volume> (<issue>2</issue>), <fpage>163</fpage>&#x02013;<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.038379</pub-id>.<pub-id pub-id-type="pmid">33222501</pub-id>
</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Shu</surname><given-names>H.</given-names></name>; <name><surname>Peng</surname><given-names>Y.</given-names></name>; <name><surname>Hang</surname><given-names>W.</given-names></name>; <name><surname>Nie</surname><given-names>J.</given-names></name>; <name><surname>Zhou</surname><given-names>N.</given-names></name>; <name><surname>Wang</surname><given-names>D. W.</given-names></name>
<article-title>The role of CD36 in cardiovascular disease</article-title>. <source>Cardiovasc. Res.</source>
<year>2022</year>, <volume>118</volume> (<issue>1</issue>), <fpage>115</fpage>&#x02013;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvaa319</pub-id>.<pub-id pub-id-type="pmid">33210138</pub-id>
</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Cui</surname><given-names>W.</given-names></name>; <name><surname>Silverstein</surname><given-names>R. L.</given-names></name>
<article-title>CD36,a
signaling receptor and fatty acid transporter that regulates immune
cell metabolism and fate</article-title>. <source>J. Exp. Med.</source>
<year>2022</year>, <volume>219</volume> (<issue>6</issue>), <elocation-id>e20211314</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20211314</pub-id>.<pub-id pub-id-type="pmid">35438721</pub-id>
</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Yang</surname><given-names>M.</given-names></name>; <name><surname>Huang</surname><given-names>W.</given-names></name>; <name><surname>Chen</surname><given-names>W.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Schulte</surname><given-names>M. L.</given-names></name>; <name><surname>Volberding</surname><given-names>P.</given-names></name>; <name><surname>Gerbec</surname><given-names>Z.</given-names></name>; <name><surname>Zimmermann</surname><given-names>M. T.</given-names></name>; <name><surname>Zeighami</surname><given-names>A.</given-names></name>; <name><surname>Demos</surname><given-names>W.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Knaack</surname><given-names>D. A.</given-names></name>; <name><surname>Smith</surname><given-names>B. C.</given-names></name>; <name><surname>Cui</surname><given-names>W.</given-names></name>; <name><surname>Malarkannan</surname><given-names>S.</given-names></name>; <name><surname>Sodhi</surname><given-names>K.</given-names></name>; <name><surname>Shapiro</surname><given-names>J. I.</given-names></name>; <name><surname>Xie</surname><given-names>Z.</given-names></name>; <name><surname>Sahoo</surname><given-names>D.</given-names></name>; <name><surname>Silverstein</surname><given-names>R. L.</given-names></name>
<article-title>Mitochondrial Metabolic Reprogramming by CD36 Signaling
Drives Macrophage Inflammatory Responses</article-title>. <source>Circ.
Res.</source>
<year>2019</year>, <volume>125</volume> (<issue>12</issue>), <fpage>1087</fpage>&#x02013;<lpage>1102</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.315833</pub-id>.<pub-id pub-id-type="pmid">31625810</pub-id>
</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Cheng</surname><given-names>J.</given-names></name>; <name><surname>Peng</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Wei</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>
<article-title>Research progress
on the relationship between macrophage autophagy and atherosclerosis</article-title>. <source>J. Gannan Med. Univ.</source>
<year>2023</year>, <volume>43</volume> (<issue>5</issue>), <fpage>435</fpage>&#x02013;<lpage>441</lpage>.</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Toutouzas</surname><given-names>K.</given-names></name>; <name><surname>Benetos</surname><given-names>G.</given-names></name>; <name><surname>Karanasos</surname><given-names>A.</given-names></name>; <name><surname>Chatzizisis</surname><given-names>Y. S.</given-names></name>; <name><surname>Giannopoulos</surname><given-names>A. A.</given-names></name>; <name><surname>Tousoulis</surname><given-names>D.</given-names></name>
<article-title>Vulnerable plaque imaging: updates
on new pathobiological mechanisms</article-title>. <source>Eur. Heart
J.</source>
<year>2015</year>, <volume>36</volume> (<issue>45</issue>), <fpage>3147</fpage>&#x02013;<lpage>3154</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehv508</pub-id>.<pub-id pub-id-type="pmid">26419623</pub-id>
</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="thesis" id="cit27"><person-group person-group-type="allauthors"><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Cerium
oxide-based
multi-functional nanoprobes for accurate diagnosis and treatment of
atherosclerosis</article-title>. <publisher-name>Jinan: Shandong Normal
University</publisher-name>, <year>2018</year>.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Dai</surname><given-names>Y.</given-names></name>; <name><surname>Sha</surname><given-names>X.</given-names></name>; <name><surname>Song</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Xing</surname><given-names>M.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Xu</surname><given-names>K.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>
<article-title>Targeted Therapy of Atherosclerosis Vulnerable Plaque
by ROS-Scavenging Nanoparticles and MR/Fluorescence Dual-Modality
Imaging Tracing</article-title>. <source>Int.J.Nanomedicine.</source>
<year>2022</year>, <volume>17</volume>, <fpage>5413</fpage>&#x02013;<lpage>5429</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S371873</pub-id>.<pub-id pub-id-type="pmid">36419720</pub-id>
</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Khambhati</surname><given-names>J.</given-names></name>; <name><surname>Engels</surname><given-names>M.</given-names></name>; <name><surname>Allard-Ratick</surname><given-names>M.</given-names></name>; <name><surname>Sandesara</surname><given-names>P. B.</given-names></name>; <name><surname>Quyyumi</surname><given-names>A. A.</given-names></name>; <name><surname>Sperling</surname><given-names>L.</given-names></name>
<article-title>Immunotherapy for the
prevention
of atherosclerotic cardiovascular disease: promise and possibilities</article-title>. <source>Atherosclerosis.</source>
<year>2018</year>, <volume>276</volume>, <fpage>1</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2018.07.007</pub-id>.<pub-id pub-id-type="pmid">30006321</pub-id>
</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Roth</surname><given-names>G. A.</given-names></name>; <name><surname>Johnson</surname><given-names>C.</given-names></name>; <name><surname>Abajobir</surname><given-names>A.</given-names></name>; <name><surname>Abd-Allah</surname><given-names>F.</given-names></name>; <name><surname>Abera</surname><given-names>S. F.</given-names></name>; <name><surname>Abyu</surname><given-names>G.</given-names></name>; <name><surname>Ahmed</surname><given-names>M.</given-names></name>; <name><surname>Aksut</surname><given-names>B.</given-names></name>; <name><surname>Alam</surname><given-names>T.</given-names></name>; <name><surname>Alam</surname><given-names>K.</given-names></name>; <name><surname>Alla</surname><given-names>F.</given-names></name>; <name><surname>Alvis-Guzman</surname><given-names>N.</given-names></name>; <name><surname>Amrock</surname><given-names>S.</given-names></name>; <name><surname>Ansari</surname><given-names>H.</given-names></name>; <name><surname>&#x000c4;rnl&#x000f6;v</surname><given-names>J.</given-names></name>; <name><surname>Asayesh</surname><given-names>H.</given-names></name>; <name><surname>Atey</surname><given-names>T. M.</given-names></name>; <name><surname>Avila-Burgos</surname><given-names>L.</given-names></name>; <name><surname>Awasthi</surname><given-names>A.</given-names></name>; <name><surname>Banerjee</surname><given-names>A.</given-names></name>; <name><surname>Murray</surname><given-names>C.</given-names></name>; et al. <article-title>Global,
regional, and national burden of cardiovascular diseases for 10 causes,1990
to 2015</article-title>. <source>J. Am. Coll. Cardiol.</source>
<year>2017</year>, <volume>70</volume> (<issue>1</issue>), <fpage>1</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2017.04.052</pub-id>.<pub-id pub-id-type="pmid">28527533</pub-id>
</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Cheng</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name>; <name><surname>Dey</surname><given-names>R.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>
<article-title>Nanomaterials for cancer therapy:
current progress and perspectives</article-title>. <source>J. Hematol.
Oncol.</source>
<year>2021</year>, <volume>14</volume> (<issue>1</issue>), <fpage>85</fpage><pub-id pub-id-type="doi">10.1186/s13045-021-01096-0</pub-id>.<pub-id pub-id-type="pmid">34059100</pub-id>
</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Flores</surname><given-names>A. M.</given-names></name>; <name><surname>Ye</surname><given-names>J.</given-names></name>; <name><surname>Jarr</surname><given-names>K.-U.</given-names></name>; <name><surname>Hosseini-Nassab</surname><given-names>N.</given-names></name>; <name><surname>Smith</surname><given-names>B. R.</given-names></name>; <name><surname>Leeper</surname><given-names>N. J.</given-names></name>
<article-title>Nanoparticle
Therapy for Vascular Diseases</article-title>. <source>Arterioscl. Throm.
Vas.</source>
<year>2019</year>, <volume>39</volume> (<issue>4</issue>), <fpage>635</fpage>&#x02013;<lpage>646</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.118.311569</pub-id>.</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Manzanares</surname><given-names>D.</given-names></name>; <name><surname>Ce&#x000f1;a</surname><given-names>V.</given-names></name>
<article-title>Endocytosis: The Nanoparticle and
Submicron Nanocompounds
Gateway into the Cell</article-title>. <source>Pharmaceutics.</source>
<year>2020</year>, <volume>12</volume> (<issue>4</issue>), <fpage>371</fpage>&#x02013;<lpage>371</lpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics12040371</pub-id>.<pub-id pub-id-type="pmid">32316537</pub-id>
</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Gonzalez</surname><given-names>K. M.</given-names></name>; <name><surname>Chung</surname><given-names>J.</given-names></name>; <name><surname>Kim</surname><given-names>M.</given-names></name>; <name><surname>Lu</surname><given-names>J.</given-names></name>
<article-title>Surface-modified
nanotherapeutics targeting atherosclerosis</article-title>. <source>Biomaterials Sci.</source>
<year>2022</year>, <volume>10</volume> (<issue>19</issue>), <fpage>5459</fpage>&#x02013;<lpage>5471</lpage>. <pub-id pub-id-type="doi">10.1039/D2BM00660J</pub-id>.</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Sun</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>B.</given-names></name>; <name><surname>Du</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Gu</surname><given-names>N.</given-names></name>
<article-title>Construction
of functional magnetic scaffold with temperature control
switch for long-distance vascular injury</article-title>. <source>Biomaterials</source>
<year>2022</year>, <volume>290</volume>, <fpage>121862</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121862</pub-id>.<pub-id pub-id-type="pmid">36326512</pub-id>
</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Chen</surname><given-names>B.</given-names></name>; <name><surname>Yang</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>S.</given-names></name>
<article-title>Progress in
new carriers for topical
medication of dermatology</article-title>. <source>Chin. J. Mod. Appl.
Pharm.</source>
<year>2018</year>, <volume>35</volume> (<issue>4</issue>), <fpage>615</fpage>&#x02013;<lpage>621</lpage>.</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Hadinoto</surname><given-names>K.</given-names></name>; <name><surname>Sundaresan</surname><given-names>A.</given-names></name>; <name><surname>Cheow</surname><given-names>W. S.</given-names></name>
<article-title>Lipid-polymer hybrid nanoparticles
as a new generation therapeutic delivery platform: A review</article-title>. <source>Eur. J. Pharm. Biopharm.</source>
<year>2013</year>, <volume>85</volume> (<issue>3</issue>), <fpage>427</fpage>&#x02013;<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2013.07.002</pub-id>.<pub-id pub-id-type="pmid">23872180</pub-id>
</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Zhang</surname><given-names>T.</given-names></name>; <name><surname>Tang</surname><given-names>Q.</given-names></name>
<article-title>Application of lipid
nanoparticles in cardiovascular diseases</article-title>. <source>Med.
J. Wuhan Univ.</source>
<year>2023</year>, <fpage>1</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Jung</surname><given-names>H.</given-names></name>; <name><surname>Lee</surname><given-names>S.</given-names></name>; <name><surname>Lee</surname><given-names>S.</given-names></name>; <name><surname>Youn</surname><given-names>H.</given-names></name>; <name><surname>Im</surname><given-names>H.</given-names></name>
<article-title>Lipid nanoparticles
for delivery of RNA therapeutics: Current status and the role of in
vivo imaging</article-title>. <source>Theranostics.</source>
<year>2022</year>, <volume>12</volume> (<issue>17</issue>), <fpage>7509</fpage>&#x02013;<lpage>7531</lpage>. <pub-id pub-id-type="doi">10.7150/thno.77259</pub-id>.<pub-id pub-id-type="pmid">36438494</pub-id>
</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Ding</surname><given-names>B.</given-names></name>; <name><surname>Dziubla</surname><given-names>T.</given-names></name>; <name><surname>Shuvaev</surname><given-names>V. V.</given-names></name>; <name><surname>Muro</surname><given-names>S.</given-names></name>; <name><surname>Muzykantov</surname><given-names>V.</given-names></name>
<article-title>Advanced drug
delivery systems that target the vascular endothelium</article-title>. <source>Mol.Interv.</source>
<year>2006</year>, <volume>6</volume> (<issue>2</issue>), <fpage>98</fpage>&#x02013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1124/mi.6.2.7</pub-id>.<pub-id pub-id-type="pmid">16565472</pub-id>
</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Hua</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>S. Y.</given-names></name>
<article-title>The use of lipid-based nanocarriers for targeted pain therapies</article-title>. <source>Front. Pharmacol.</source>
<year>2013</year>, <volume>4</volume>, <fpage>143</fpage><pub-id pub-id-type="doi">10.3389/fphar.2013.00143</pub-id>.<pub-id pub-id-type="pmid">24319430</pub-id>
</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Robson</surname><given-names>A. L.</given-names></name>; <name><surname>Dastoor</surname><given-names>P. C.</given-names></name>; <name><surname>Flynn</surname><given-names>J.</given-names></name>; <name><surname>Palmer</surname><given-names>W.</given-names></name>; <name><surname>Martin</surname><given-names>A.</given-names></name>; <name><surname>Smith</surname><given-names>D. W.</given-names></name>; <name><surname>Woldu</surname><given-names>A.</given-names></name>; <name><surname>Hua</surname><given-names>S.</given-names></name>
<article-title>Advantages and Limitations
of Current Imaging Techniques for Characterizing Liposome Morphology</article-title>. <source>Front. Pharmacol.</source>
<year>2018</year>, <volume>9</volume>, <fpage>80</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.00080</pub-id>.<pub-id pub-id-type="pmid">29467660</pub-id>
</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Paunovska</surname><given-names>K.</given-names></name>; <name><surname>Da Silva Sanchez</surname><given-names>A. J.</given-names></name>; <name><surname>Lokugamage</surname><given-names>M. P.</given-names></name>; <name><surname>Loughrey</surname><given-names>D.</given-names></name>; <name><surname>Echeverri</surname><given-names>E. S.</given-names></name>; <name><surname>Cristian</surname><given-names>A.</given-names></name>; <name><surname>Hatit</surname><given-names>M. Z. C.</given-names></name>; <name><surname>Santangelo</surname><given-names>P. J.</given-names></name>; <name><surname>Zhao</surname><given-names>K.</given-names></name>; <name><surname>Dahlman</surname><given-names>J. E.</given-names></name>
<article-title>The Extent to Which Lipid Nanoparticles
Require Apolipoprotein E and Low-Density Lipoprotein Receptor for
Delivery Changes with Ionizable Lipid Structure</article-title>. <source>Nano.Lett.</source>
<year>2022</year>, <volume>22</volume> (<issue>24</issue>), <fpage>10025</fpage>&#x02013;<lpage>10033</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.2c03741</pub-id>.<pub-id pub-id-type="pmid">36521071</pub-id>
</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Da
Silva Sanchez</surname><given-names>A. J.</given-names></name>; <name><surname>Dobrowolski</surname><given-names>C.</given-names></name>; <name><surname>Cristian</surname><given-names>A.</given-names></name>; <name><surname>Echeverri</surname><given-names>E. S.</given-names></name>; <name><surname>Zhao</surname><given-names>K.</given-names></name>; <name><surname>Hatit</surname><given-names>M. Z. C.</given-names></name>; <name><surname>Loughrey</surname><given-names>D.</given-names></name>; <name><surname>Paunovska</surname><given-names>K.</given-names></name>; <name><surname>Dahlman</surname><given-names>J. E.</given-names></name>
<article-title>Universal Barcoding Predicts In Vivo ApoE-Independent
Lipid Nanoparticle Delivery</article-title>. <source>Nano.Lett.</source>
<year>2022</year>, <volume>22</volume> (<issue>12</issue>), <fpage>4822</fpage>&#x02013;<lpage>4830</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.2c01133</pub-id>.<pub-id pub-id-type="pmid">35671473</pub-id>
</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Sakurai</surname><given-names>Y.</given-names></name>; <name><surname>Yoshikawa</surname><given-names>K.</given-names></name>; <name><surname>Arai</surname><given-names>K.</given-names></name>; <name><surname>Kazaoka</surname><given-names>A.</given-names></name>; <name><surname>Aoki</surname><given-names>S.</given-names></name>; <name><surname>Ito</surname><given-names>K.</given-names></name>; <name><surname>Nakai</surname><given-names>Y.</given-names></name>; <name><surname>Tange</surname><given-names>K.</given-names></name>; <name><surname>Furihata</surname><given-names>T.</given-names></name>; <name><surname>Tanaka</surname><given-names>H.</given-names></name>; <name><surname>Akita</surname><given-names>H.</given-names></name>
<article-title>siRNA delivery to lymphatic endothelial cells via ApoE-mediated uptake
by lipid nanoparticles</article-title>. <source>J.Control.Release.</source>
<year>2023</year>, <volume>353</volume>, <fpage>125</fpage>&#x02013;<lpage>133</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2022.11.036</pub-id>.<pub-id pub-id-type="pmid">36414194</pub-id>
</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Liu</surname><given-names>K.</given-names></name>; <name><surname>Nilsson</surname><given-names>R.</given-names></name>; <name><surname>L&#x000e1;zaro-Ib&#x000e1;&#x000f1;ez</surname><given-names>E.</given-names></name>; <name><surname>Du&#x000e0;n</surname><given-names>H.</given-names></name>; <name><surname>Miliotis</surname><given-names>T.</given-names></name>; <name><surname>Strimfors</surname><given-names>M.</given-names></name>; <name><surname>Lerche</surname><given-names>M.</given-names></name>; <name><surname>Salgado Ribeiro</surname><given-names>A. R.</given-names></name>; <name><surname>Ulander</surname><given-names>J.</given-names></name>; <name><surname>Lind&#x000e9;n</surname><given-names>D.</given-names></name>; <name><surname>Salvati</surname><given-names>A.</given-names></name>; <name><surname>Sabirsh</surname><given-names>A.</given-names></name>
<article-title>Multiomics analysis of naturally
efficacious lipid nanoparticle coronas reveals high density lipoprotein
is necessary for their function</article-title>. <source>Nat. Commun.</source>
<year>2023</year>, <volume>14</volume> (<issue>1</issue>), <fpage>4007</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-39768-9</pub-id>.<pub-id pub-id-type="pmid">37414857</pub-id>
</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Lim</surname><given-names>H. Y.</given-names></name>; <name><surname>Thiam</surname><given-names>C. H.</given-names></name>; <name><surname>Yeo</surname><given-names>K. P.</given-names></name>; <name><surname>Bisoendial</surname><given-names>R.</given-names></name>; <name><surname>Hii</surname><given-names>C. S.</given-names></name>; <name><surname>McGrath</surname><given-names>K. C.</given-names></name>; <name><surname>Tan</surname><given-names>K. W.</given-names></name>; <name><surname>Heather</surname><given-names>A.</given-names></name>; <name><surname>Alexander</surname><given-names>J. S.</given-names></name>; <name><surname>Angeli</surname><given-names>V.</given-names></name>
<article-title>Lymphatic vessels are
essential for
the removal of cholesterol from peripheral tissues by SR-BI-mediated
transport of HDL</article-title>. <source>Cell.Metab.</source>
<year>2013</year>, <volume>17</volume> (<issue>5</issue>), <fpage>671</fpage>&#x02013;<lpage>684</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2013.04.002</pub-id>.<pub-id pub-id-type="pmid">23663736</pub-id>
</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Randolph</surname><given-names>G. J.</given-names></name>; <name><surname>Miller</surname><given-names>N. E.</given-names></name>
<article-title>Lymphatic transport
of high-density lipoproteins and
chylomicrons</article-title>. <source>J.Clin.Invest.</source>
<year>2014</year>, <volume>124</volume> (<issue>3</issue>), <fpage>929</fpage>&#x02013;<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1172/JCI71610</pub-id>.<pub-id pub-id-type="pmid">24590278</pub-id>
</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Liu</surname><given-names>M.</given-names></name>; <name><surname>Feng</surname><given-names>Y.</given-names></name>; <name><surname>Lu</surname><given-names>Y.</given-names></name>; <name><surname>Huang</surname><given-names>R.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Mo</surname><given-names>R.</given-names></name>
<article-title>Lymph-targeted
high-density lipoprotein-mimetic
nanovaccine for multi-antigenic personalized cancer immunotherapy</article-title>. <source>Sci. Adv.</source>
<year>2024</year>, <volume>10</volume> (<issue>11</issue>), <elocation-id>eadk2444</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.adk2444</pub-id>.<pub-id pub-id-type="pmid">38478602</pub-id>
</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Diditchenko</surname><given-names>S.</given-names></name>; <name><surname>Gille</surname><given-names>A.</given-names></name>; <name><surname>Pragst</surname><given-names>I.</given-names></name>; <name><surname>Stadler</surname><given-names>D.</given-names></name>; <name><surname>Waelchli</surname><given-names>M.</given-names></name>; <name><surname>Hamilton</surname><given-names>R.</given-names></name>; <name><surname>Leis</surname><given-names>A.</given-names></name>; <name><surname>Wright</surname><given-names>S. D.</given-names></name>
<article-title>Novel formulation
of a reconstituted high-density lipoprotein(CSL112) dramatically enhances
ABCA1-dependent cholesterol efflux</article-title>. <source>Arterioscler.
Thromb. Vasc. Biol.</source>
<year>2013</year>, <volume>33</volume> (<issue>9</issue>), <fpage>2202</fpage>&#x02013;<lpage>2211</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.113.301981</pub-id>.<pub-id pub-id-type="pmid">23868939</pub-id>
</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name><surname>Xu</surname><given-names>R.</given-names></name>; <name><surname>Li</surname><given-names>S.</given-names></name>; <name><surname>Shi</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>N.</given-names></name>; et al. <article-title>Peptide-based
high-density lipoprotein promotes adipose
tissue browning and restrains development of atherosclerosis and type
2 diabetes</article-title>. <source>Nano Today</source>
<year>2021</year>, <volume>36</volume>, <fpage>36</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2020.101054</pub-id>.</mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>Nandwana</surname><given-names>V.</given-names></name>; <name><surname>Ryoo</surname><given-names>S.-R.</given-names></name>; <name><surname>Kanthala</surname><given-names>S.</given-names></name>; <name><surname>McMahon</surname><given-names>K. M.</given-names></name>; <name><surname>Rink</surname><given-names>J. S.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Venkatraman</surname><given-names>S. S.</given-names></name>; <name><surname>Thaxton</surname><given-names>C. S.</given-names></name>; <name><surname>Dravid</surname><given-names>V. P.</given-names></name>
<article-title>High-Density
Lipoprotein-like Magnetic Nanostructures(HDL-MNS): Theranostic Agents
for Cardiovascular Disease</article-title>. <source>Chem. Mater.</source>
<year>2017</year>, <volume>29</volume> (<issue>5</issue>), <fpage>2276</fpage>&#x02013;<lpage>2282</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemmater.6b05357</pub-id>.</mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name><surname>He</surname><given-names>B.</given-names></name>; <name><surname>Yang</surname><given-names>Q.</given-names></name>
<article-title>Recent Development
of LDL-Based Nanoparticles for Cancer Therapy</article-title>. <source>Pharmaceuticals.</source>
<year>2023</year>, <volume>16</volume> (<issue>1</issue>), <fpage>18</fpage><pub-id pub-id-type="doi">10.3390/ph16010018</pub-id>.</mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name><surname>Fracassi</surname><given-names>A.</given-names></name>; <name><surname>Cao</surname><given-names>J.</given-names></name>; <name><surname>Yoshizawa</surname><given-names>S. N.</given-names></name>; <name><surname>T&#x000f3;th</surname><given-names>&#x000c9;.</given-names></name>; <name><surname>Archer</surname><given-names>C.</given-names></name>; et al. <article-title>LDL-mimetic
lipid nanoparticles prepared by surface KAT ligation for MRI of atherosclerosis</article-title>. <source>Chem. Sci.</source>
<year>2020</year>, <volume>11</volume> (<issue>44</issue>), <fpage>11998</fpage>&#x02013;<lpage>12008</lpage>. <pub-id pub-id-type="doi">10.1039/D0SC04106H</pub-id>.<pub-id pub-id-type="pmid">34094421</pub-id>
</mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name><surname>Li</surname><given-names>R.</given-names></name>; <name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>Zhan</surname><given-names>Y.</given-names></name>; <name><surname>Luo</surname><given-names>G.</given-names></name>
<article-title>Comparison of MRI and ultrasound
in diagnosis of carotid atherosclerosis</article-title>. <source>Chin.
J. Modern Drug Appl.</source>
<year>2021</year>, <volume>15</volume> (<issue>9</issue>), <fpage>90</fpage>&#x02013;<lpage>92</lpage>.</mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name><surname>Luo</surname><given-names>H.</given-names></name>; <name><surname>Yang</surname><given-names>Q.</given-names></name>; <name><surname>Xiang</surname><given-names>B.</given-names></name>; <name><surname>Yang</surname><given-names>X.</given-names></name>
<article-title>MRI in diagnosing atherosclerotic
plaque of carotid arteries: Meta-analysis</article-title>. <source>Chinese
J. Interv. Imag. Ther.</source>
<year>2018</year>, <volume>15</volume> (<issue>7</issue>), <fpage>409</fpage>&#x02013;<lpage>412</lpage>.</mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><name><surname>Dai</surname><given-names>Z.</given-names></name>; <name><surname>Xiao</surname><given-names>J.</given-names></name>; <name><surname>Xiao</surname><given-names>Z.</given-names></name>
<article-title>Value Analysis of 3.0 T High Resolution
Magnetic Resonance Imaging for Detection of Internal Components of
Carotid Atherosclerotic Plaque and Determination of Plaque Stability</article-title>. <source>Chin. Foreign Med. Treat.</source>
<year>2019</year>, <volume>38</volume> (<issue>27</issue>), <fpage>1</fpage>.</mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><name><surname>Pan</surname><given-names>T.</given-names></name>; <name><surname>Gao</surname><given-names>Y.</given-names></name>; <name><surname>Huang</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>M.</given-names></name>
<article-title>Research progress on imaging technology
for reviewing coronary atherosclerosis and carotid atherosclerosis</article-title>. <source>Chin. J. Evidence-Based Cardiovasc. Med.</source>
<year>2023</year>, <volume>15</volume> (<issue>2</issue>), <fpage>248</fpage>&#x02013;<lpage>250</lpage>.</mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name><surname>Din</surname><given-names>E.</given-names></name>; <name><surname>Lu</surname><given-names>D.</given-names></name>; <name><surname>Wei</surname><given-names>L.</given-names></name>; <name><surname>Shen</surname><given-names>J.</given-names></name>
<article-title>The Diagnostic Value of 18F-NaF and
18F-FDG PET/CT Imaging in Atherosclerotic Vulnerable Plaque</article-title>. <source>Chin. J. CT MRI</source>
<year>2022</year>, <volume>20</volume> (<issue>11</issue>), <fpage>170</fpage>&#x02013;<lpage>173</lpage>.</mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal" id="cit60"><name><surname>Maier</surname><given-names>A.</given-names></name>; <name><surname>Toner</surname><given-names>Y. C.</given-names></name>; <name><surname>Munitz</surname><given-names>J.</given-names></name>; <name><surname>Sullivan</surname><given-names>N. A. T.</given-names></name>; <name><surname>Sakurai</surname><given-names>K.</given-names></name>; <name><surname>Meerwaldt</surname><given-names>A. E.</given-names></name>; <name><surname>Brechb&#x000fc;hl</surname><given-names>E. E.
S.</given-names></name>; <name><surname>Pr&#x000e9;vot</surname><given-names>G.</given-names></name>; <name><surname>van Elsas</surname><given-names>Y.</given-names></name>; <name><surname>Maas</surname><given-names>R. J. F.</given-names></name>; <name><surname>Ranzenigo</surname><given-names>A.</given-names></name>; <name><surname>Soultanidis</surname><given-names>G.</given-names></name>; <name><surname>Rashidian</surname><given-names>M.</given-names></name>; <name><surname>P&#x000e9;rez-Medina</surname><given-names>C.</given-names></name>; <name><surname>Heo</surname><given-names>G. S.</given-names></name>; <name><surname>Gropler</surname><given-names>R. J.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Reiner</surname><given-names>T.</given-names></name>; <name><surname>Nahrendorf</surname><given-names>M.</given-names></name>; <name><surname>Swirski</surname><given-names>F. K.</given-names></name>; <name><surname>Strijkers</surname><given-names>G. J.</given-names></name>; <name><surname>Teunissen</surname><given-names>A. J. P.</given-names></name>; <name><surname>Calcagno</surname><given-names>C.</given-names></name>; <name><surname>Fayad</surname><given-names>Z. A.</given-names></name>; <name><surname>Mulder</surname><given-names>W. J. M.</given-names></name>; <name><surname>van Leent</surname><given-names>M. M. T.</given-names></name>
<article-title>Multiparametric Immunoimaging Maps
Inflammatory Signatures in Murine Myocardial Infarction Models</article-title>. <source>JACC.Basic.Transl.Sci.</source>
<year>2023</year>, <volume>8</volume> (<issue>7</issue>), <fpage>801</fpage>&#x02013;<lpage>816</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacbts.2022.12.014</pub-id>.<pub-id pub-id-type="pmid">37547068</pub-id>
</mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal" id="cit61"><name><surname>Lobatto</surname><given-names>M. E.</given-names></name>; <name><surname>Calcagno</surname><given-names>C.</given-names></name>; <name><surname>Otten</surname><given-names>M. J.</given-names></name>; <name><surname>Millon</surname><given-names>A.</given-names></name>; <name><surname>Ramachandran</surname><given-names>S.</given-names></name>; <name><surname>Paridaans</surname><given-names>M. P.</given-names></name>; <name><surname>van der Valk</surname><given-names>F. M.</given-names></name>; <name><surname>Storm</surname><given-names>G.</given-names></name>; <name><surname>Stroes</surname><given-names>E. S.</given-names></name>; <name><surname>Fayad</surname><given-names>Z. A.</given-names></name>; <name><surname>Mulder</surname><given-names>W. J.</given-names></name>; <name><surname>Metselaar</surname><given-names>J. M.</given-names></name>
<article-title>Pharmaceutical
development and preclinical evaluation of a GMP-grade anti-inflammatory
nanotherapy</article-title>. <source>Nanomedicine.</source>
<year>2015</year>, <volume>11</volume> (<issue>5</issue>), <fpage>1133</fpage>&#x02013;<lpage>1140</lpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2015.02.020</pub-id>.<pub-id pub-id-type="pmid">25791805</pub-id>
</mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal" id="cit62"><name><surname>Wust</surname><given-names>R. C.I.</given-names></name>; <name><surname>Calcagno</surname><given-names>C.</given-names></name>; <name><surname>Daal</surname><given-names>M. R.R.</given-names></name>; <name><surname>Nederveen</surname><given-names>A. J.</given-names></name>; <name><surname>Coolen</surname><given-names>B. F.</given-names></name>; <name><surname>Strijkers</surname><given-names>G. J.</given-names></name>
<article-title>Emerging
Magnetic Resonance Imaging
Techniques for Atherosclerosis Imaging</article-title>. <source>Arterioscler.
Thromb. Vasc. Biol.</source>
<year>2019</year>, <volume>39</volume> (<issue>5</issue>), <fpage>841</fpage>&#x02013;<lpage>849</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.118.311756</pub-id>.<pub-id pub-id-type="pmid">30917678</pub-id>
</mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal" id="cit63"><name><surname>Ahmadi</surname><given-names>A.</given-names></name>; <name><surname>Argulian</surname><given-names>E.</given-names></name>; <name><surname>Leipsic</surname><given-names>J.</given-names></name>; <name><surname>Newby</surname><given-names>D. E.</given-names></name>; <name><surname>Narula</surname><given-names>J.</given-names></name>
<article-title>From Subclinical
Atherosclerosis to Plaque Progression and Acute Coronary Events: JACC
State-of-the-Art Review</article-title>. <source>J.Am.Coll.Cardiol.</source>
<year>2019</year>, <volume>74</volume> (<issue>12</issue>), <fpage>1608</fpage>&#x02013;<lpage>1617</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2019.08.012</pub-id>.<pub-id pub-id-type="pmid">31537271</pub-id>
</mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal" id="cit64"><name><surname>Buhaescu</surname><given-names>I.</given-names></name>; <name><surname>Izzedine</surname><given-names>H.</given-names></name>
<article-title>Gadolinium-induced nephrotoxicity</article-title>. <source>Int.J.Clin.Pract.</source>
<year>2008</year>, <volume>62</volume> (<issue>7</issue>), <fpage>1113</fpage>&#x02013;<lpage>1118</lpage>. <pub-id pub-id-type="doi">10.1111/j.1742-1241.2007.01582.x</pub-id>.<pub-id pub-id-type="pmid">18218006</pub-id>
</mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal" id="cit65"><name><surname>Grobner</surname><given-names>T.</given-names></name>; <name><surname>Prischl</surname><given-names>F. C.</given-names></name>
<article-title>Gadolinium and nephrogenic
systemic fibrosis</article-title>. <source>Kidney. Int.</source>
<year>2007</year>, <volume>72</volume> (<issue>3</issue>), <fpage>260</fpage>&#x02013;<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ki.5002338</pub-id>.<pub-id pub-id-type="pmid">17507905</pub-id>
</mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal" id="cit66"><name><surname>Slastan</surname><given-names>M.</given-names></name>; <name><surname>Dobrota</surname><given-names>D.</given-names></name>
<article-title>Barium Retention Following
Examination for Pylorus
Stenosis</article-title>. <source>Gastroenterol. Res.</source>
<year>2019</year>, <volume>12</volume> (<issue>4</issue>), <fpage>216</fpage>&#x02013;<lpage>220</lpage>. <pub-id pub-id-type="doi">10.14740/gr1191</pub-id>.</mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal" id="cit67"><name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Zhou</surname><given-names>S.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Jiang</surname><given-names>X.</given-names></name>
<article-title>Fluorescence Imaging
of Inflammation with Optical Probes</article-title>. <source>Methods
Mol. Biol.</source>
<year>2023</year>, <volume>1</volume> (<issue>6</issue>), <fpage>495</fpage>&#x02013;<lpage>508</lpage>. <pub-id pub-id-type="doi">10.1021/cbmi.3c00039</pub-id>.</mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal" id="cit68"><name><surname>Deng</surname><given-names>H.</given-names></name>; <name><surname>Li</surname><given-names>Xu.</given-names></name>; <name><surname>Ju</surname><given-names>J.</given-names></name>; <name><surname>Mo</surname><given-names>X.</given-names></name>; <name><surname>Ge</surname><given-names>G.</given-names></name>; <name><surname>Zhu</surname><given-names>X.</given-names></name>
<article-title>Multifunctional
nanoprobes for macrophage imaging</article-title>. <source>Biomaterials</source>
<year>2022</year>, <volume>290</volume>, <fpage>121824</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121824</pub-id>.<pub-id pub-id-type="pmid">36209580</pub-id>
</mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal" id="cit69"><name><surname>Thakor</surname><given-names>A. S.</given-names></name>; <name><surname>Jokerst</surname><given-names>J. V.</given-names></name>; <name><surname>Ghanouni</surname><given-names>P.</given-names></name>; <name><surname>Campbell</surname><given-names>J. L.</given-names></name>; <name><surname>Mittra</surname><given-names>E.</given-names></name>; <name><surname>Gambhir</surname><given-names>S. S.</given-names></name>
<article-title>Clinically Approved
Nanoparticle Imaging Agents</article-title>. <source>J. Nucl. Med.</source>
<year>2016</year>, <volume>57</volume> (<issue>12</issue>), <fpage>1833</fpage>&#x02013;<lpage>1837</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.116.181362</pub-id>.<pub-id pub-id-type="pmid">27738007</pub-id>
</mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal" id="cit70"><name><surname>P&#x000e9;Rigo</surname><given-names>E. A.</given-names></name>; <name><surname>Hemery</surname><given-names>G.</given-names></name>; <name><surname>Sandre</surname><given-names>O.</given-names></name>; <name><surname>Ortega</surname><given-names>D.</given-names></name>; <name><surname>Garaio</surname><given-names>E.</given-names></name>; <name><surname>Plazaola</surname><given-names>F.</given-names></name>; <name><surname>Teran</surname><given-names>F. J.</given-names></name>
<article-title>Fundamentals and advances in magnetic
hyperthermia</article-title>. <source>Appl. Phys. Rev.</source>
<year>2015</year>, <volume>2</volume> (<issue>4</issue>), <fpage>041302</fpage><pub-id pub-id-type="doi">10.1063/1.4935688</pub-id>.</mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal" id="cit71"><name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>He</surname><given-names>H.</given-names></name>; <name><surname>Mao</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Gu</surname><given-names>N.</given-names></name>
<article-title>Advances in Atherosclerosis
Theranostics Harnessing Iron Oxide-Based Nanoparticles</article-title>. <source>Adv. Sci.</source>
<year>2024</year>, <volume>11</volume> (<issue>17</issue>), <elocation-id>e2308298</elocation-id><pub-id pub-id-type="doi">10.1002/advs.202308298</pub-id>.</mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal" id="cit72"><name><surname>Dadfar</surname><given-names>S. M.</given-names></name>; <name><surname>Roemhild</surname><given-names>K.</given-names></name>; <name><surname>Drude</surname><given-names>N. I.</given-names></name>; <name><surname>von Stillfried</surname><given-names>S.</given-names></name>; <name><surname>Kn&#x000fc;chel</surname><given-names>R.</given-names></name>; <name><surname>Kiessling</surname><given-names>F.</given-names></name>; <name><surname>Lammers</surname><given-names>T.</given-names></name>
<article-title>Iron oxide nanoparticles:
Diagnostic, therapeutic and theranostic applications</article-title>. <source>Adv.Drug.DeliveryRev.</source>
<year>2019</year>, <volume>138</volume>, <fpage>302</fpage>&#x02013;<lpage>325</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2019.01.005</pub-id>.</mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal" id="cit73"><name><surname>Chhour</surname><given-names>P.</given-names></name>; <name><surname>Naha</surname><given-names>P. C.</given-names></name>; <name><surname>O&#x02019;Neill</surname><given-names>S. M.</given-names></name>; <name><surname>Litt</surname><given-names>H. I.</given-names></name>; <name><surname>Reilly</surname><given-names>M. P.</given-names></name>; <name><surname>Ferrari</surname><given-names>V. A.</given-names></name>; <name><surname>Cormode</surname><given-names>D. P.</given-names></name>
<article-title>Labeling
monocytes with gold nanoparticles
to track their recruitment in atherosclerosis with computed tomography</article-title>. <source>Biomaterials.</source>
<year>2016</year>, <volume>87</volume>, <fpage>93</fpage>&#x02013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.02.009</pub-id>.<pub-id pub-id-type="pmid">26914700</pub-id>
</mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal" id="cit74"><name><surname>Liu</surname><given-names>T.</given-names></name>; <name><surname>Li</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Shuai</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>L.</given-names></name>; <name><surname>Xu</surname><given-names>S.</given-names></name>
<article-title>Nanoparticle-and
Exosome-based Targeted Drug Delivery Systems Used
in the Diagnosis and Treatment of Atherosclerosis: Opportunities and
Challenges</article-title>. <source>CGPJ</source>
<year>2023</year>, <volume>26</volume> (<issue>08</issue>), <fpage>903</fpage>&#x02013;<lpage>910</lpage>.</mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal" id="cit75"><name><surname>Ai</surname><given-names>K.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Yuan</surname><given-names>Q.</given-names></name>; <name><surname>He</surname><given-names>Y.</given-names></name>; <name><surname>Lu</surname><given-names>L.</given-names></name>
<article-title>Large-scale
synthesis of Bi(2)S(3) nanodots as a contrast agent for in vivo X-ray
computed tomography imaging</article-title>. <source>Adv. Mater.</source>
<year>2011</year>, <volume>23</volume> (<issue>42</issue>), <fpage>4886</fpage>&#x02013;<lpage>4891</lpage>. <pub-id pub-id-type="doi">10.1002/adma.201103289</pub-id>.<pub-id pub-id-type="pmid">21956662</pub-id>
</mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal" id="cit76"><name><surname>Yang</surname><given-names>Z.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Yu</surname><given-names>X.</given-names></name>
<article-title>Application
of bismuth sulfide based nanomaterials in cancer diagnosis and treatment</article-title>. <source>Nano Today.</source>
<year>2023</year>, <volume>49</volume>, <fpage>101799</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2023.101799</pub-id>.</mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal" id="cit77"><name><surname>Wen</surname><given-names>L.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Zheng</surname><given-names>S.</given-names></name>; <name><surname>Zeng</surname><given-names>J.</given-names></name>; <name><surname>Duan</surname><given-names>G.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>G.</given-names></name>; <name><surname>Chai</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Gao</surname><given-names>M.</given-names></name>
<article-title>Ultrasmall
Biocompatible WO3- x Nanodots for Multi-Modality Imaging
and Combined Therapy of Cancers</article-title>. <source>Adv. Mater.</source>
<year>2016</year>, <volume>28</volume> (<issue>25</issue>), <fpage>5072</fpage>&#x02013;<lpage>5079</lpage>. <pub-id pub-id-type="doi">10.1002/adma.201506428</pub-id>.<pub-id pub-id-type="pmid">27136070</pub-id>
</mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal" id="cit78"><name><surname>Kheirolomoom</surname><given-names>A.</given-names></name>; <name><surname>Kim</surname><given-names>C. W.</given-names></name>; <name><surname>Seo</surname><given-names>J. W.</given-names></name>; <name><surname>Kumar</surname><given-names>S.</given-names></name>; <name><surname>Son</surname><given-names>D. J.</given-names></name>; <name><surname>Gagnon</surname><given-names>M. K.</given-names></name>; <name><surname>Ingham</surname><given-names>E. S.</given-names></name>; <name><surname>Ferrara</surname><given-names>K. W.</given-names></name>; <name><surname>Jo</surname><given-names>H.</given-names></name>
<article-title>Multifunctional
nanoparticles facilitate molecular targeting and miRNA delivery to
inhibit atherosclerosis in ApoE(&#x02212;/&#x02212;) mice</article-title>. <source>ACS.Nano.</source>
<year>2015</year>, <volume>9</volume> (<issue>9</issue>), <fpage>8885</fpage>&#x02013;<lpage>8897</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.5b02611</pub-id>.<pub-id pub-id-type="pmid">26308181</pub-id>
</mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal" id="cit79"><name><surname>Calin</surname><given-names>M.</given-names></name>; <name><surname>Stan</surname><given-names>D.</given-names></name>; <name><surname>Schlesinger</surname><given-names>M.</given-names></name>; <name><surname>Simion</surname><given-names>V.</given-names></name>; <name><surname>Deleanu</surname><given-names>M.</given-names></name>; <name><surname>Constantinescu</surname><given-names>C. A.</given-names></name>; <name><surname>Gan</surname><given-names>A. M.</given-names></name>; <name><surname>Pirvulescu</surname><given-names>M. M.</given-names></name>; <name><surname>Butoi</surname><given-names>E.</given-names></name>; <name><surname>Manduteanu</surname><given-names>I.</given-names></name>; <name><surname>Bota</surname><given-names>M.</given-names></name>; <name><surname>Enachescu</surname><given-names>M.</given-names></name>; <name><surname>Borsig</surname><given-names>L.</given-names></name>; <name><surname>Bendas</surname><given-names>G.</given-names></name>; <name><surname>Simionescu</surname><given-names>M.</given-names></name>
<article-title>VCAM-1 directed
target-sensitive liposomes carrying CCR2 antagonists bind to activated
endothelium and reduce adhesion and transmigration of monocytes</article-title>. <source>Eur.J.Pharm.Biopharm.</source>
<year>2015</year>, <volume>89</volume> (<issue>89</issue>), <fpage>18</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2014.11.016</pub-id>.<pub-id pub-id-type="pmid">25438248</pub-id>
</mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal" id="cit80"><name><surname>Poon</surname><given-names>C.</given-names></name>; <name><surname>Gallo</surname><given-names>J.</given-names></name>; <name><surname>Joo</surname><given-names>J.</given-names></name>; <name><surname>Chang</surname><given-names>T.</given-names></name>; <name><surname>Ba&#x000f1;obre-L&#x000f3;pez</surname><given-names>M.</given-names></name>; <name><surname>Chung</surname><given-names>E. J.</given-names></name>
<article-title>Hybrid, metal oxide-peptide amphiphile micelles for
molecular magnetic resonance imaging of atherosclerosis</article-title>. <source>J. Nanobiotechnol.</source>
<year>2018</year>, <volume>16</volume> (<issue>1</issue>), <fpage>92</fpage><pub-id pub-id-type="doi">10.1186/s12951-018-0420-8</pub-id>.</mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal" id="cit81"><name><surname>Yoo</surname><given-names>S. P.</given-names></name>; <name><surname>Pineda</surname><given-names>F.</given-names></name>; <name><surname>Barrett</surname><given-names>J. C.</given-names></name>; <name><surname>Poon</surname><given-names>C.</given-names></name>; <name><surname>Tirrell</surname><given-names>M.</given-names></name>; <name><surname>Chung</surname><given-names>E. J.</given-names></name>
<article-title>Gadolinium-Functionalized Peptide
Amphiphile Micelles
for Multimodal Imaging of Atherosclerotic Lesions</article-title>. <source>ACS.omega.</source>
<year>2016</year>, <volume>1</volume> (<issue>5</issue>), <fpage>996</fpage>&#x02013;<lpage>1003</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.6b00210</pub-id>.<pub-id pub-id-type="pmid">27917409</pub-id>
</mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal" id="cit82"><name><surname>Ma</surname><given-names>B.</given-names></name>; <name><surname>Xu</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Yang</surname><given-names>L.</given-names></name>; <name><surname>Zhuang</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>G.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>
<article-title>Biomimetic-Coated
Nanoplatform with Lipid-Specific Imaging and ROS
Responsiveness for Atherosclerosis-Targeted Theranostics</article-title>. <source>ACS. Appl. Mater. Interfaces</source>
<year>2021</year>, <volume>13</volume> (<issue>30</issue>), <fpage>35410</fpage>&#x02013;<lpage>35421</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.1c08552</pub-id>.<pub-id pub-id-type="pmid">34286950</pub-id>
</mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal" id="cit83"><name><surname>Poh</surname><given-names>S.</given-names></name>; <name><surname>Putt</surname><given-names>K. S.</given-names></name>; <name><surname>Low</surname><given-names>P. S.</given-names></name>
<article-title>Folate-targeted
dendrimers selectively
accumulate at sites of inflammation in mouse models of ulcerative
colitis and atherosclerosis</article-title>. <source>Biomacromolecules.</source>
<year>2017</year>, <volume>18</volume> (<issue>10</issue>), <fpage>3082</fpage>&#x02013;<lpage>3088</lpage>. <pub-id pub-id-type="doi">10.1021/acs.biomac.7b00728</pub-id>.<pub-id pub-id-type="pmid">28863264</pub-id>
</mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal" id="cit84"><name><surname>Allen</surname><given-names>S. D.</given-names></name>; <name><surname>Liu</surname><given-names>Y. G.</given-names></name>; <name><surname>Kim</surname><given-names>T.</given-names></name>; <name><surname>Bobbala</surname><given-names>S.</given-names></name>; <name><surname>Yi</surname><given-names>S.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Choi</surname><given-names>J.</given-names></name>; <name><surname>Scott</surname><given-names>E. A.</given-names></name>
<article-title>Celastrol-loaded
PEG-b-PPS nanocarriers as an anti-inflammatory treatment for atherosclerosis</article-title>. <source>Biomater.Sci.</source>
<year>2019</year>, <volume>7</volume> (<issue>2</issue>), <fpage>657</fpage>&#x02013;<lpage>668</lpage>. <pub-id pub-id-type="doi">10.1039/C8BM01224E</pub-id>.<pub-id pub-id-type="pmid">30601470</pub-id>
</mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal" id="cit85"><name><surname>He</surname><given-names>H.</given-names></name>; <name><surname>Han</surname><given-names>Q.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Long</surname><given-names>M.</given-names></name>; <name><surname>Zhang</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Gu</surname><given-names>N.</given-names></name>
<article-title>Design of a Multifunctional Nanozyme
for Resolving the Proinflammatory Plaque Microenvironment and Attenuating
Atherosclerosis</article-title>. <source>ACS.Nano.</source>
<year>2023</year>, <volume>17</volume> (<issue>15</issue>), <fpage>14555</fpage>&#x02013;<lpage>14571</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.3c01420</pub-id>.<pub-id pub-id-type="pmid">37350440</pub-id>
</mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal" id="cit86"><name><surname>Gao</surname><given-names>C.</given-names></name>; <name><surname>Huang</surname><given-names>Q.</given-names></name>; <name><surname>Liu</surname><given-names>C.</given-names></name>; <name><surname>Kwong</surname><given-names>C. H. T.</given-names></name>; <name><surname>Yue</surname><given-names>L.</given-names></name>; <name><surname>Wan</surname><given-names>J. B.</given-names></name>; <name><surname>Lee</surname><given-names>S.M. Y.</given-names></name>; <name><surname>Wang</surname><given-names>R.</given-names></name>
<article-title>Treatment of atherosclerosis
by macrophage-biomimetic nanoparticles via targeted pharmacotherapy
and sequestration of proinflammatory cytokines</article-title>. <source>Nat. Commun.</source>
<year>2020</year>, <volume>11</volume> (<issue>1</issue>), <fpage>2622</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16439-7</pub-id>.<pub-id pub-id-type="pmid">32457361</pub-id>
</mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal" id="cit87"><name><surname>Boada</surname><given-names>C.</given-names></name>; <name><surname>Boada</surname><given-names>C.</given-names></name>; <name><surname>Zinger</surname><given-names>A.</given-names></name>; <name><surname>Tsao</surname><given-names>C.</given-names></name>; <name><surname>Zhao</surname><given-names>P.</given-names></name>; et al. <article-title>Rapamycin-Loaded Biomimetic Nanoparticles Reverse Vascular Inflammation</article-title>. <source>Circ. Res.</source>
<year>2020</year>, <volume>126</volume> (<issue>1</issue>), <fpage>25</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.315185</pub-id>.<pub-id pub-id-type="pmid">31647755</pub-id>
</mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal" id="cit88"><name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>He</surname><given-names>M.</given-names></name>; <name><surname>Yuan</surname><given-names>Y.</given-names></name>; <name><surname>Nie</surname><given-names>C.</given-names></name>; <name><surname>Wei</surname><given-names>K.</given-names></name>; <name><surname>Zhang</surname><given-names>T.</given-names></name>; <name><surname>Chen</surname><given-names>T.</given-names></name>; <name><surname>Chu</surname><given-names>X.</given-names></name>
<article-title>Neutrophil-Membrane-Coated
Biomineralized
Metal-Organic Framework Nanoparticles for Atherosclerosis Treatment
by Targeting Gene Silencing</article-title>. <source>ACS.Nano.</source>
<year>2023</year>, <volume>17</volume> (<issue>8</issue>), <fpage>7721</fpage>&#x02013;<lpage>7732</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.3c00288</pub-id>.<pub-id pub-id-type="pmid">37023215</pub-id>
</mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal" id="cit89"><name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Zhen</surname><given-names>X.</given-names></name>; <name><surname>Lyu</surname><given-names>Y.</given-names></name>; <name><surname>Jiang</surname><given-names>Y.</given-names></name>; <name><surname>Huang</surname><given-names>J.</given-names></name>; <name><surname>Pu</surname><given-names>K.</given-names></name>
<article-title>Cell Membrane Coated
Semiconducting Polymer Nanoparticles for Enhanced
Multimodal Cancer Phototheranostics</article-title>. <source>ACS.Nano.</source>
<year>2018</year>, <volume>12</volume> (<issue>8</issue>), <fpage>8520</fpage>&#x02013;<lpage>8530</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.8b04066</pub-id>.<pub-id pub-id-type="pmid">30071159</pub-id>
</mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal" id="cit90"><name><surname>Kunde</surname><given-names>S. S.</given-names></name>; <name><surname>Wairkar</surname><given-names>S.</given-names></name>
<article-title>Platelet membrane camoufaged nanoparticles: Biomimetic
architecture for targeted therapy</article-title>. <source>Int. J. Pharm.</source>
<year>2021</year>, <volume>598</volume>, <fpage>120395</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120395</pub-id>.<pub-id pub-id-type="pmid">33639226</pub-id>
</mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal" id="cit91"><name><surname>Oroojalian</surname><given-names>F.</given-names></name>; <name><surname>Beygi</surname><given-names>M.</given-names></name>; <name><surname>Baradaran</surname><given-names>B.</given-names></name>; <name><surname>Mokhtarzadeh</surname><given-names>A.</given-names></name>; <name><surname>Shahbazi</surname><given-names>M. A.</given-names></name>
<article-title>Immune Cell Membrane-Coated Biomimetic
Nanoparticles
for Targeted Cancer Therapy</article-title>. <source>Small</source>
<year>2021</year>, <volume>17</volume> (<issue>12</issue>), <elocation-id>e2006484</elocation-id><pub-id pub-id-type="doi">10.1002/smll.202006484</pub-id>.<pub-id pub-id-type="pmid">33577127</pub-id>
</mixed-citation></ref><ref id="ref92"><mixed-citation publication-type="journal" id="cit92"><name><surname>Liu</surname><given-names>G.</given-names></name>; <name><surname>Zhao</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Min</surname><given-names>H.</given-names></name>; <name><surname>Shi</surname><given-names>J.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Wei</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Nie</surname><given-names>G.</given-names></name>
<article-title>Engineering
Biomimetic Platesomes
for pH-Responsive Drug Delivery and Enhanced Antitumor Activity</article-title>. <source>Adv. Mater.</source>
<year>2019</year>, <volume>31</volume> (<issue>32</issue>), <elocation-id>e1900795</elocation-id><pub-id pub-id-type="doi">10.1002/adma.201900795</pub-id>.<pub-id pub-id-type="pmid">31222856</pub-id>
</mixed-citation></ref><ref id="ref93"><mixed-citation publication-type="journal" id="cit93"><name><surname>Gao</surname><given-names>Z.</given-names></name>; <name><surname>Ma</surname><given-names>T.</given-names></name>; <name><surname>Zhao</surname><given-names>E.</given-names></name>; <name><surname>Docter</surname><given-names>D.</given-names></name>; <name><surname>Yang</surname><given-names>W.</given-names></name>; <name><surname>Stauber</surname><given-names>R. H.</given-names></name>; <name><surname>Gao</surname><given-names>M.</given-names></name>
<article-title>Small is Smarter:
Nano MRI Contrast Agents-Advantages and Recent
Achievements</article-title>. <source>Small.</source>
<year>2016</year>, <volume>12</volume> (<issue>5</issue>), <fpage>556</fpage>&#x02013;<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1002/smll.201502309</pub-id>.<pub-id pub-id-type="pmid">26680328</pub-id>
</mixed-citation></ref><ref id="ref94"><mixed-citation publication-type="journal" id="cit94"><name><surname>Hyafil</surname><given-names>F.</given-names></name>; <name><surname>Feldman</surname><given-names>L.</given-names></name>; <name><surname>Fayad</surname><given-names>Z. A.</given-names></name>; <name><surname>Le Guludec</surname><given-names>D.</given-names></name>
<article-title>Imaging atherosclerotic
plaques with MRI: Role of Contrast Agents</article-title>. <source>Curr.
Cardiovasc. Imag.</source>
<year>2013</year>, <volume>6</volume> (<issue>1</issue>), <fpage>76</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1007/s12410-012-9179-8</pub-id>.</mixed-citation></ref><ref id="ref95"><mixed-citation publication-type="journal" id="cit95"><name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Tang</surname><given-names>Z.</given-names></name>; <name><surname>Wang</surname><given-names>Q.</given-names></name>
<article-title>Research progress on ophthalmic drug
delivery systems</article-title>. <source>Chin. J. Mod. Appl. Pharm.</source>
<year>2021</year>, <volume>38</volume> (<issue>18</issue>), <fpage>2296</fpage>&#x02013;<lpage>2304</lpage>.</mixed-citation></ref><ref id="ref96"><mixed-citation publication-type="journal" id="cit96"><name><surname>Han</surname><given-names>Y.</given-names></name>; <name><surname>Zhou</surname><given-names>X.</given-names></name>; <name><surname>Qian</surname><given-names>Y.</given-names></name>; <name><surname>Hu</surname><given-names>H.</given-names></name>; <name><surname>Zhou</surname><given-names>Z.</given-names></name>; <name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Tang</surname><given-names>J.</given-names></name>; <name><surname>Shen</surname><given-names>Y.</given-names></name>
<article-title>Hypoxia-targeting
dendritic MRI contrast
agent based on internally hydroxy dendrimer for tumor imaging</article-title>. <source>Biomaterials.</source>
<year>2019</year>, <volume>213</volume>, <fpage>119195</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.05.006</pub-id>.<pub-id pub-id-type="pmid">31132643</pub-id>
</mixed-citation></ref><ref id="ref97"><mixed-citation publication-type="journal" id="cit97"><name><surname>Zhang</surname><given-names>S.</given-names></name>; <name><surname>Lloveras</surname><given-names>V.</given-names></name>; <name><surname>Pulido</surname><given-names>D.</given-names></name>; <name><surname>Liko</surname><given-names>F.</given-names></name>; <name><surname>Pinto</surname><given-names>L. F.</given-names></name>; <name><surname>Albericio</surname><given-names>F.</given-names></name>; <name><surname>Royo</surname><given-names>M.</given-names></name>; <name><surname>Vidal-Gancedo</surname><given-names>J.</given-names></name>
<article-title>Radical dendrimers
based on biocompatible oligoethylene glycol dendrimers as contrast
agents for MRI</article-title>. <source>Pharmaceutics</source>
<year>2020</year>, <volume>12</volume> (<issue>8</issue>), <fpage>772</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics12080772</pub-id>.<pub-id pub-id-type="pmid">32823903</pub-id>
</mixed-citation></ref><ref id="ref98"><mixed-citation publication-type="journal" id="cit98"><name><surname>Cao</surname><given-names>Y.</given-names></name>; <name><surname>Zu</surname><given-names>G.</given-names></name>; <name><surname>Kuang</surname><given-names>Y.</given-names></name>; <name><surname>He</surname><given-names>Y.</given-names></name>; <name><surname>Mao</surname><given-names>Z.</given-names></name>; <name><surname>Liu</surname><given-names>M.</given-names></name>; <name><surname>Xiong</surname><given-names>D.</given-names></name>; <name><surname>Pei</surname><given-names>R.</given-names></name>
<article-title>Biodegradable
Nanoglobular Magnetic
Resonance Imaging Contrast Agent Constructed with Host-Guest Self-Assembly
for Tumor-Targeted Imaging</article-title>. <source>ACS.Appl.Mater.Interfaces.</source>
<year>2018</year>, <volume>10</volume> (<issue>32</issue>), <fpage>26906</fpage>&#x02013;<lpage>26916</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.8b08021</pub-id>.<pub-id pub-id-type="pmid">30028584</pub-id>
</mixed-citation></ref><ref id="ref99"><mixed-citation publication-type="journal" id="cit99"><name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Centurion</surname><given-names>F.</given-names></name>; <name><surname>Chen</surname><given-names>R.</given-names></name>; <name><surname>Gu</surname><given-names>Z.</given-names></name>
<article-title>Intravascular Imaging
of Atherosclerosis by Using Engineered Nanoparticles</article-title>. <source>Biosensors</source>
<year>2023</year>, <volume>13</volume> (<issue>3</issue>), <fpage>319</fpage><pub-id pub-id-type="doi">10.3390/bios13030319</pub-id>.<pub-id pub-id-type="pmid">36979531</pub-id>
</mixed-citation></ref><ref id="ref100"><mixed-citation publication-type="journal" id="cit100"><name><surname>Fabbri</surname><given-names>F.</given-names></name>; <name><surname>Salvi</surname><given-names>S.</given-names></name>; <name><surname>Bravaccini</surname><given-names>S.</given-names></name>
<article-title>Know your
enemy: Genetics, aging, exposomic and inflammation in the war against
triple negative breast cancer</article-title>. <source>Semin.Cancer.Biol.</source>
<year>2020</year>, <volume>60</volume>, <fpage>285</fpage>&#x02013;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2019.10.015</pub-id>.<pub-id pub-id-type="pmid">31669505</pub-id>
</mixed-citation></ref><ref id="ref101"><mixed-citation publication-type="journal" id="cit101"><name><surname>Hwang</surname><given-names>S. Y.</given-names></name>; <name><surname>Park</surname><given-names>S.</given-names></name>; <name><surname>Kwon</surname><given-names>Y.</given-names></name>
<article-title>Recent therapeutic
trends and promising targets in triple negative breast cancer</article-title>. <source>Pharmacol.Ther.</source>
<year>2019</year>, <volume>199</volume>, <fpage>30</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2019.02.006</pub-id>.<pub-id pub-id-type="pmid">30825473</pub-id>
</mixed-citation></ref><ref id="ref102"><mixed-citation publication-type="journal" id="cit102"><name><surname>Muri</surname><given-names>J.</given-names></name>; <name><surname>Kopf</surname><given-names>M.</given-names></name>
<article-title>Redox regulation of
immunometabolism</article-title>. <source>Nat.Rev.Immunol.</source>
<year>2021</year>, <volume>21</volume> (<issue>6</issue>), <fpage>363</fpage>&#x02013;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-020-00478-8</pub-id>.<pub-id pub-id-type="pmid">33340021</pub-id>
</mixed-citation></ref><ref id="ref103"><mixed-citation publication-type="journal" id="cit103"><name><surname>Gao</surname><given-names>F.</given-names></name>; <name><surname>Tang</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>W.</given-names></name>; <name><surname>Zou</surname><given-names>M.</given-names></name>; <name><surname>Huang</surname><given-names>C.</given-names></name>; <name><surname>Liu</surname><given-names>C.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>
<article-title>Intra/Extracellular
Lactic Acid Exhaustion for Synergistic
Metabolic Therapy and Immunotherapy of Tumors</article-title>. <source>Adv. Mater.</source>
<year>2019</year>, <volume>31</volume> (<issue>51</issue>), <elocation-id>e1904639</elocation-id><pub-id pub-id-type="doi">10.1002/adma.201904639</pub-id>.<pub-id pub-id-type="pmid">31692128</pub-id>
</mixed-citation></ref><ref id="ref104"><mixed-citation publication-type="journal" id="cit104"><name><surname>Chauhan</surname><given-names>V. P.</given-names></name>; <name><surname>Chen</surname><given-names>I. X.</given-names></name>; <name><surname>Tong</surname><given-names>R.</given-names></name>; <name><surname>Ng</surname><given-names>M. R.</given-names></name>; <name><surname>Martin</surname><given-names>J. D.</given-names></name>; <name><surname>Naxerova</surname><given-names>K.</given-names></name>; <name><surname>Wu</surname><given-names>M. W.</given-names></name>; <name><surname>Huang</surname><given-names>P.</given-names></name>; <name><surname>Boucher</surname><given-names>Y.</given-names></name>; <name><surname>Kohane</surname><given-names>D. S.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Jain</surname><given-names>R. K.</given-names></name>
<article-title>Reprogramming
the microenvironment with tumor-selective angiotensin blockers enhances
cancer immunotherapy</article-title>. <source>Proc.Natl.Acad.Sci.U.S.A.</source>
<year>2019</year>, <volume>116</volume> (<issue>22</issue>), <fpage>10674</fpage>&#x02013;<lpage>10680</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1819889116</pub-id>.<pub-id pub-id-type="pmid">31040208</pub-id>
</mixed-citation></ref><ref id="ref105"><mixed-citation publication-type="journal" id="cit105"><name><surname>Choi</surname><given-names>H.</given-names></name>; <name><surname>Choi</surname><given-names>W.</given-names></name>; <name><surname>Kim</surname><given-names>J.</given-names></name>; <name><surname>Kong</surname><given-names>W. H.</given-names></name>; <name><surname>Kim</surname><given-names>K. S.</given-names></name>; <name><surname>Kim</surname><given-names>C.</given-names></name>; <name><surname>Hahn</surname><given-names>S. K.</given-names></name>
<article-title>Multifunctional
Nanodroplets Encapsulating Naphthalocyanine and Perfluorohexane for
Bimodal Image-Guided Therapy</article-title>. <source>Biomacromolecules.</source>
<year>2019</year>, <volume>20</volume> (<issue>10</issue>), <fpage>3767</fpage>&#x02013;<lpage>3777</lpage>. <pub-id pub-id-type="doi">10.1021/acs.biomac.9b00842</pub-id>.<pub-id pub-id-type="pmid">31483619</pub-id>
</mixed-citation></ref><ref id="ref106"><mixed-citation publication-type="journal" id="cit106"><name><surname>Yang</surname><given-names>X.</given-names></name>; <name><surname>Zhao</surname><given-names>M.</given-names></name>; <name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Guo</surname><given-names>Q.</given-names></name>; <name><surname>Wang</surname><given-names>Q.</given-names></name>; <name><surname>Liang</surname><given-names>S.</given-names></name>; <name><surname>Hu</surname><given-names>S.</given-names></name>; <name><surname>Duan</surname><given-names>Y.</given-names></name>; <name><surname>Sun</surname><given-names>Y.</given-names></name>
<article-title>Nano-ultrasonic
Contrast Agent for Chemoimmunotherapy of Breast Cancer by Immune Metabolism
Reprogramming and Tumor Autophagy</article-title>. <source>ACS.Nano.</source>
<year>2022</year>, <volume>16</volume> (<issue>2</issue>), <fpage>3417</fpage>&#x02013;<lpage>3431</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.2c00462</pub-id>.<pub-id pub-id-type="pmid">35156370</pub-id>
</mixed-citation></ref><ref id="ref107"><mixed-citation publication-type="journal" id="cit107"><name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Yi</surname><given-names>Z.</given-names></name>; <name><surname>Guo</surname><given-names>J.</given-names></name>; <name><surname>Liao</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Xu</surname><given-names>S.</given-names></name>; <name><surname>Tan</surname><given-names>W.</given-names></name>; et al. <article-title>In vivo ultrasound-induced
luminescence molecular imaging</article-title>. <source>Nat. Photon.</source>
<year>2024</year>, <volume>18</volume> (<issue>4</issue>), <fpage>334</fpage>&#x02013;<lpage>343</lpage>. <pub-id pub-id-type="doi">10.1038/s41566-024-01387-1</pub-id>.</mixed-citation></ref><ref id="ref108"><mixed-citation publication-type="journal" id="cit108"><name><surname>Sherry</surname><given-names>A. D.</given-names></name>; <name><surname>Caravan</surname><given-names>P.</given-names></name>; <name><surname>Lenkinski</surname><given-names>R. E.</given-names></name>
<article-title>Primer
on gadolinium chemistry</article-title>. <source>J.Magn.Reson.Imaging.</source>
<year>2009</year>, <volume>30</volume> (<issue>6</issue>), <fpage>1240</fpage>&#x02013;<lpage>1248</lpage>. <pub-id pub-id-type="doi">10.1002/jmri.21966</pub-id>.<pub-id pub-id-type="pmid">19938036</pub-id>
</mixed-citation></ref><ref id="ref109"><mixed-citation publication-type="journal" id="cit109"><name><surname>Hao</surname><given-names>D.</given-names></name>; <name><surname>Ai</surname><given-names>T.</given-names></name>; <name><surname>Goerner</surname><given-names>F.</given-names></name>; <name><surname>Hu</surname><given-names>X.</given-names></name>; <name><surname>Runge</surname><given-names>V. M.</given-names></name>; <name><surname>Tweedle</surname><given-names>M.</given-names></name>
<article-title>MRI contrast
agents: basic chemistry and safety</article-title>. <source>J.Magn.Reson.Imaging.</source>
<year>2012</year>, <volume>36</volume> (<issue>5</issue>), <fpage>1060</fpage>&#x02013;<lpage>1071</lpage>. <pub-id pub-id-type="doi">10.1002/jmri.23725</pub-id>.<pub-id pub-id-type="pmid">23090917</pub-id>
</mixed-citation></ref><ref id="ref110"><mixed-citation publication-type="journal" id="cit110"><name><surname>Kim</surname><given-names>H. K.</given-names></name>; <name><surname>Lee</surname><given-names>G. H.</given-names></name>; <name><surname>Chang</surname><given-names>Y.</given-names></name>
<article-title>Gadolinium as an MRI
contrast agent</article-title>. <source>Future Med.Chem.</source>
<year>2018</year>, <volume>10</volume> (<issue>6</issue>), <fpage>639</fpage>&#x02013;<lpage>661</lpage>. <pub-id pub-id-type="doi">10.4155/fmc-2017-0215</pub-id>.<pub-id pub-id-type="pmid">29412006</pub-id>
</mixed-citation></ref><ref id="ref111"><mixed-citation publication-type="journal" id="cit111"><name><surname>Werner</surname><given-names>E. J.</given-names></name>; <name><surname>Datta</surname><given-names>A.</given-names></name>; <name><surname>Jocher</surname><given-names>C. J.</given-names></name>; <name><surname>Raymond</surname><given-names>K. N.</given-names></name>
<article-title>High-relaxivity
MRI contrast agents: where coordination chemistry meets medical imaging</article-title>. <source>Angew.Chem.Int.Ed.</source>
<year>2008</year>, <volume>47</volume> (<issue>45</issue>), <fpage>8568</fpage>&#x02013;<lpage>8580</lpage>. <pub-id pub-id-type="doi">10.1002/anie.200800212</pub-id>.</mixed-citation></ref><ref id="ref112"><mixed-citation publication-type="journal" id="cit112"><name><surname>Lin</surname><given-names>Y. H.</given-names></name>; <name><surname>Hwang</surname><given-names>R. M.</given-names></name>; <name><surname>Chen</surname><given-names>B. B.</given-names></name>; <name><surname>Hsu</surname><given-names>C. Y.</given-names></name>; <name><surname>Yu</surname><given-names>C. W.</given-names></name>; <name><surname>Kao</surname><given-names>J. H.</given-names></name>; <name><surname>Lee</surname><given-names>H. S.</given-names></name>; <name><surname>Liang</surname><given-names>P. C.</given-names></name>; <name><surname>Wei</surname><given-names>S. Y.</given-names></name>; <name><surname>Shih</surname><given-names>T. T.</given-names></name>
<article-title>Vascular and hepatic
enhancements
at MR imaging: comparison of Gd-EOB-DTPA and Gd-DTPA in the same subjects</article-title>. <source>Clin.Imaging.</source>
<year>2014</year>, <volume>38</volume> (<issue>3</issue>), <fpage>287</fpage>&#x02013;<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinimag.2014.01.001</pub-id>.<pub-id pub-id-type="pmid">24556332</pub-id>
</mixed-citation></ref><ref id="ref113"><mixed-citation publication-type="journal" id="cit113"><name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Cheng</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>S.</given-names></name>; <name><surname>Zhang</surname><given-names>P.</given-names></name>; <name><surname>Gan</surname><given-names>Z.</given-names></name>; <name><surname>Hou</surname><given-names>Y.</given-names></name>
<article-title>High-Resolution Magnetic
Resonance Angiography of Tumor Vasculatures with an Interlocking Contrast
Agent</article-title>. <source>ACS.Nano.</source>
<year>2024</year>, <volume>18</volume> (<issue>37</issue>), <fpage>25647</fpage>&#x02013;<lpage>25656</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.4c07533</pub-id>.<pub-id pub-id-type="pmid">39216081</pub-id>
</mixed-citation></ref><ref id="ref114"><mixed-citation publication-type="journal" id="cit114"><name><surname>Zhang</surname><given-names>P.</given-names></name>; <name><surname>Cheng</surname><given-names>J.</given-names></name>; <name><surname>Lu</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>N.</given-names></name>; <name><surname>Wu</surname><given-names>X.</given-names></name>; <name><surname>Lin</surname><given-names>H.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Winnik</surname><given-names>M. A.</given-names></name>; <name><surname>Gan</surname><given-names>Z.</given-names></name>; <name><surname>Hou</surname><given-names>Y.</given-names></name>
<article-title>Hypersensitive
MR angiography based on interlocking
stratagem for diagnosis of cardiac-cerebral vascular diseases</article-title>. <source>Nat. Commun.</source>
<year>2023</year>, <volume>14</volume> (<issue>1</issue>), <fpage>6149</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-41783-9</pub-id>.<pub-id pub-id-type="pmid">37783733</pub-id>
</mixed-citation></ref><ref id="ref115"><mixed-citation publication-type="journal" id="cit115"><name><surname>Maiseyeu</surname><given-names>A.</given-names></name>; <name><surname>Mihai</surname><given-names>G.</given-names></name>; <name><surname>Kampfrath</surname><given-names>T.</given-names></name>; <name><surname>Simonetti</surname><given-names>O. P.</given-names></name>; <name><surname>Sen</surname><given-names>C. K.</given-names></name>; <name><surname>Roy</surname><given-names>S.</given-names></name>; <name><surname>Rajagopalan</surname><given-names>S.</given-names></name>; <name><surname>Parthasarathy</surname><given-names>S.</given-names></name>
<article-title>Gadolinium-containing phosphatidylserine liposomes
for molecular imaging of atherosclerosis</article-title>. <source>J.Lipid.Res.</source>
<year>2009</year>, <volume>50</volume> (<issue>11</issue>), <fpage>2157</fpage>&#x02013;<lpage>2163</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M800405-JLR200</pub-id>.<pub-id pub-id-type="pmid">19017616</pub-id>
</mixed-citation></ref><ref id="ref116"><mixed-citation publication-type="journal" id="cit116"><name><surname>Dellinger</surname><given-names>A.</given-names></name>; <name><surname>Olson</surname><given-names>J.</given-names></name>; <name><surname>Link</surname><given-names>K.</given-names></name>; <name><surname>Vance</surname><given-names>S.</given-names></name>; <name><surname>Sandros</surname><given-names>M. G.</given-names></name>; <name><surname>Yang</surname><given-names>J.</given-names></name>; <name><surname>Zhou</surname><given-names>Z.</given-names></name>; <name><surname>Kepley</surname><given-names>C. L.</given-names></name>
<article-title>Functionalization
of gadolinium metallofullerenes for detecting atherosclerotic plaque
lesions by cardiovascular magnetic resonance</article-title>. <source>J.Cardiovasc.Magn.Reson.</source>
<year>2013</year>, <volume>15</volume> (<issue>1</issue>), <fpage>7</fpage><pub-id pub-id-type="doi">10.1186/1532-429X-15-7</pub-id>.<pub-id pub-id-type="pmid">23324435</pub-id>
</mixed-citation></ref><ref id="ref117"><mixed-citation publication-type="journal" id="cit117"><name><surname>Mou</surname><given-names>X.</given-names></name>; <name><surname>Wu</surname><given-names>Q.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>C.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Fan</surname><given-names>K.</given-names></name>; <name><surname>Liu</surname><given-names>H.</given-names></name>
<article-title>Nanozymes
for Regenerative Medicine</article-title>. <source>Small Methods</source>
<year>2022</year>, <volume>6</volume> (<issue>11</issue>), <elocation-id>e2200997</elocation-id><pub-id pub-id-type="doi">10.1002/smtd.202200997</pub-id>.<pub-id pub-id-type="pmid">36202750</pub-id>
</mixed-citation></ref><ref id="ref118"><mixed-citation publication-type="journal" id="cit118"><name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Zhou</surname><given-names>Y.</given-names></name>; <name><surname>Liang</surname><given-names>X.</given-names></name>; <name><surname>Xu</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>N.</given-names></name>; <name><surname>Zhao</surname><given-names>K.</given-names></name>
<article-title>Platinum-Cerium Bimetallic Nano-Raspberry for Atherosclerosis
Treatment via Synergistic Foam Cell Inhibition and P2Y12 Targeted
Antiplatelet Aggregation</article-title>. <source>Chem.Eng.J.</source>
<year>2022</year>, <volume>430</volume>, <fpage>132859</fpage><pub-id pub-id-type="doi">10.1016/j.cej.2021.132859</pub-id>.</mixed-citation></ref><ref id="ref119"><mixed-citation publication-type="journal" id="cit119"><name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>W.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wei</surname><given-names>H.</given-names></name>
<article-title>Nanozyme-Enabled Treatment of Cardio-and Cerebrovascular
Diseases</article-title>. <source>Small</source>
<year>2023</year>, <volume>19</volume> (<issue>13</issue>), <elocation-id>e2204809</elocation-id><pub-id pub-id-type="doi">10.1002/smll.202204809</pub-id>.<pub-id pub-id-type="pmid">36192166</pub-id>
</mixed-citation></ref><ref id="ref120"><mixed-citation publication-type="journal" id="cit120"><name><surname>Fu</surname><given-names>X.</given-names></name>; <name><surname>Yu</surname><given-names>X.</given-names></name>; <name><surname>Jiang</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Yang</surname><given-names>Z.</given-names></name>; <name><surname>Yu</surname><given-names>C.</given-names></name>
<article-title>Small Molecule-Assisted
Assembly
of Multifunctional Ceria Nanozymes for Synergistic Treatment of Atherosclerosis</article-title>. <source>Nat. Commun.</source>
<year>2022</year>, <volume>13</volume>, <fpage>6528</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-34248-y</pub-id>.<pub-id pub-id-type="pmid">36319632</pub-id>
</mixed-citation></ref><ref id="ref121"><mixed-citation publication-type="journal" id="cit121"><name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Chen</surname><given-names>D.</given-names></name>; <name><surname>Tu</surname><given-names>J.</given-names></name>; <name><surname>Sun</surname><given-names>C.</given-names></name>; <name><surname>Du</surname><given-names>Y.</given-names></name>
<article-title>Hyaluronic
Acid-Guided Assembly of
Ceria Nanozymes as Plaque-Targeting ROS Scavengers for Anti-Atherosclerotic
Therapy</article-title>. <source>Carbohydr. Polym.</source>
<year>2022</year>, <volume>296</volume>, <fpage>119940</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2022.119940</pub-id>.<pub-id pub-id-type="pmid">36087989</pub-id>
</mixed-citation></ref><ref id="ref122"><mixed-citation publication-type="journal" id="cit122"><name><surname>Gao</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Zeng</surname><given-names>X.</given-names></name>; <name><surname>Guo</surname><given-names>Z.</given-names></name>; <name><surname>Chen</surname><given-names>D.</given-names></name>; <name><surname>Li</surname><given-names>S.</given-names></name>; <name><surname>Tian</surname><given-names>Z.</given-names></name>; <name><surname>Qu</surname><given-names>Y.</given-names></name>
<article-title>Reduction
of Reactive Oxygen Species
Accumulation Using Gadolinium-Doped Ceria for the Alleviation of Atherosclerosis</article-title>. <source>ACS.Appl.Mater.Interfaces.</source>
<year>2023</year>, <volume>15</volume> (<issue>8</issue>), <fpage>10414</fpage>&#x02013;<lpage>10425</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.2c20492</pub-id>.<pub-id pub-id-type="pmid">36802486</pub-id>
</mixed-citation></ref><ref id="ref123"><mixed-citation publication-type="thesis" id="cit123"><person-group person-group-type="allauthors"><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Study on the diagnosis
and drug release behavior of multifunctional composite nanoparticles
with atherosclerosis</article-title>. <publisher-name>Jilin University</publisher-name>, <year>2019</year>.</mixed-citation></ref><ref id="ref124"><mixed-citation publication-type="journal" id="cit124"><name><surname>Rabin</surname><given-names>O.</given-names></name>; <name><surname>Manuel Perez</surname><given-names>J.</given-names></name>; <name><surname>Grimm</surname><given-names>J.</given-names></name>; <name><surname>Wojtkiewicz</surname><given-names>G.</given-names></name>; <name><surname>Weissleder</surname><given-names>R.</given-names></name>
<article-title>An X-ray computed
tomography imaging agent based on
long-circulating bismuth sulphide nanoparticles</article-title>. <source>Nat. Mater.</source>
<year>2006</year>, <volume>5</volume> (<issue>2</issue>), <fpage>118</fpage>&#x02013;<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1038/nmat1571</pub-id>.<pub-id pub-id-type="pmid">16444262</pub-id>
</mixed-citation></ref><ref id="ref125"><mixed-citation publication-type="journal" id="cit125"><name><surname>Du</surname><given-names>F.</given-names></name>; <name><surname>Lou</surname><given-names>J.</given-names></name>; <name><surname>Jiang</surname><given-names>R.</given-names></name>; <name><surname>Fang</surname><given-names>Z.</given-names></name>; <name><surname>Zhao</surname><given-names>X.</given-names></name>; <name><surname>Niu</surname><given-names>Y.</given-names></name>; <name><surname>Zou</surname><given-names>S.</given-names></name>; <name><surname>Zhang</surname><given-names>M.</given-names></name>; <name><surname>Gong</surname><given-names>A.</given-names></name>; <name><surname>Wu</surname><given-names>C.</given-names></name>
<article-title>Hyaluronic
acid-functionalized bismuth oxide nanoparticles for computed tomography
imaging-guided radiotherapy of tumor</article-title>. <source>Int.J.Nanomedicine.</source>
<year>2017</year>, <volume>12</volume>, <fpage>5973</fpage>&#x02013;<lpage>5992</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S130455</pub-id>.<pub-id pub-id-type="pmid">28860761</pub-id>
</mixed-citation></ref><ref id="ref126"><mixed-citation publication-type="journal" id="cit126"><name><surname>Hu</surname><given-names>X.</given-names></name>; <name><surname>Sun</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>F.</given-names></name>; <name><surname>Li</surname><given-names>R.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>He</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>N.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Zhou</surname><given-names>F.</given-names></name>; <name><surname>Sun</surname><given-names>X.</given-names></name>; <name><surname>Kim</surname><given-names>D.</given-names></name>; <name><surname>Hyeon</surname><given-names>T.</given-names></name>; <name><surname>Ling</surname><given-names>D.</given-names></name>
<article-title>Renal-Clearable Hollow
Bismuth Subcarbonate Nanotubes for Tumor Targeted Computed Tomography
Imaging and Chemoradiotherapy</article-title>. <source>Nano.Lett.</source>
<year>2018</year>, <volume>18</volume> (<issue>2</issue>), <fpage>1196</fpage>&#x02013;<lpage>1204</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.7b04741</pub-id>.<pub-id pub-id-type="pmid">29297694</pub-id>
</mixed-citation></ref><ref id="ref127"><mixed-citation publication-type="journal" id="cit127"><name><surname>Su</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Han</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Qi</surname><given-names>S.</given-names></name>; <name><surname>Gao</surname><given-names>L.</given-names></name>; <name><surname>Shao</surname><given-names>Y.</given-names></name>; <name><surname>Qiao</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Liang</surname><given-names>S.</given-names></name>; <name><surname>Nie</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Cao</surname><given-names>F.</given-names></name>
<article-title>Multimodality imaging of angiogenesis
in a rabbit atherosclerotic model by GEBP11 Peptide targeted nanoparticles</article-title>. <source>Theranostics.</source>
<year>2017</year>, <volume>7</volume> (<issue>19</issue>), <fpage>4791</fpage>&#x02013;<lpage>4804</lpage>. <pub-id pub-id-type="doi">10.7150/thno.20767</pub-id>.<pub-id pub-id-type="pmid">29187904</pub-id>
</mixed-citation></ref><ref id="ref128"><mixed-citation publication-type="journal" id="cit128"><name><surname>Yang</surname><given-names>C.</given-names></name>; <name><surname>Ghosh</surname><given-names>K. K.</given-names></name>; <name><surname>Padmanabhan</surname><given-names>P.</given-names></name>; <name><surname>Langer</surname><given-names>O.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Eng</surname><given-names>D. N. C.</given-names></name>; <name><surname>Halldin</surname><given-names>C.</given-names></name>; <name><surname>Guly&#x000e1;s</surname><given-names>B.</given-names></name>
<article-title>PET-MR and SPECT-MR multimodality probes: development
and challenges</article-title>. <source>Theranostics.</source>
<year>2018</year>, <volume>8</volume> (<issue>22</issue>), <fpage>6210</fpage>&#x02013;<lpage>6232</lpage>. <pub-id pub-id-type="doi">10.7150/thno.26610</pub-id>.<pub-id pub-id-type="pmid">30613293</pub-id>
</mixed-citation></ref><ref id="ref129"><mixed-citation publication-type="journal" id="cit129"><name><surname>Seifert</surname><given-names>R.</given-names></name>; <name><surname>Kuhlmann</surname><given-names>M. T.</given-names></name>; <name><surname>Eligehausen</surname><given-names>S.</given-names></name>; <name><surname>Kiefer</surname><given-names>F.</given-names></name>; <name><surname>Hermann</surname><given-names>S.</given-names></name>; <name><surname>Sch&#x000e4;fers</surname><given-names>M.</given-names></name>
<article-title>Molecular
imaging of MMP activity discriminates unstable from stable plaque
phenotypes in shear-stress induced murine atherosclerosis</article-title>. <source>PLoS.One.</source>
<year>2018</year>, <volume>13</volume> (<issue>10</issue>), <elocation-id>e0204305</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0204305</pub-id>.<pub-id pub-id-type="pmid">30304051</pub-id>
</mixed-citation></ref><ref id="ref130"><mixed-citation publication-type="journal" id="cit130"><name><surname>Tu</surname><given-names>Y.</given-names></name>; <name><surname>Ma</surname><given-names>X.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Fan</surname><given-names>Y.</given-names></name>; <name><surname>Jiang</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>R.</given-names></name>; <name><surname>Cheng</surname><given-names>Z.</given-names></name>
<article-title>Molecular Imaging of
Matrix Metalloproteinase-2
in Atherosclerosis Using a Smart Multifunctional PET/MRI Nanoparticle</article-title>. <source>Int.J.Nanomedicine.</source>
<year>2022</year>, <volume>17</volume>, <fpage>6773</fpage>&#x02013;<lpage>6789</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S385679</pub-id>.<pub-id pub-id-type="pmid">36600879</pub-id>
</mixed-citation></ref><ref id="ref131"><mixed-citation publication-type="journal" id="cit131"><name><surname>Manzanares</surname><given-names>D.</given-names></name>; <name><surname>Cena</surname><given-names>V.</given-names></name>
<article-title>Endocytosis: The Nanoparticle and
Submicron Nanocompounds Gateway into the Cell</article-title>. <source>Pharmaceutics</source>
<year>2020</year>, <volume>12</volume> (<issue>4</issue>), <fpage>371</fpage>&#x02013;<lpage>371</lpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics12040371</pub-id>.<pub-id pub-id-type="pmid">32316537</pub-id>
</mixed-citation></ref><ref id="ref132"><mixed-citation publication-type="journal" id="cit132"><name><surname>Sun</surname><given-names>X.</given-names></name>; <name><surname>Dong</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>A.</given-names></name>; <name><surname>Sun</surname><given-names>X.</given-names></name>; <name><surname>Tong</surname><given-names>Y.</given-names></name>; <name><surname>Mao</surname><given-names>L.</given-names></name>
<article-title>Current Situation and Future Prospect
of Nano-Sized CT Contrast Agents</article-title>. <source>Chin. Basic
Sci.</source>
<year>2021</year>, <volume>23</volume> (<issue>6</issue>), <fpage>78</fpage>&#x02013;<lpage>84</lpage>.</mixed-citation></ref><ref id="ref133"><mixed-citation publication-type="journal" id="cit133"><name><surname>Li</surname><given-names>Q.</given-names></name>; <name><surname>Ding</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>K.</given-names></name>; <name><surname>Zhu</surname><given-names>R.</given-names></name>; <name><surname>Jiang</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>T.</given-names></name>
<article-title>Estimation
of Medium Depolarization
Index with Noise Immunity in Catheter-Based PS-OCT toward Vascular
Plaques Detection</article-title>. <source>Chem.Biomed.Imaging.</source>
<year>2024</year>, <volume>2</volume> (<issue>4</issue>), <fpage>293</fpage>&#x02013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1021/cbmi.3c00119</pub-id>.<pub-id pub-id-type="pmid">39473773</pub-id>
</mixed-citation></ref><ref id="ref134"><mixed-citation publication-type="journal" id="cit134"><name><surname>Tian</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Pei</surname><given-names>H.</given-names></name>; <name><surname>Tian</surname><given-names>Y.</given-names></name>; <name><surname>Zuo</surname><given-names>Z.</given-names></name>; <name><surname>Zhao</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>C.</given-names></name>; <name><surname>Zhao</surname><given-names>Z.</given-names></name>
<article-title>The pathogenesis and
drug therapy of hyperlipidemia</article-title>. <source>Chem. Life</source>
<year>2022</year>, <volume>42</volume> (<issue>12</issue>), <fpage>2237</fpage>&#x02013;<lpage>2247</lpage>.</mixed-citation></ref><ref id="ref135"><mixed-citation publication-type="journal" id="cit135"><name><surname>Tarantini</surname><given-names>G.</given-names></name>; <name><surname>Nai Fovino</surname><given-names>L.</given-names></name>; <name><surname>Le Prince</surname><given-names>P.</given-names></name>; <name><surname>Darremont</surname><given-names>O.</given-names></name>; <name><surname>Urena</surname><given-names>M.</given-names></name>; <name><surname>Bartorelli</surname><given-names>A. L.</given-names></name>; <name><surname>Vincent</surname><given-names>F.</given-names></name>; <name><surname>Hovorka</surname><given-names>T.</given-names></name>; <name><surname>Alcala Navarro</surname><given-names>Y.</given-names></name>; <name><surname>Dumonteil</surname><given-names>N.</given-names></name>; <name><surname>Ohlmann</surname><given-names>P.</given-names></name>; <name><surname>Wendler</surname><given-names>O.</given-names></name>
<article-title>Coronary Access and
Percutaneous Coronary Intervention Up to 3 Years After Transcatheter
Aortic Valve Implantation With a Balloon-Expandable Valve</article-title>. <source>Circ. Cardiovasc. Interv.</source>
<year>2020</year>, <volume>13</volume> (<issue>7</issue>), <elocation-id>e008972</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.120.008972</pub-id>.<pub-id pub-id-type="pmid">32580586</pub-id>
</mixed-citation></ref><ref id="ref136"><mixed-citation publication-type="journal" id="cit136"><name><surname>Ma</surname><given-names>C.</given-names></name>; <name><surname>Huo</surname><given-names>Y.</given-names></name>; <name><surname>Fang</surname><given-names>W.</given-names></name>; et al. <article-title>Interventional Cardiology</article-title>. <source>People&#x02019;s
Health Publishing House</source>
<year>2012</year>, <fpage>2</fpage>.</mixed-citation></ref><ref id="ref137"><mixed-citation publication-type="journal" id="cit137"><name><surname>Xiao</surname><given-names>X.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Wu</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Shi</surname><given-names>C.</given-names></name>; <name><surname>Wu</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>
<article-title>Clinical application
and pharmacokinetic study of nanocarriers in drug delivery system</article-title>. <source>Acta. Pharm. Sin.</source>
<year>2023</year>, <volume>58</volume> (<issue>4</issue>), <fpage>856</fpage>&#x02013;<lpage>866</lpage>.</mixed-citation></ref><ref id="ref138"><mixed-citation publication-type="thesis" id="cit138"><person-group person-group-type="allauthors"><name><surname>Zhan</surname><given-names>J.</given-names></name></person-group><article-title>Study on MRI Contrast
Agent with Tumor Targeting Effect</article-title>. <publisher-name>Qingdao University of Science and Technology</publisher-name>, <year>2022</year>.</mixed-citation></ref><ref id="ref139"><mixed-citation publication-type="journal" id="cit139"><name><surname>Libby</surname><given-names>P.</given-names></name>
<article-title>Inflammation during the life cycle
of the atherosclerotic plaque</article-title>. <source>Cardiovasc. Res.</source>
<year>2021</year>, <volume>117</volume> (<issue>13</issue>), <fpage>2525</fpage>&#x02013;<lpage>2536</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvab303</pub-id>.<pub-id pub-id-type="pmid">34550337</pub-id>
</mixed-citation></ref><ref id="ref140"><mixed-citation publication-type="journal" id="cit140"><name><surname>Karami</surname><given-names>Z.</given-names></name>; <name><surname>Akrami</surname><given-names>M.</given-names></name>; <name><surname>Mehrzad</surname><given-names>J.</given-names></name>; <name><surname>Esfandyari-Manesh</surname><given-names>M.</given-names></name>; <name><surname>Haririan</surname><given-names>I.</given-names></name>; <name><surname>Nateghi</surname><given-names>S.</given-names></name>
<article-title>An anti-inflammatory Glyburide-loaded
nanoghost for atherosclerosis therapy: A red blood cell based bio-mimetic
strategy</article-title>. <source>Giant.</source>
<year>2023</year>, <volume>16</volume>, <fpage>100206</fpage><pub-id pub-id-type="doi">10.1016/j.giant.2023.100206</pub-id>.</mixed-citation></ref><ref id="ref141"><mixed-citation publication-type="journal" id="cit141"><name><surname>Wu</surname><given-names>G.</given-names></name>; <name><surname>Wei</surname><given-names>W.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Nie</surname><given-names>W.</given-names></name>; <name><surname>Yuan</surname><given-names>L.</given-names></name>; <name><surname>Huang</surname><given-names>Y.</given-names></name>; <name><surname>Zuo</surname><given-names>L.</given-names></name>; <name><surname>Huang</surname><given-names>L.</given-names></name>; <name><surname>Xi</surname><given-names>X.</given-names></name>; <name><surname>Xie</surname><given-names>H.-Y.</given-names></name>
<article-title>A self-driven bioinspired nanovehicle by leukocyte
membrane-hitchhiking for early detection and treatment of atherosclerosis</article-title>. <source>Biomaterials</source>
<year>2020</year>, <volume>250</volume>, <fpage>119963</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.119963</pub-id>.<pub-id pub-id-type="pmid">32334199</pub-id>
</mixed-citation></ref><ref id="ref142"><mixed-citation publication-type="journal" id="cit142"><name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Che</surname><given-names>J.</given-names></name>; <name><surname>Chang</surname><given-names>L.</given-names></name>; <name><surname>Guo</surname><given-names>M.</given-names></name>; <name><surname>Bao</surname><given-names>X.</given-names></name>; <name><surname>Mu</surname><given-names>D.</given-names></name>; <name><surname>Sun</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Lu</surname><given-names>W.</given-names></name>; <name><surname>Xie</surname><given-names>J.</given-names></name>
<article-title>CD47- and
Integrin &#x003b1;4/&#x003b2;1-Comodified-Macrophage-Membrane-Coated Nanoparticles
Enable Delivery of Colchicine to Atherosclerotic Plaque</article-title>. <source>Adv. Healthc. Mater.</source>
<year>2022</year>, <volume>11</volume> (<issue>4</issue>), <elocation-id>e2101788</elocation-id><pub-id pub-id-type="doi">10.1002/adhm.202270025</pub-id>.<pub-id pub-id-type="pmid">34786845</pub-id>
</mixed-citation></ref><ref id="ref143"><mixed-citation publication-type="journal" id="cit143"><name><surname>Wu</surname><given-names>Y.</given-names></name>; <name><surname>Yang</surname><given-names>Y.</given-names></name>; <name><surname>Zhao</surname><given-names>W.</given-names></name>; <name><surname>Xu</surname><given-names>Z.</given-names></name>; <name><surname>Little</surname><given-names>P. J.</given-names></name>; <name><surname>Whittaker</surname><given-names>A. K.</given-names></name>; <name><surname>Zhang</surname><given-names>R.</given-names></name>; <name><surname>Ta</surname><given-names>H. T.</given-names></name>
<article-title>Novel iron
oxide-cerium
oxide core-shell nanoparticle as a potential theranostic material
for inflammatory diseases</article-title>. <source>J.Mater.Chem.B</source>
<year>2018</year>, <volume>6</volume> (<issue>30</issue>), <fpage>4937</fpage>&#x02013;<lpage>4951</lpage>. <pub-id pub-id-type="doi">10.1039/C8TB00022K</pub-id>.<pub-id pub-id-type="pmid">32255067</pub-id>
</mixed-citation></ref><ref id="ref144"><mixed-citation publication-type="thesis" id="cit144"><person-group><name><surname>Liu</surname><given-names>R.</given-names></name></person-group><article-title>In
vitro and in vivo studies on anti-atherosclerotic
activity of an orally delivered ROS-responsive multifunctional nanotherapy</article-title>. <publisher-name>Army Medical University</publisher-name>, <year>2021</year>.</mixed-citation></ref><ref id="ref145"><mixed-citation publication-type="journal" id="cit145"><name><surname>Wan</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>J.</given-names></name>; <name><surname>Lei</surname><given-names>W.</given-names></name>; <name><surname>Xiao</surname><given-names>Z.</given-names></name>; <name><surname>Zhou</surname><given-names>P.</given-names></name>; <name><surname>Zheng</surname><given-names>S.</given-names></name>; <name><surname>Zhu</surname><given-names>P.</given-names></name>
<source>Int.J.Nanomedicine.</source>
<year>2023</year>, <volume>18</volume>, <fpage>579</fpage>&#x02013;<lpage>594</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S384675</pub-id>.<pub-id pub-id-type="pmid">36756051</pub-id>
</mixed-citation></ref><ref id="ref146"><mixed-citation publication-type="journal" id="cit146"><name><surname>Cai</surname><given-names>F.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Lei</surname><given-names>Y.</given-names></name>; <name><surname>Jin</surname><given-names>S.</given-names></name>; <name><surname>Guo</surname><given-names>Z.</given-names></name>; <name><surname>Zhu</surname><given-names>D.</given-names></name>; <name><surname>Guo</surname><given-names>X.</given-names></name>; <name><surname>Zhao</surname><given-names>H.</given-names></name>; <name><surname>Niu</surname><given-names>X.</given-names></name>; <name><surname>Xi</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Chen</surname><given-names>G.</given-names></name>
<article-title>Epigallocatechin-3
gallate regulates
macrophage subtypes and immunometabolism to ameliorate experimental
autoimmune encephalomyelitis</article-title>. <source>Cell.Immunol.</source>
<year>2021</year>, <volume>368</volume>, <fpage>104421</fpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2021.104421</pub-id>.<pub-id pub-id-type="pmid">34385001</pub-id>
</mixed-citation></ref><ref id="ref147"><mixed-citation publication-type="journal" id="cit147"><name><surname>Li</surname><given-names>N.</given-names></name>; <name><surname>Zhan</surname><given-names>X.</given-names></name>
<article-title>Machine Learning Identifies
Pan-Cancer Landscape of
Nrf2 Oxidative Stress Response Pathway-Related Genes</article-title>. <source>Oxid. Med. Cell. Longev.</source>
<year>2022</year>, <volume>2022</volume>, <fpage>8450087</fpage><pub-id pub-id-type="doi">10.1155/2022/8450087</pub-id>.<pub-id pub-id-type="pmid">35242279</pub-id>
</mixed-citation></ref><ref id="ref148"><mixed-citation publication-type="journal" id="cit148"><name><surname>Maiocchi</surname><given-names>S.</given-names></name>; <name><surname>Cartaya</surname><given-names>A.</given-names></name>; <name><surname>Buglak</surname><given-names>N.</given-names></name>; <name><surname>Torzone</surname><given-names>S.</given-names></name>; <name><surname>Peterson</surname><given-names>A.</given-names></name>; <name><surname>Akerman</surname><given-names>A.</given-names></name>; <name><surname>Bahnson</surname><given-names>E. M.</given-names></name>
<article-title>Selective Delivery
of Antioxidant Response Activating nanoParticles (ARAPas) Reduces
Atherosclerotic Burden in LDL KO Mice</article-title>. <source>Free.Radical.Bio.Med.</source>
<year>2022</year>, <volume>192</volume>, <fpage>66</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2022.10.111</pub-id>.</mixed-citation></ref><ref id="ref149"><mixed-citation publication-type="thesis" id="cit149"><person-group person-group-type="allauthors"><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>Preparation of
Hyaluronic acid-based multifunctional drug delivery system and its
application in the treatment of atherosclerosis</article-title>. <publisher-name>Jilin University</publisher-name>, <year>2023</year>.</mixed-citation></ref><ref id="ref150"><mixed-citation publication-type="journal" id="cit150"><name><surname>Mu</surname><given-names>D.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Qi</surname><given-names>Y.</given-names></name>; <name><surname>Sun</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Shen</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Xu</surname><given-names>B.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>
<article-title>Hyaluronic
acid-coated polymeric micelles with hydrogen peroxide scavenging to
encapsulate statins for alleviating atherosclerosis</article-title>. <source>J. Nanobiotechnol.</source>
<year>2020</year>, <volume>18</volume> (<issue>1</issue>), <fpage>179</fpage><pub-id pub-id-type="doi">10.1186/s12951-020-00744-w</pub-id>.</mixed-citation></ref><ref id="ref151"><mixed-citation publication-type="journal" id="cit151"><name><surname>Zhou</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Hao</surname><given-names>Y.</given-names></name>; <name><surname>An</surname><given-names>P.</given-names></name>; <name><surname>Luo</surname><given-names>J.</given-names></name>; <name><surname>Luo</surname><given-names>Y.</given-names></name>
<article-title>Dandelion Polysaccharides Ameliorate High-Fat-Diet-Induced
Atherosclerosis in Mice through Antioxidant and Anti-Inflammatory
Capabilities</article-title>. <source>Nutrients.</source>
<year>2023</year>, <volume>15</volume> (<issue>19</issue>), <fpage>4120</fpage><pub-id pub-id-type="doi">10.3390/nu15194120</pub-id>.<pub-id pub-id-type="pmid">37836404</pub-id>
</mixed-citation></ref><ref id="ref152"><mixed-citation publication-type="journal" id="cit152"><name><surname>Fredman</surname><given-names>G.</given-names></name>; <name><surname>Hellmann</surname><given-names>J.</given-names></name>; <name><surname>Proto</surname><given-names>J. D.</given-names></name>; <name><surname>Kuriakose</surname><given-names>G.</given-names></name>; <name><surname>Colas</surname><given-names>R. A.</given-names></name>; <name><surname>Dorweiler</surname><given-names>B.</given-names></name>; <name><surname>Connolly</surname><given-names>E. S.</given-names></name>; <name><surname>Solomon</surname><given-names>R.</given-names></name>; <name><surname>Jones</surname><given-names>D. M.</given-names></name>; <name><surname>Heyer</surname><given-names>E. J.</given-names></name>; <name><surname>Spite</surname><given-names>M.</given-names></name>; <name><surname>Tabas</surname><given-names>I.</given-names></name>
<article-title>An imbalance
between specialized pro-resolving lipid mediators and pro-inflammatory
leukotrienes promotes instability of atherosclerotic plaques</article-title>. <source>Nat. Commun.</source>
<year>2016</year>, <volume>7</volume>, <fpage>12859</fpage><pub-id pub-id-type="doi">10.1038/ncomms12859</pub-id>.<pub-id pub-id-type="pmid">27659679</pub-id>
</mixed-citation></ref><ref id="ref153"><mixed-citation publication-type="journal" id="cit153"><name><surname>Liu</surname><given-names>C.</given-names></name>; <name><surname>Shin</surname><given-names>J.</given-names></name>; <name><surname>Son</surname><given-names>S.</given-names></name>; <name><surname>Choe</surname><given-names>Y.</given-names></name>; <name><surname>Farokhzad</surname><given-names>N.</given-names></name>; <name><surname>Tang</surname><given-names>Z.</given-names></name>; <name><surname>Xiao</surname><given-names>Y.</given-names></name>; <name><surname>Kong</surname><given-names>N.</given-names></name>; <name><surname>Xie</surname><given-names>T.</given-names></name>; <name><surname>Kim</surname><given-names>J. S.</given-names></name>; <name><surname>Tao</surname><given-names>W.</given-names></name>
<article-title>Pnictogens
in medicinal chemistry:
evolution from erstwhile drugs to emerging layered photonic nanomedicine</article-title>. <source>Chem.Soc.Rev.</source>
<year>2021</year>, <volume>50</volume> (<issue>4</issue>), <fpage>2260</fpage>&#x02013;<lpage>2279</lpage>. <pub-id pub-id-type="doi">10.1039/D0CS01175D</pub-id>.<pub-id pub-id-type="pmid">33367452</pub-id>
</mixed-citation></ref><ref id="ref154"><mixed-citation publication-type="journal" id="cit154"><name><surname>Hu</surname><given-names>K.</given-names></name>; <name><surname>Xie</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Hanyu</surname><given-names>M.</given-names></name>; <name><surname>Yang</surname><given-names>Z.</given-names></name>; <name><surname>Nagatsu</surname><given-names>K.</given-names></name>; <name><surname>Suzuki</surname><given-names>H.</given-names></name>; <name><surname>Ouyang</surname><given-names>J.</given-names></name>; <name><surname>Ji</surname><given-names>X.</given-names></name>; <name><surname>Wei</surname><given-names>J.</given-names></name>; <name><surname>Xu</surname><given-names>H.</given-names></name>; <name><surname>Farokhzad</surname><given-names>O. C.</given-names></name>; <name><surname>Liang</surname><given-names>S. H.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Tao</surname><given-names>W.</given-names></name>; <name><surname>Zhang</surname><given-names>M. R.</given-names></name>
<article-title>Marriage of black phosphorus and Cu<sup>2+</sup> as
effective photothermal agents for PET-guided combination cancer therapy</article-title>. <source>Nat. Commun.</source>
<year>2020</year>, <volume>11</volume> (<issue>1</issue>), <fpage>2778</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16513-0</pub-id>.<pub-id pub-id-type="pmid">32513979</pub-id>
</mixed-citation></ref><ref id="ref155"><mixed-citation publication-type="journal" id="cit155"><name><surname>Huang</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>C.</given-names></name>; <name><surname>Kong</surname><given-names>N.</given-names></name>; <name><surname>Xiao</surname><given-names>Y.</given-names></name>; <name><surname>Yurdagul</surname><given-names>A.</given-names><suffix>Jr</suffix></name>; <name><surname>Tabas</surname><given-names>I.</given-names></name>; <name><surname>Tao</surname><given-names>W.</given-names></name>
<article-title>Synthesis
of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic
lesional macrophages</article-title>. <source>Nat.Protoc.</source>
<year>2022</year>, <volume>17</volume> (<issue>3</issue>), <fpage>748</fpage>&#x02013;<lpage>780</lpage>. <pub-id pub-id-type="doi">10.1038/s41596-021-00665-4</pub-id>.<pub-id pub-id-type="pmid">35121853</pub-id>
</mixed-citation></ref><ref id="ref156"><mixed-citation publication-type="journal" id="cit156"><name><surname>Del Re</surname><given-names>D. P.</given-names></name>; <name><surname>Amgalan</surname><given-names>D.</given-names></name>; <name><surname>Linkermann</surname><given-names>A.</given-names></name>; <name><surname>Liu</surname><given-names>Q.</given-names></name>; <name><surname>Kitsis</surname><given-names>R. N.</given-names></name>
<article-title>Fundamental mechanisms of regulated cell death and
implications for heart disease</article-title>. <source>Physiol.Rev.</source>
<year>2019</year>, <volume>99</volume> (<issue>4</issue>), <fpage>1765</fpage>&#x02013;<lpage>1817</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00022.2018</pub-id>.<pub-id pub-id-type="pmid">31364924</pub-id>
</mixed-citation></ref><ref id="ref157"><mixed-citation publication-type="journal" id="cit157"><name><surname>Dixon</surname><given-names>S. J.</given-names></name>; <name><surname>Lemberg</surname><given-names>K. M.</given-names></name>; <name><surname>Lamprecht</surname><given-names>M. R.</given-names></name>; <name><surname>Skouta</surname><given-names>R.</given-names></name>; <name><surname>Zaitsev</surname><given-names>E. M.</given-names></name>; <name><surname>Gleason</surname><given-names>C. E.</given-names></name>; <name><surname>Patel</surname><given-names>D. N.</given-names></name>; <name><surname>Bauer</surname><given-names>A. J.</given-names></name>; <name><surname>Cantley</surname><given-names>A. M.</given-names></name>; <name><surname>Yang</surname><given-names>W. S.</given-names></name>; <name><surname>Morrison</surname><given-names>B.</given-names><suffix>3rd</suffix></name>; <name><surname>Stockwell</surname><given-names>B. R.</given-names></name>
<article-title>Ferroptosis:
an iron- dependent form
of nonapoptotic cell death</article-title>. <source>Cell.</source>
<year>2012</year>, <volume>149</volume> (<issue>5</issue>), <fpage>1060</fpage>&#x02013;<lpage>1072</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id>.<pub-id pub-id-type="pmid">22632970</pub-id>
</mixed-citation></ref><ref id="ref158"><mixed-citation publication-type="journal" id="cit158"><name><surname>Fang</surname><given-names>X.</given-names></name>; <name><surname>Ardehali</surname><given-names>H.</given-names></name>; <name><surname>Min</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>F.</given-names></name>
<article-title>The molecular
and metabolic landscape of iron and ferroptosis in cardiovascular
disease</article-title>. <source>Nat.Rev.Cardiol.</source>
<year>2023</year>, <volume>20</volume> (<issue>1</issue>), <fpage>7</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1038/s41569-022-00735-4</pub-id>.<pub-id pub-id-type="pmid">35788564</pub-id>
</mixed-citation></ref><ref id="ref159"><mixed-citation publication-type="journal" id="cit159"><name><surname>Lin</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>M.-X.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>D.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Li</surname><given-names>Y.-l.</given-names></name>
<article-title>Autophagy, Pyroptosis,
and Ferroptosis: New Regulatory Mechanisms
for Atherosclerosis</article-title>. <source>Front. Cell. Dev. Biol.</source>
<year>2022</year>, <volume>9</volume>, <fpage>809955</fpage><pub-id pub-id-type="doi">10.3389/fcell.2021.809955</pub-id>.<pub-id pub-id-type="pmid">35096837</pub-id>
</mixed-citation></ref><ref id="ref160"><mixed-citation publication-type="journal" id="cit160"><name><surname>Ma</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Tian</surname><given-names>J.</given-names></name>; <name><surname>Shen</surname><given-names>W.</given-names></name>
<article-title>The Role of Macrophage Iron Overload
and Ferroptosis in Atherosclerosis</article-title>. <source>Biomolecules</source>
<year>2022</year>, <volume>12</volume> (<issue>11</issue>), <fpage>1702</fpage><pub-id pub-id-type="doi">10.3390/biom12111702</pub-id>.<pub-id pub-id-type="pmid">36421722</pub-id>
</mixed-citation></ref><ref id="ref161"><mixed-citation publication-type="journal" id="cit161"><name><surname>Tang</surname><given-names>D.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Kang</surname><given-names>R.</given-names></name>; <name><surname>Kroemer</surname><given-names>G.</given-names></name>
<article-title>Ferroptosis:
molecular mechanisms and health implications</article-title>. <source>Cell.Res.</source>
<year>2021</year>, <volume>31</volume> (<issue>2</issue>), <fpage>107</fpage>&#x02013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-00441-1</pub-id>.<pub-id pub-id-type="pmid">33268902</pub-id>
</mixed-citation></ref><ref id="ref162"><mixed-citation publication-type="journal" id="cit162"><name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Cao</surname><given-names>F.</given-names></name>; <name><surname>Yin</surname><given-names>H.</given-names></name>; <name><surname>Huang</surname><given-names>Z.</given-names></name>; <name><surname>Lin</surname><given-names>Z.</given-names></name>; <name><surname>Mao</surname><given-names>N.</given-names></name>; <name><surname>Sun</surname><given-names>B.</given-names></name>; <name><surname>Wang</surname><given-names>G.</given-names></name>
<article-title>Ferroptosis: past,
present and future</article-title>. <source>Cell Death Dis.</source>
<year>2020</year>, <volume>11</volume> (<issue>2</issue>), <fpage>88</fpage><pub-id pub-id-type="doi">10.1038/s41419-020-2298-2</pub-id>.<pub-id pub-id-type="pmid">32015325</pub-id>
</mixed-citation></ref><ref id="ref163"><mixed-citation publication-type="journal" id="cit163"><name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>Geng</surname><given-names>Y.</given-names></name>; <name><surname>Lu</surname><given-names>X.</given-names></name>; <name><surname>Shi</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>G.</given-names></name>; <name><surname>Zhang</surname><given-names>M.</given-names></name>; <name><surname>Shan</surname><given-names>B.</given-names></name>; <name><surname>Pan</surname><given-names>H.</given-names></name>; <name><surname>Yuan</surname><given-names>J.</given-names></name>
<article-title>Chaperone-mediated
autophagy is involved in the execution of ferroptosis</article-title>. <source>Proc.Natl.Acad.Sci.U.S.A.</source>
<year>2019</year>, <volume>116</volume> (<issue>8</issue>), <fpage>2996</fpage>&#x02013;<lpage>3005</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1819728116</pub-id>.<pub-id pub-id-type="pmid">30718432</pub-id>
</mixed-citation></ref><ref id="ref164"><mixed-citation publication-type="journal" id="cit164"><name><surname>Kuang</surname><given-names>F.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Kang</surname><given-names>R.</given-names></name>; <name><surname>Tang</surname><given-names>D.</given-names></name>
<article-title>Cathepsin B is a mediator of organelle-specific
initiation of ferroptosis</article-title>. <source>Biochem. Biophys.
Res. Commun.</source>
<year>2020</year>, <volume>533</volume> (<issue>4</issue>), <fpage>1464</fpage>&#x02013;<lpage>1469</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2020.10.035</pub-id>.<pub-id pub-id-type="pmid">33268027</pub-id>
</mixed-citation></ref><ref id="ref165"><mixed-citation publication-type="journal" id="cit165"><name><surname>Hirayama</surname><given-names>T.</given-names></name>; <name><surname>Miki</surname><given-names>A.</given-names></name>; <name><surname>Nagasawa</surname><given-names>H.</given-names></name>
<article-title>Organelle-specific
analysis of labile Fe(ii) during ferroptosis by using a cocktail of
various colour organelle-targeted fluorescent probes</article-title>. <source>Metallomics.</source>
<year>2019</year>, <volume>11</volume> (<issue>1</issue>), <fpage>111</fpage>&#x02013;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1039/C8MT00212F</pub-id>.<pub-id pub-id-type="pmid">30215439</pub-id>
</mixed-citation></ref><ref id="ref166"><mixed-citation publication-type="journal" id="cit166"><name><surname>Gao</surname><given-names>M.</given-names></name>; <name><surname>Yi</surname><given-names>J.</given-names></name>; <name><surname>Zhu</surname><given-names>J.</given-names></name>; <name><surname>Minikes</surname><given-names>A. M.</given-names></name>; <name><surname>Monian</surname><given-names>P.</given-names></name>; <name><surname>Thompson</surname><given-names>C. B.</given-names></name>; <name><surname>Jiang</surname><given-names>X.</given-names></name>
<article-title>Role of Mitochondria in Ferroptosis</article-title>. <source>Mol. Cell</source>
<year>2019</year>, <volume>73</volume> (<issue>2</issue>), <fpage>354</fpage>&#x02013;<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2018.10.042</pub-id>.<pub-id pub-id-type="pmid">30581146</pub-id>
</mixed-citation></ref><ref id="ref167"><mixed-citation publication-type="journal" id="cit167"><name><surname>Wang</surname><given-names>K.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Cheng</surname><given-names>X.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Zhou</surname><given-names>L.</given-names></name>; <name><surname>Wang</surname><given-names>K.</given-names></name>
<article-title>Emerging roles of ferroptosis
in cardiovascular diseases</article-title>. <source>Cell. Death Discov.</source>
<year>2022</year>, <volume>8</volume> (<issue>1</issue>), <fpage>394</fpage>&#x02013;<lpage>394</lpage>. <pub-id pub-id-type="doi">10.1038/s41420-022-01183-2</pub-id>.<pub-id pub-id-type="pmid">36127318</pub-id>
</mixed-citation></ref><ref id="ref168"><mixed-citation publication-type="journal" id="cit168"><name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Luo</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Dong</surname><given-names>D.</given-names></name>; <name><surname>Shen</surname><given-names>Y.</given-names></name>; <name><surname>Fang</surname><given-names>Y.</given-names></name>; <name><surname>Hu</surname><given-names>L.</given-names></name>; <name><surname>Liu</surname><given-names>M.</given-names></name>; <name><surname>Dai</surname><given-names>C.</given-names></name>; <name><surname>Peng</surname><given-names>S.</given-names></name>; <name><surname>Fang</surname><given-names>Z.</given-names></name>; <name><surname>Shang</surname><given-names>P.</given-names></name>
<article-title>Iron and magnetic:
new research direction of the ferroptosis-based cancer therapy</article-title>. <source>Am. J. Cancer. Res.</source>
<year>2018</year>, <volume>8</volume> (<issue>10</issue>), <fpage>1933</fpage>&#x02013;<lpage>1946</lpage>.<pub-id pub-id-type="pmid">30416846</pub-id>
</mixed-citation></ref><ref id="ref169"><mixed-citation publication-type="journal" id="cit169"><name><surname>Liu</surname><given-names>Q.</given-names></name>; <name><surname>Yang</surname><given-names>R.</given-names></name>; <name><surname>Wang</surname><given-names>D.</given-names></name>
<article-title>Ferritinophagy in vascular
endothelial
cells regulated by nanoparticles may benefit the prevention of atherosclerosis
and in-stent restenosis</article-title>. <source>Biomed.Pharmacother.</source>
<year>2022</year>, <volume>148</volume>, <fpage>112702</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2022.112702</pub-id>.<pub-id pub-id-type="pmid">35228066</pub-id>
</mixed-citation></ref><ref id="ref170"><mixed-citation publication-type="journal" id="cit170"><name><surname>Lu</surname><given-names>C.</given-names></name>; <name><surname>Xiao</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Sun</surname><given-names>F.</given-names></name>; <name><surname>Qiu</surname><given-names>Y.</given-names></name>; <name><surname>Mu</surname><given-names>H.</given-names></name>; <name><surname>Duan</surname><given-names>J.</given-names></name>
<article-title>Hyaluronic Acid-Based
Levofloxacin Nanomicelles for
Nitric Oxide-Triggered Drug Delivery to Treat Bacterial Infections</article-title>. <source>Carbohydr. Polym.</source>
<year>2020</year>, <volume>229</volume>, <fpage>115479</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2019.115479</pub-id>.<pub-id pub-id-type="pmid">31826506</pub-id>
</mixed-citation></ref><ref id="ref171"><mixed-citation publication-type="journal" id="cit171"><name><surname>He</surname><given-names>W.</given-names></name>; <name><surname>Kapate</surname><given-names>N.</given-names></name>; <name><surname>Shields</surname><given-names>C. W.</given-names><suffix>4th</suffix></name>; <name><surname>Mitragotri</surname><given-names>S.</given-names></name>
<article-title>Drug Delivery
to Macrophages: A Review of Targeting Drugs and Drug Carriers to Macrophages
for Inflammatory Diseases</article-title>. <source>Adv.Drug.Delivery.Rev.</source>
<year>2020</year>, <volume>165&#x02013;166</volume>, <fpage>15</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2019.12.001</pub-id>.</mixed-citation></ref><ref id="ref172"><mixed-citation publication-type="journal" id="cit172"><name><surname>Mu</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Lv</surname><given-names>P.</given-names></name>; <name><surname>Liu</surname><given-names>R.</given-names></name>; <name><surname>Tan</surname><given-names>Y.</given-names></name>; <name><surname>Zhong</surname><given-names>C.</given-names></name>; <name><surname>Qi</surname><given-names>Y.</given-names></name>; <name><surname>Sun</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Shen</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Xu</surname><given-names>B.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>
<article-title>Ultrasmall
Fe(III)-Tannic Acid Nanoparticles To Prevent Progression of Atherosclerotic
Plaques</article-title>. <source>ACS.Appl.Mater.Interfaces.</source>
<year>2021</year>, <volume>13</volume> (<issue>29</issue>), <fpage>33915</fpage>&#x02013;<lpage>33925</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.1c09480</pub-id>.<pub-id pub-id-type="pmid">34279905</pub-id>
</mixed-citation></ref><ref id="ref173"><mixed-citation publication-type="journal" id="cit173"><name><surname>Mitchell</surname><given-names>A.</given-names></name>; <name><surname>Fujisawa</surname><given-names>T.</given-names></name>; <name><surname>Newby</surname><given-names>D.</given-names></name>; <name><surname>Mills</surname><given-names>N.</given-names></name>; <name><surname>Cruden</surname><given-names>N. L.</given-names></name>
<article-title>Vascular
injury and repair: a potential target for
cell therapies</article-title>. <source>Future.Cardiol.</source>
<year>2015</year>, <volume>11</volume> (<issue>1</issue>), <fpage>45</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.2217/fca.14.77</pub-id>.<pub-id pub-id-type="pmid">25606702</pub-id>
</mixed-citation></ref><ref id="ref174"><mixed-citation publication-type="journal" id="cit174"><name><surname>Tasev</surname><given-names>D.</given-names></name>; <name><surname>Koolwijk</surname><given-names>P.</given-names></name>; <name><surname>van Hinsbergh</surname><given-names>V. W.</given-names></name>
<article-title>Therapeutic
Potential of Human-Derived Endothelial-Colony Forming Cells in Animal
Models</article-title>. <source>Tissue.Eng.Part.B.Rev.</source>
<year>2016</year>, <volume>22</volume> (<issue>5</issue>), <fpage>371</fpage>&#x02013;<lpage>382</lpage>. <pub-id pub-id-type="doi">10.1089/ten.teb.2016.0050</pub-id>.<pub-id pub-id-type="pmid">27032435</pub-id>
</mixed-citation></ref><ref id="ref175"><mixed-citation publication-type="journal" id="cit175"><name><surname>Skrzypkowska</surname><given-names>M.</given-names></name>; <name><surname>My&#x0015b;liwska</surname><given-names>J.</given-names></name>; <name><surname>S&#x00142;omi&#x00144;ski</surname><given-names>B.</given-names></name>; <name><surname>Siebert</surname><given-names>J.</given-names></name>; <name><surname>Gutknecht</surname><given-names>P.</given-names></name>; <name><surname>Ryba-Stanis&#x00142;awowska</surname><given-names>M.</given-names></name>
<article-title>Quantitative
and functional characteristics of endothelial progenitor cells in
newly diagnosed hypertensive patients</article-title>. <source>J.Hum.Hypertens.</source>
<year>2015</year>, <volume>29</volume> (<issue>5</issue>), <fpage>324</fpage>&#x02013;<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1038/jhh.2014.85</pub-id>.<pub-id pub-id-type="pmid">25296717</pub-id>
</mixed-citation></ref><ref id="ref176"><mixed-citation publication-type="journal" id="cit176"><name><surname>Paradisi</surname><given-names>G.</given-names></name>; <name><surname>Bracaglia</surname><given-names>M.</given-names></name>; <name><surname>Basile</surname><given-names>F.</given-names></name>; et al. <article-title>Effect
of pravastatin on endothelial function and endothelial progenitor
cells in healthy postmenopausal women</article-title>. <source>Clin.
Exp. Obstet. Gynecol.</source>
<year>2012</year>, <volume>39</volume> (<issue>2</issue>), <fpage>153</fpage>&#x02013;<lpage>159</lpage>.<pub-id pub-id-type="pmid">22905454</pub-id>
</mixed-citation></ref><ref id="ref177"><mixed-citation publication-type="thesis" id="cit177"><person-group person-group-type="allauthors"><name><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Study on improvement
of endothelial progenitor cell biological function and repair of damaged
blood vessels by pitavastatin nanoparticles</article-title>. <publisher-name>Third Military Medical University</publisher-name>, <year>2016</year>.</mixed-citation></ref><ref id="ref178"><mixed-citation publication-type="journal" id="cit178"><name><surname>Bai</surname><given-names>B.</given-names></name>; <name><surname>Yang</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>Q.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name>; <name><surname>Tian</surname><given-names>C.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Aung</surname><given-names>L. H. H.</given-names></name>; <name><surname>Li</surname><given-names>P.-f.</given-names></name>; <name><surname>Yu</surname><given-names>T.</given-names></name>; <name><surname>Chu</surname><given-names>X.-m.</given-names></name>
<article-title>NLRP3 inflammasome
in endothelial dysfunction</article-title>. <source>Cell. Death. Dis.</source>
<year>2020</year>, <volume>11</volume> (<issue>9</issue>), <fpage>776</fpage><pub-id pub-id-type="doi">10.1038/s41419-020-02985-x</pub-id>.<pub-id pub-id-type="pmid">32948742</pub-id>
</mixed-citation></ref><ref id="ref179"><mixed-citation publication-type="journal" id="cit179"><name><surname>Poznyak</surname><given-names>A. V.</given-names></name>; <name><surname>Orekhova</surname><given-names>V. A.</given-names></name>; <name><surname>Sukhorukov</surname><given-names>V. N.</given-names></name>; <name><surname>Khotina</surname><given-names>V. A.</given-names></name>; <name><surname>Popov</surname><given-names>M. A.</given-names></name>; <name><surname>Orekhov</surname><given-names>A. N.</given-names></name>
<article-title>Atheroprotective
Aspects of Heat Shock Protein</article-title>. <source>Int. J. Mol.
Sci.</source>
<year>2023</year>, <volume>24</volume> (<issue>14</issue>), <fpage>11750</fpage><pub-id pub-id-type="doi">10.3390/ijms241411750</pub-id>.<pub-id pub-id-type="pmid">37511509</pub-id>
</mixed-citation></ref><ref id="ref180"><mixed-citation publication-type="journal" id="cit180"><name><surname>van Puijvelde</surname><given-names>G. H.</given-names></name>; <name><surname>van Es</surname><given-names>T.</given-names></name>; <name><surname>van Wanrooij</surname><given-names>E. J.</given-names></name>; <name><surname>Habets</surname><given-names>K. L.</given-names></name>; <name><surname>de Vos</surname><given-names>P.</given-names></name>; <name><surname>van der Zee</surname><given-names>R.</given-names></name>; <name><surname>van Eden</surname><given-names>W.</given-names></name>; <name><surname>van Berkel</surname><given-names>T. J.</given-names></name>; <name><surname>Kuiper</surname><given-names>J.</given-names></name>
<article-title>Induction of Oral Tolerance
to HSP60 or an HSP60-Peptide Activates T Cell Regulation and Reduces
Atherosclerosis</article-title>. <source>Arterioscler.Thromb.Vasc.Biol.</source>
<year>2007</year>, <volume>27</volume> (<issue>12</issue>), <fpage>2677</fpage>&#x02013;<lpage>2683</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.107.151274</pub-id>.<pub-id pub-id-type="pmid">17901374</pub-id>
</mixed-citation></ref><ref id="ref181"><mixed-citation publication-type="journal" id="cit181"><name><surname>Shi</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Xu</surname><given-names>X.</given-names></name>; <name><surname>Cheng</surname><given-names>Y.</given-names></name>; <name><surname>Meng</surname><given-names>B.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Xiang</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>He</surname><given-names>K.</given-names></name>; <name><surname>Tong</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Xiang</surname><given-names>L.</given-names></name>; <name><surname>Xiang</surname><given-names>G.</given-names></name>
<article-title>Brown adipose tissue-derived
Nrg4 alleviates endothelial inflammation and atherosclerosis in male
mice</article-title>. <source>Nat.Metab.</source>
<year>2022</year>, <volume>4</volume> (<issue>11</issue>), <fpage>1573</fpage>&#x02013;<lpage>1590</lpage>. <pub-id pub-id-type="doi">10.1038/s42255-022-00671-0</pub-id>.<pub-id pub-id-type="pmid">36400933</pub-id>
</mixed-citation></ref><ref id="ref182"><mixed-citation publication-type="journal" id="cit182"><name><surname>Schumacher</surname><given-names>M. A.</given-names></name>; <name><surname>Hedl</surname><given-names>M.</given-names></name>; <name><surname>Abraham</surname><given-names>C.</given-names></name>; <name><surname>Bernard</surname><given-names>J. K.</given-names></name>; <name><surname>Lozano</surname><given-names>P. R.</given-names></name>; <name><surname>Hsieh</surname><given-names>J. J.</given-names></name>; <name><surname>Almohazey</surname><given-names>D.</given-names></name>; <name><surname>Bucar</surname><given-names>E. B.</given-names></name>; <name><surname>Punit</surname><given-names>S.</given-names></name>; <name><surname>Dempsey</surname><given-names>P. J.</given-names></name>; <name><surname>Frey</surname><given-names>M. R.</given-names></name>
<article-title>ErbB4 signaling
stimulates pro-inflammatory macrophage apoptosis and limits colonic
inflammation</article-title>. <source>Cell.Death.dis.</source>
<year>2017</year>, <volume>8</volume> (<issue>2</issue>), <elocation-id>e2622</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2017.42</pub-id>.<pub-id pub-id-type="pmid">28230865</pub-id>
</mixed-citation></ref><ref id="ref183"><mixed-citation publication-type="journal" id="cit183"><name><surname>Kochegarov</surname><given-names>A.</given-names></name>; <name><surname>Lemanski</surname><given-names>L. F.</given-names></name>
<article-title>New Trends in Heart
Regeneration:
A Review</article-title>. <source>J. Stem Cell. Regen. Med.</source>
<year>2016</year>, <volume>12</volume> (<issue>2</issue>), <fpage>61</fpage>&#x02013;<lpage>68</lpage>.</mixed-citation></ref><ref id="ref184"><mixed-citation publication-type="journal" id="cit184"><name><surname>Zaghary</surname><given-names>W. A.</given-names></name>; <name><surname>Elansary</surname><given-names>M. M.</given-names></name>; <name><surname>Shouman</surname><given-names>D. N.</given-names></name>; <name><surname>Abdelrahim</surname><given-names>A. A.</given-names></name>; <name><surname>Abu-Zied</surname><given-names>K. M.</given-names></name>; <name><surname>Sakr</surname><given-names>T. M.</given-names></name>
<article-title>Can nanotechnology
overcome challenges
facing stem cell therapy? A review</article-title>. <source>J. Drug
Delivery Sci. Technol.</source>
<year>2021</year>, <volume>66</volume>, <fpage>102883</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2021.102883</pub-id>.</mixed-citation></ref><ref id="ref185"><mixed-citation publication-type="journal" id="cit185"><name><surname>Yuan</surname><given-names>H.</given-names></name>; <name><surname>Gomez</surname><given-names>J. A.</given-names></name>; <name><surname>Chien</surname><given-names>J. S.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Wilson</surname><given-names>C. M.</given-names></name>; <name><surname>Li</surname><given-names>S.</given-names></name>; <name><surname>Fales</surname><given-names>A. M.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Grant</surname><given-names>G. A.</given-names></name>; <name><surname>Mirotsou</surname><given-names>M.</given-names></name>; <name><surname>Dzau</surname><given-names>V. J.</given-names></name>; <name><surname>Vo-Dinh</surname><given-names>T.</given-names></name>
<article-title>Tracking mesenchymal
stromal cells using an ultra-bright TAT-functionalized plasmonic-active
nanoplatform</article-title>. <source>J.Biophotonics.</source>
<year>2016</year>, <volume>9</volume> (<issue>4</issue>), <fpage>406</fpage>&#x02013;<lpage>413</lpage>. <pub-id pub-id-type="doi">10.1002/jbio.201500173</pub-id>.<pub-id pub-id-type="pmid">27095616</pub-id>
</mixed-citation></ref><ref id="ref186"><mixed-citation publication-type="journal" id="cit186"><name><surname>Adjei</surname><given-names>I. M.</given-names></name>; <name><surname>Yang</surname><given-names>H.</given-names></name>; <name><surname>Plumton</surname><given-names>G.</given-names></name>; <name><surname>Maldonado-Camargo</surname><given-names>L.</given-names></name>; <name><surname>Dobson</surname><given-names>J.</given-names></name>; <name><surname>Rinaldi</surname><given-names>C.</given-names></name>; <name><surname>Jiang</surname><given-names>H.</given-names></name>; <name><surname>Sharma</surname><given-names>B.</given-names></name>
<article-title>Multifunctional
nanoparticles for intracellular drug delivery and photoacoustic imaging
of mesenchymal stem cells</article-title>. <source>Drug Delivery Transl.
Res.</source>
<year>2019</year>, <volume>9</volume> (<issue>3</issue>), <fpage>652</fpage>&#x02013;<lpage>666</lpage>. <pub-id pub-id-type="doi">10.1007/s13346-019-00621-6</pub-id>.</mixed-citation></ref><ref id="ref187"><mixed-citation publication-type="journal" id="cit187"><name><surname>Guo</surname><given-names>P.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>
<article-title>Progress in
the Mechanism
and Clinical Treatment of Antiplatelet Resistance of Aspirin and Clopidogrel</article-title>. <source>Chin. J. Clin. Neurosci.</source>
<year>2019</year>, <volume>27</volume> (<issue>3</issue>), <fpage>321</fpage>&#x02013;<lpage>328</lpage>.</mixed-citation></ref><ref id="ref188"><mixed-citation publication-type="journal" id="cit188"><name><surname>Aquib</surname><given-names>T. I.</given-names></name>; <name><surname>Hoque</surname><given-names>S. M.</given-names></name>; <name><surname>Uddin</surname><given-names>M. H.</given-names></name>
<article-title>Lignin
Nanoparticles
as pH-responsive Nanocarriers for Gastric-Irritant Oral Drug Aspirin</article-title>. <source>Curr. Drug Delivery</source>
<year>2024</year>, <pub-id pub-id-type="doi">10.2174/0115672018318035240910050003</pub-id>.</mixed-citation></ref><ref id="ref189"><mixed-citation publication-type="journal" id="cit189"><name><surname>Al Jbour</surname><given-names>N. D.</given-names></name>
<article-title>Enhanced oral bioavailability through
nanotechnology
in Saudi Arabia: A meta-analysis</article-title>. <source>Arab. J. Chem.</source>
<year>2022</year>, <volume>15</volume> (<issue>4</issue>), <fpage>103715</fpage><pub-id pub-id-type="doi">10.1016/j.arabjc.2022.103715</pub-id>.</mixed-citation></ref><ref id="ref190"><mixed-citation publication-type="journal" id="cit190"><name><surname>Dur&#x000e1;n-Lobato</surname><given-names>M.</given-names></name>; <name><surname>L&#x000f3;pez-Est&#x000e9;vez</surname><given-names>A. M.</given-names></name>; <name><surname>Cordeiro</surname><given-names>A. S.</given-names></name>; <name><surname>Dacoba</surname><given-names>T. G.</given-names></name>; <name><surname>Crecente-Campo</surname><given-names>J.</given-names></name>; <name><surname>Torres</surname><given-names>D.</given-names></name>; <name><surname>Alonso</surname><given-names>M. J.</given-names></name>
<article-title>Nanotechnologies for the delivery
of biologicals: historical perspective and current landscape</article-title>. <source>Adv.Drug DeliveryRev.</source>
<year>2021</year>, <volume>176</volume>, <fpage>113899</fpage>&#x02013;<lpage>113899</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2021.113899</pub-id>.</mixed-citation></ref><ref id="ref191"><mixed-citation publication-type="journal" id="cit191"><name><surname>Zelikin</surname><given-names>A. N.</given-names></name>; <name><surname>Ehrhardt</surname><given-names>C.</given-names></name>; <name><surname>Healy</surname><given-names>A. M.</given-names></name>
<article-title>Materials and methods
for delivery of biological drugs</article-title>. <source>Nat. Chem.</source>
<year>2016</year>, <volume>8</volume> (<issue>11</issue>), <fpage>997</fpage>&#x02013;<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1038/nchem.2629</pub-id>.<pub-id pub-id-type="pmid">27768097</pub-id>
</mixed-citation></ref><ref id="ref192"><mixed-citation publication-type="journal" id="cit192"><name><surname>Ji</surname><given-names>N.</given-names></name>; <name><surname>Hong</surname><given-names>Y.</given-names></name>; <name><surname>Gu</surname><given-names>Z.</given-names></name>; <name><surname>Cheng</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>
<article-title>Chitosan coating of
zein- carboxymethylated short-chain amylose nanocomposites
improves oral bioavailability of insulin in vitro and in vivo</article-title>. <source>J.Control.Release.</source>
<year>2019</year>, <volume>313</volume>, <fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2019.10.006</pub-id>.<pub-id pub-id-type="pmid">31622690</pub-id>
</mixed-citation></ref><ref id="ref193"><mixed-citation publication-type="journal" id="cit193"><name><surname>Suzuki</surname><given-names>K.</given-names></name>; <name><surname>Kim</surname><given-names>K. S.</given-names></name>; <name><surname>Bae</surname><given-names>Y. H.</given-names></name>
<article-title>Long-term oral administration
of Exendin-4 to control type 2 diabetes in a rat model</article-title>. <source>J.Control.Release.</source>
<year>2019</year>, <volume>294</volume>, <fpage>259</fpage>&#x02013;<lpage>267</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2018.12.028</pub-id>.<pub-id pub-id-type="pmid">30572033</pub-id>
</mixed-citation></ref><ref id="ref194"><mixed-citation publication-type="journal" id="cit194"><name><surname>Wang</surname><given-names>A.</given-names></name>; <name><surname>Yang</surname><given-names>T.</given-names></name>; <name><surname>Fan</surname><given-names>W.</given-names></name>; <name><surname>Yang</surname><given-names>Y.</given-names></name>; <name><surname>Zhu</surname><given-names>Q.</given-names></name>; <name><surname>Guo</surname><given-names>S.</given-names></name>; <name><surname>Zhu</surname><given-names>C.</given-names></name>; <name><surname>Yuan</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>T.</given-names></name>; <name><surname>Gan</surname><given-names>Y.</given-names></name>
<article-title>Protein Corona Liposomes Achieve Efficient Oral Insulin Delivery
by Overcoming Mucus and Epithelial Barriers</article-title>. <source>Adv. Healthc. Mater.</source>
<year>2019</year>, <volume>8</volume> (<issue>12</issue>), <elocation-id>e1801123</elocation-id><pub-id pub-id-type="doi">10.1002/adhm.201801123</pub-id>.<pub-id pub-id-type="pmid">30485708</pub-id>
</mixed-citation></ref><ref id="ref195"><mixed-citation publication-type="journal" id="cit195"><name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Zheng</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>L.</given-names></name>; <name><surname>Zhu</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Huang</surname><given-names>Y.</given-names></name>
<article-title>Novel Solid Lipid Nanoparticle with
Endosomal Escape Function for
Oral Delivery of Insulin</article-title>. <source>ACS.Appl.Mater.Interfaces.</source>
<year>2018</year>, <volume>10</volume> (<issue>11</issue>), <fpage>9315</fpage>&#x02013;<lpage>9324</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.8b00507</pub-id>.<pub-id pub-id-type="pmid">29484890</pub-id>
</mixed-citation></ref><ref id="ref196"><mixed-citation publication-type="journal" id="cit196"><name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Van Hul</surname><given-names>M.</given-names></name>; <name><surname>Suriano</surname><given-names>F.</given-names></name>; <name><surname>Preat</surname><given-names>V.</given-names></name>; <name><surname>Cani</surname><given-names>P. D</given-names></name>; <name><surname>Beloqui</surname><given-names>A.</given-names></name>
<article-title>Novel strategy
for oral peptide delivery in incretin-based
diabetes treatment</article-title>. <source>Gut</source>
<year>2020</year>, <volume>69</volume> (<issue>5</issue>), <fpage>911</fpage>&#x02013;<lpage>919</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2019-319146</pub-id>.<pub-id pub-id-type="pmid">31401561</pub-id>
</mixed-citation></ref><ref id="ref197"><mixed-citation publication-type="journal" id="cit197"><name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>De Keersmaecker</surname><given-names>H.</given-names></name>; <name><surname>Braeckmans</surname><given-names>K.</given-names></name>; <name><surname>De Smedt</surname><given-names>S.</given-names></name>; <name><surname>Cani</surname><given-names>P. D.</given-names></name>; <name><surname>Pr&#x000e9;at</surname><given-names>V.</given-names></name>; <name><surname>Beloqui</surname><given-names>A.</given-names></name>
<article-title>Targeted nanoparticles towards increased L cell stimulation
as a strategy to improve oral peptide delivery in incretin-based diabetes
treatment</article-title>. <source>Biomaterials.</source>
<year>2020</year>, <volume>255</volume>, <fpage>120209</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120209</pub-id>.<pub-id pub-id-type="pmid">32580098</pub-id>
</mixed-citation></ref><ref id="ref198"><mixed-citation publication-type="journal" id="cit198"><name><surname>Banerjee</surname><given-names>A.</given-names></name>; <name><surname>Ibsen</surname><given-names>K.</given-names></name>; <name><surname>Brown</surname><given-names>T.</given-names></name>; <name><surname>Chen</surname><given-names>R.</given-names></name>; <name><surname>Agatemor</surname><given-names>C.</given-names></name>; <name><surname>Mitragotri</surname><given-names>S.</given-names></name>
<article-title>Ionic liquids
for oral insulin delivery</article-title>. <source>Proc. Natl. Acad.
Sci. U.S.A.</source>
<year>2018</year>, <volume>115</volume> (<issue>28</issue>), <fpage>7296</fpage>&#x02013;<lpage>7301</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1722338115</pub-id>.<pub-id pub-id-type="pmid">29941553</pub-id>
</mixed-citation></ref><ref id="ref199"><mixed-citation publication-type="journal" id="cit199"><name><surname>Angsantikul</surname><given-names>P.</given-names></name>; <name><surname>Peng</surname><given-names>K.</given-names></name>; <name><surname>Curreri</surname><given-names>A. M.</given-names></name>; <name><surname>Chua</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>K. Z.</given-names></name>; <name><surname>Ehondor</surname><given-names>J.</given-names></name>; <name><surname>Mitragotri</surname><given-names>S.</given-names></name>
<article-title>Ionic Liquids
and Deep Eutectic Solvents for Enhanced Delivery of Antibodies in
the Gastrointestinal Tract</article-title>. <source>Adv. Funct. Mater.</source>
<year>2021</year>, <volume>31</volume> (<issue>44</issue>), <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1002/adfm.202002912</pub-id>.</mixed-citation></ref><ref id="ref200"><mixed-citation publication-type="journal" id="cit200"><name><surname>Hassan</surname><given-names>R. H.</given-names></name>; <name><surname>Gad</surname><given-names>H. A.</given-names></name>; <name><surname>El-Din</surname><given-names>S. B.</given-names></name>; <name><surname>Shaker</surname><given-names>D. S.</given-names></name>; <name><surname>Ishak</surname><given-names>R. A. H.</given-names></name>
<article-title>Chitosan
nanoparticles for intranasal delivery of olmesartan
medoxomil: Pharmacokinetic and pharmacodynamic perspectives</article-title>. <source>Int. J. Pharm.</source>
<year>2022</year>, <volume>628</volume>, <fpage>122278</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.122278</pub-id>.<pub-id pub-id-type="pmid">36243325</pub-id>
</mixed-citation></ref><ref id="ref201"><mixed-citation publication-type="journal" id="cit201"><name><surname>Huo</surname><given-names>D.</given-names></name>; <name><surname>Lu</surname><given-names>X.</given-names></name>; <name><surname>An</surname><given-names>Q.</given-names></name>; <name><surname>Liang</surname><given-names>X.</given-names></name>; <name><surname>Gu</surname><given-names>Y.</given-names></name>
<article-title>Research progress
on molecularly modified nanocarriers with the improvement oral bioavailability
of drugs</article-title>. <source>West Chin. J. Pharm. Sci.</source>
<year>2023</year>, <volume>38</volume> (<issue>5</issue>), <fpage>575</fpage>&#x02013;<lpage>580</lpage>.</mixed-citation></ref><ref id="ref202"><mixed-citation publication-type="journal" id="cit202"><name><surname>Pillai</surname><given-names>S. C.</given-names></name>; <name><surname>Borah</surname><given-names>A.</given-names></name>; <name><surname>Jacob</surname><given-names>E. M.</given-names></name>; <name><surname>Kumar</surname><given-names>D. S.</given-names></name>
<article-title>Nanotechnological
approach to delivering nutraceuticals as promising drug candidates
for the treatment of atherosclerosis</article-title>. <source>Drug deliv.</source>
<year>2021</year>, <volume>28</volume> (<issue>1</issue>), <fpage>550</fpage>&#x02013;<lpage>568</lpage>. <pub-id pub-id-type="doi">10.1080/10717544.2021.1892241</pub-id>.<pub-id pub-id-type="pmid">33703990</pub-id>
</mixed-citation></ref><ref id="ref203"><mixed-citation publication-type="journal" id="cit203"><name><surname>Bejarano</surname><given-names>J.</given-names></name>; <name><surname>Navarro-Marquez</surname><given-names>M.</given-names></name>; <name><surname>Morales-Zavala</surname><given-names>F.</given-names></name>; <name><surname>Morales</surname><given-names>J. O.</given-names></name>; <name><surname>Garcia-Carvajal</surname><given-names>I.</given-names></name>; <name><surname>Araya-Fuentes</surname><given-names>E.</given-names></name>; <name><surname>Flores</surname><given-names>Y.</given-names></name>; <name><surname>Verdejo</surname><given-names>H. E.</given-names></name>; <name><surname>Castro</surname><given-names>P. F.</given-names></name>; <name><surname>Lavandero</surname><given-names>S.</given-names></name>; <name><surname>Kogan</surname><given-names>M. J.</given-names></name>
<article-title>Nanoparticles for diagnosis and therapy
of atherosclerosis
and myocardial infarction: evolution toward prospective theranostic
approaches</article-title>. <source>Theranostics.</source>
<year>2018</year>, <volume>8</volume> (<issue>17</issue>), <fpage>4710</fpage>&#x02013;<lpage>4732</lpage>. <pub-id pub-id-type="doi">10.7150/thno.26284</pub-id>.<pub-id pub-id-type="pmid">30279733</pub-id>
</mixed-citation></ref><ref id="ref204"><mixed-citation publication-type="journal" id="cit204"><name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Cao</surname><given-names>F.</given-names></name>
<article-title>Development of molecular
imaging
and precision medicine in coronary atherosclerosis plaques</article-title>. <source>Chin. Heart J.</source>
<year>2016</year>, <volume>28</volume> (<issue>5</issue>), <fpage>597</fpage>&#x02013;<lpage>600</lpage>.</mixed-citation></ref><ref id="ref205"><mixed-citation publication-type="journal" id="cit205"><name><surname>Liu</surname><given-names>T.</given-names></name>; <name><surname>Li</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Shuai</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>L.</given-names></name>; <name><surname>Xu</surname><given-names>S.</given-names></name>
<article-title>Nanoparticle-and Exosome-based Targeted Drug Delivery
Systems Used in the Diagnosis and Treatment of Atherosclerosis: Opportunities
and Challenges</article-title>. <source>Chin. Gen. Pract.</source>
<year>2023</year>, <volume>26</volume> (<issue>8</issue>), <fpage>903</fpage>&#x02013;<lpage>910</lpage>.</mixed-citation></ref><ref id="ref206"><mixed-citation publication-type="thesis" id="cit206"><person-group person-group-type="allauthors"><name><surname>Zhang</surname><given-names>S.</given-names></name></person-group><article-title>Applications of
inflammatory microenvironment-targeted nanozymes in the treatment
of atherosclerosis and ischemia-reperfusion injury</article-title>. <publisher-name>Jilin University</publisher-name>, <year>2023</year>.</mixed-citation></ref></ref-list></back></article>